EP1399406A2 - Novel estrogen receptor ligands and methods i - Google Patents

Novel estrogen receptor ligands and methods i

Info

Publication number
EP1399406A2
EP1399406A2 EP01272663A EP01272663A EP1399406A2 EP 1399406 A2 EP1399406 A2 EP 1399406A2 EP 01272663 A EP01272663 A EP 01272663A EP 01272663 A EP01272663 A EP 01272663A EP 1399406 A2 EP1399406 A2 EP 1399406A2
Authority
EP
European Patent Office
Prior art keywords
methyl
rac
phenanthren
hydroxy
butyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP01272663A
Other languages
German (de)
French (fr)
Other versions
EP1399406B1 (en
Inventor
Konrad Koehler
Cecilia Henssen
Marita Nilsson
Mikael Gillner
Ye Liu
Andrei Sanin
Robert R. Wilkening
Ronald W. Ratcliffe
David Wensbo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karo Healthcare AB
Merck and Co Inc
Original Assignee
Karo Bio AB
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0100163A external-priority patent/GB0100163D0/en
Priority claimed from GB0100164A external-priority patent/GB0100164D0/en
Priority claimed from GB0106434A external-priority patent/GB0106434D0/en
Application filed by Karo Bio AB, Merck and Co Inc filed Critical Karo Bio AB
Publication of EP1399406A2 publication Critical patent/EP1399406A2/en
Application granted granted Critical
Publication of EP1399406B1 publication Critical patent/EP1399406B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/44—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups being part of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/17—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
    • C07C39/17—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings containing other rings in addition to the six-membered aromatic rings, e.g. cyclohexylphenol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/24—Halogenated derivatives
    • C07C39/42—Halogenated derivatives containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
    • C07C49/747—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/06—Five-membered rings having the hetero atoms in positions 1 and 3, e.g. cyclic dithiocarbonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/08—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/26—Phenanthrenes; Hydrogenated phenanthrenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/93—Spiro compounds
    • C07C2603/95—Spiro compounds containing "not free" spiro atoms
    • C07C2603/96—Spiro compounds containing "not free" spiro atoms containing at least one ring with less than six members

Definitions

  • This invention relates to novel compounds which are estrogen receptor ligands and are preferably selective for either the estrogen receptor ⁇ or ⁇ isoforms, to methods of preparing such compounds and to methods for using such compounds such as for estrogen hormone replacement therapy and for diseases modulated by the estrogen receptor such as osteoporosis, elevated blood triglyercide levels, atherosclerosis, endometriosis, cognitive disorders, urinary incontinence, autoimmune disease, and cancer of the lung, colon, breast, uterus and prostate.
  • diseases modulated by the estrogen receptor such as osteoporosis, elevated blood triglyercide levels, atherosclerosis, endometriosis, cognitive disorders, urinary incontinence, autoimmune disease, and cancer of the lung, colon, breast, uterus and prostate.
  • the estrogen receptor is a ligand activated mammalian transcription factor involved in the up and down regulation of gene expression.
  • the natural hormone for the estrogen receptor is ⁇ -17-estradiol (E2) and closely related metabolites. Binding of estradiol to the estrogen receptor causes a dimerization of the receptor and the dimer in turn binds to estrogen response elements (ERE's) on DNA.
  • E2 ⁇ -17-estradiol
  • E2 estrogen response elements
  • the ER/DNA complex recruits other transcription factors responsible for the transcription of DNA downstream from the ERE into mRNA which is eventually is translated into protein.
  • the interaction of ER with DNA may be indirect through the intermediacy of other transcription factors, most notably fos and jun.
  • Estrogens are critical for sexvial development in females.
  • estrogens play an important role in maintaining bone density, regulation of blood lipid levels, and appear to have neuroprotective effects. Consequently decreased estrogen production in post-menopausal women is associated with a number of diseases such as osteoporosis, atherosclerosis, and cognitive disorders.
  • certain types of proliferative diseases such as breast and uterine cancer and endometriosis are stimulated by estrogens and therefore antiestrogens (t ' .e., estrogen antagonists) have utility in the prevention and treatment of these types of disorders.
  • prostatic cancer In addition to women suffering from breast cancer, men afflicted with prostatic cancer can also benefit from anti-estrogen compounds. Prostatic cancer is often endocrine sensitive and androgen stimulation fosters tumor growth, while androgen suppression retards tumor growth. The administration of estrogen is helpful in the treatment and control of prostatic cancer because estrogen administration lowers the level of gonadotropin and consequently androgen levels.
  • hormone replacement therapy has been shown to markedly decrease the risk of osteoporosis.
  • hormone replacement therapy has cardiovascular and neuroprotective benefits.
  • hormone replacement therapy is also associated with an increase risk of breast and uterine cancer.
  • certain types of synthetic ER ligands display a mixed agonist/antagonist profile of activity showing agonist activity in some tissues and antagonist activity in other tissues.
  • Such ligands are referred to as selective estrogen receptor modulators (SERMS).
  • SERMS selective estrogen receptor modulators
  • tamoxifen and raloxifene are known to be agonists in bone (and therefore prevent osteoporosis) while displaying antagonistic properties in breast (and therefore lowers the risk of breast cancer).
  • the compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive function, cerebral degenerative disorders, restinosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, autoimmune disease and cancer of the lung, colon, breast, uterus, and prostate.
  • compounds which are estrogen receptor ligands and have the general formula I, II, or III
  • R A is selected from the group hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, aryl or arylalkyl;
  • R ⁇ and R ⁇ are the same or are different and each is an R A group;
  • R a (of compounds of general formula I or II) is a hydroxyl or R A group or is a hydroxyalkyl or aminoalkyl group of 1 to 2 carbon atoms;
  • R 3 ⁇ and R 3 ⁇ may together be a single oxygen or sulfur atom; or R 3 ⁇ and R 3 ⁇ may together be a single nitrogen atom which in turn is bonded to a group selected from R A or OR A ; or R 3 ⁇ and R 3 ⁇ may together be a single carbon atom (i.e., an exo methylene carbon atom) which in turn is bonded to two R A groups which may be the same or are different; or R 3 ⁇ and R 3 ⁇ may be the same or are different and each may be selected from R A , OR A , SR A , or N(R A ) 2 wherein the individual R A groups may be the same or are different and may be taken together with any attached and intervening atoms to form a 3-8 membered ring;
  • R 2 ⁇ and R 2 ⁇ may together be a single oxygen or sulfur atom; or R 3 ⁇ and Rs ⁇ may together be a single nitrogen atom which in turn is bonded to a group selected from R A or OR A ; or R 2 and R 2 ⁇ may together be a single carbon atom which in turn is bonded to two R A groups which may be the same or are different; or R 2 ⁇ and R 2 ⁇ may be the same or are different and each may be selected from hydroxyalkyl, aminoalkyl, R A , OR A , SR A , or N(R A ) 2 wherein the individual R A groups may be the same or are different and may optionally be taken together with any attached and intervening atoms to form a 3-8 membered ring;
  • R 3 (of compounds of general formula II or III) is an R A group; Rt is an R A group;
  • Rtgro is a hydrogen atom or a methyl or ethyl group in compounds of formula I or II, or a methyl or ethyl group in compounds of formula III.;
  • R 7 is a hydrogen atom or a linear or branched alkyl or cycloalkyl group or acyl group of 1 to 4 carbon atoms;
  • R 10a is an R A group
  • R ]5 R 2 , R 3 and R( are hydrogen in compounds of formula I or II, and that ⁇ is not hydrogen in compounds of formula III. and pharmaceutically acceptable salts and stereoisomers thereof.
  • the present invention relates to compounds useful as estrogen receptor modulators and have the general formula I, II or III as described above.
  • One embodiment of the present invention relates to compounds according to the general formula I, II or III wherein the substituents R4, and R 10a have a trans relative stereochemistry.
  • R B is selected from hydrogen, /.-propyl, 2-propenyl, 2-propynyl, ra-butyl, 2-butenyl, 3-butenyl, 2-butynyl, 3-butynyl, 72-pentyl, 3-methylbutyl, 3 -methyl- 1-butenyl, 3-methyl-2-butenyl, 3-methyl ⁇ entyl, 3-ethylpentyl, cyclopropylethyl.
  • Another embodiment of the present invention relates to compounds according to the general formula II, wherein Ri is R B (where R B is defined as above) and Ri ⁇ is a hydrogen atom or methyl group.
  • Another embodiment of the present invention relates to compounds according to the general formula I, II or III wherein R ⁇ o a is R B .
  • Another embodiment of the present invention relates to compounds according to the general formula I or II, wherein R 2 is a hydrogen atom or a methyl, ethyl, or hydroxymethyl group.
  • R 2 and R- ⁇ may be the same or are different and each may be selected from hydroxyalkyl, R A , OR A or SR A where the individual R A groups (where R A is defined as above) may be the same or are different and may optionally be taken together with any attached and intervening atoms to form a 3-8 membered ring.
  • R 3 ⁇ and R 3 ⁇ may be the same or are different and each may be selected from R A OR A , or SR A where the individual R A groups (where R A is defined as above) may be the same or are different and may optionally be taken together with any attached and intervening atoms to form a 3-8 membered ring.
  • Another embodiment of the present invention relates to compounds with the general formula I, II or III wherein ( is a hydrogen atom or methyl or ethyl group.
  • Another embodiment of the present invention relates to compounds with the general formula I, II or III wherein R 7 is hydrogen atom or an acyl group of 1 to 4 carbon atoms.
  • Another embodiment of the present invention relates to compounds with the general formula I or III wherein Ri is selected from the group hydrogen, methyl, or ethyl and Rio a is R B .
  • Another embodiment of the present invention relates to compounds with the general formula I or III wherein Ri is R B and R ⁇ 0a is selected from hydrogen, methyl, or ethyl.
  • R 2 ⁇ and R 2 ⁇ may be the same or are different and each may be selected from hydroxyalkyl, R ⁇ OR A , or SR A where the individual R A groups (where R A is defined as above) may be the same or are different and may optionally be taken together with any attached and intervening atoms to form a 3-8 membered ring.
  • R ⁇ is R B and R ⁇ 0a is selected from hydrogen, methyl, or ethyl.
  • Another embodiment of the present invention relates to compounds with the general formula II, wherein Ri ⁇ is selected from hydrogen, methyl, or ethyl and R ⁇ 0a is R B .
  • Compounds of the invention include, but are not limited to, the following:
  • Another embodiment of the invention is a method of eliciting an estrogen receptor modulating effect in a mammal in need thereof, comprising administering to the mammal a therapeutically-effective amount of any of the compounds or any of the pharmaceutical compositions described above.
  • a class of this embodiment is the method wherein the estrogen receptor modulating effect is an agonizing effect.
  • a first subclass of this class of embodiment is the method wherein the estrogen receptor is an ER ⁇ receptor.
  • a second subclass of this class of embodiment is the method wherein the estrogen receptor is an ER ⁇ receptor.
  • a third subclass of this class of embodiment is the method wherein the estrogen receptor modulating effect is a mixed ER ⁇ and ER ⁇ agonizing effect.
  • a second class of this embodiment is the method wherein the estrogen receptor modulating effect is an antagonizing effect.
  • a first subclass of this class of embodiment is the method wherein the estrogen receptor is an ER ⁇ receptor.
  • a second subclass of this class of embodiment is the method wherein the estrogen receptor is an ER ⁇ receptor.
  • a third subclass of this class of embodiment is the method wherein the estrogen receptor modulating effect is a mixed ER ⁇ and ER ⁇ antagonizing effect.
  • Another embodiment of the invention is a method of treating or preventing hot flashes in a mammal in need thereof by administering to the mammal a therapeutically effective amount of any of the compounds or pharmaceutical compositions described above.
  • Exemplifying the invention is a pharmaceutical composition comprising any of the compounds described above and a pharmaceutically acceptable carrier. Also exemplifying the invention is a pharmaceutical composition made by combining any two or more of the compounds described above and a pharmaceutically acceptable carrier. An illustration of the invention is a process for making a pharmaceutical composition comprising /combining any of the compounds described above and a pharmaceutically acceptable carrier. As one specific embodiment of this invention, 140 mg of
  • Oa-octahydro-phenanthrene is formulated with sufficient finely divided lactose to provide a total amount of 580 to 590 mg to fill a size 0, hard-gelatine capsule.
  • 200 mg of (r ⁇ -4b,8-dimethyl-4b,5,6,7,9,10 -hexahydro-phenanthren-2-ol is formulated with sufficient finely divided lactose to provide a total amount of 580 to 590 mg to fill a size 0, hard-gelatine capsule.
  • any of the compounds described above in the preparation of a medicament for the treatment and/or prevention of osteoporosis in a mammal in need thereof is the use of any of the compounds described above in the preparation of a medicament for the treatment and/or prevention of bone loss, bone resorption, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restinosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, autoimmune disease, lung cancer, colon cancer, breast cancer, uterine cancer, prostate cancer, and/or disorders related to estrogen functioning.
  • the present invention is also directed to combinations of any of the compounds or any of the pharmaceutical compositions described above with one or more agents useful in the prevention or treatment of osteoporosis.
  • the compounds of the instant invention may be effectively administered in combination with effective amounts of other agents such as an organic bisphosphonate or a cathepsin K inhibitor.
  • organic bisphosphonates include adendronate, clodronate, etidronate, ibandronate, incadronate, minodronate, neridronate, risedronate, piridronate, pamidronate, tiludronate, zoledronate, pharmaceutically acceptable salts or esters therof, and mixtures thereof.
  • Preferred organic biphosphonate include alendronate and pharmaceutically acceptable salts and mixtures thereof. Most preferred is alendronate monosodium trhihydrate.
  • the precise dosage of the bisphonate will vary with the dosing schedule, the oral potency of the particular bisphosphonate chosen, the age, size, sex and condition of the mammal or human, the nature and severity of the disorder to be treated, and other relevant medical and physical factors. Thus, a precise pharmaceutically effective amount cannot be specified in advance and can be readily determined by the caregiver or clinician. An appropriate amount can be determined by routine experimentation from animal models and human clinical studies. Generally, an appropriate amount of bisphosphonate is chosen to obtain a bone resorption inhibiting effect, i.e.
  • an effective oral dose of bisphosphonate is typically from about 1.5 to about 6000 ⁇ g/kg of body weight and preferably about 10 to about 2000 ⁇ g/kg of body weight.
  • a unit dosage typically comprises from about 8.75 mg to about 140 mg of the alendronate compound, on an alendronic acid active weight basis, i.e. on the basis of the corresponding acid.
  • the compounds of the present invention can be used in combination with other agents useful for treating estrogen-mediated conditions.
  • the individual components of such combinations can be administer separately at different times during the course of therapy or concurrently in divided or single combination forms.
  • the instant invention is therefore to be understood as embracing all such regimes of simultaneous or alternating treatment and the term "administering" is to be interpreted accordingly. It will be understood that the scope of combinations of the compounds of this invention with other agents useful for treating estrogen-mediated conditions includes in principle any combination with any pharmaceutical composition useful for treating disorders related to estrogen functioning.
  • the compounds of the present invention can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powder, granules, elixirs, tinctures, suspensions, syrups and emulsions. Likewise, they may also be administered in intravenous (bolus or infusion), intraperitoneal, topical (e.g., ocular eyedrop), subcutaneous, intramuscular, or transdermal (e.g., patch) form, all using forms well known to those of ordinary skill in the pharmaceutical arts.
  • the dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex, and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed.
  • An ordinarily skilled physician, veterinarian or clinician can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
  • Oral dosages of the present invention when used for the indicated effects, will range between about 0.01 mg per kg of body weight per day (mg/kg/day) to about 100 mg/kg/day, preferably 0.01 mg per kg of body weight per day (mg/kg/day) to 10 mg/kg/day, and most preferably 0.1 to 5.0 mg/kg/day.
  • the compositions are preferably provided in the form of tablets containing 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
  • a medicament typically contains from about 0.01 mg to about 500 mg of the active ingredient, preferably from about 1 mg to about 100 mg of active ingredient.
  • the most preferred doses will range from about 0.1 to about 10 mg/kg/minute during a constant rate infusion.
  • compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.
  • preferred compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches will known to those of ordinary skill in the art.
  • the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
  • the compounds herein described in detail can form the active ingredient, and are typically administered in admixture with suitable pharmaceutical diluents, exipients or carriers (collectively referred to herein as "carrier" materials) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.
  • the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture.
  • suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture.
  • Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like.
  • Lubricants used in these dosage forms includes sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
  • Disintegrators include without limitation starch, methylcellulose, agar, bentonite, xanthan gum and the like.
  • the compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
  • Liposomes can be formed form a variety of phospholipids, such as 1,2-dipalmitoylphosphatidylcholine, phosphatidyl ethanolamine (cephalin), or phosphatidylcholine (lecithin).
  • estrogen receptor ligand as. used herein is intended to cover any moiety which binds to a estrogen receptor.
  • the ligand may act as an agonist, an antagonist, a partial agonist or a partial antagonist.
  • the ligand may be either ER ⁇ or ER ⁇ selective or display mixed ER ⁇ and ER ⁇ activity.
  • aliphatic hydrocarbon(s) refers to acyclic straight or branched chain groups which include alkyl, alkenyl or alkynyl groups.
  • aromatic hydrocarbon(s) refers to groups including aryl groups as defined herein.
  • lower alkyl as employed herein alone or as part of another group includes both straight and branched chain hydrocarbons, containing 1 to 12 carbon atoms (in the case of alkyl) in the normal chain and preferably 1 to 6 carbons, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, or isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl.
  • cycloalkyl as employed herein alone or as part of another group refers to 3- to 7-membered fully saturated mono cyclic ring system and include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
  • cycloalkylalkyl refers to an cycloalkyl group containing 3 to 7 carbon atoms attached through available carbon atoms to a straight or branched chain alkyl radical containing 1 to 6 carbon atoms and include but are not limited to cyclopropylmethyl (-CH2 H5), cyclobutylethyl (-CH 2 CH 2 C 4 H 7 ), and cyclopentylpropyl (-CH 2 CH 2 CH 2 C 5 H 9 ).
  • aryl refers to monocyclic and bicyclic aromatic groups containing 6 to 10 carbons in the ring portion and include but are not limited to phenyl, 1-naphthyl, and 2-naphthyl and may be optionally substituted through available carbon atoms with 1, 2, or 3 groups selected from hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, amino, trifluoromethyl, trifluoromethoxy, alkynyl, hydroxy, nitro, cyano, or carboxy.
  • arylalkyl refers to an aryl group containing 6 to 10 carbon atoms attached through available carbon atoms to a straight or branched chain alkyl radical containing 1 to 6 carbon atoms and include but are not limited to benzyl (-CH 2 Ph), phenethyl (-CH 2 CH 2 Ph), phenpropyl (-CH 2 CH 2 CH 2 Ph), and 1-napthylmethylene (-CH 2 C ⁇ oH 7 ).
  • lower alkenyl or “alkenyl” as used herein by itself or as part of another group refers to straight or branched chain radicals of 2 to 12 carbons, preferably 2 to 6 carbons, in the normal chain, which include one to six double bonds in the normal chain, such as vinyl, 2-propenyl, 3-butenyl, 2-butenyl, 4-pentenyl, 3-pentenyl, 2-hexenyl, 3-hexenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 3-octenyl, 3-nonenyl, 4-decenyl, 3-undecenyl, 4-dodecenyl, and the like.
  • lower alkynyl or “alkynyl” as used herein by itself or as part of another group refers to straight or branched chain radicals of 2 to 12 carbons, preferably 2 to 6 carbons, in the normal chain, which include one triple bond in the normal chain, such as 2-propynyl, 3-butynyl, 2-butynyl, 4-pentynyl, 3-pentynyl, 2-hexynyl, 3-hexynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 3-octynyl, 3-nonynyl, 4-decynyl, 3-undecynyl, 4-dodecynyl and the like.
  • halogen or "halo” as used herein alone or as part of another group refers to chlorine, bromine, fluorine, and iodine as well as CF 3 .
  • hydroxyalkyl refers to linear chain alkyl radical containing 1 to 2 carbon atoms attached through available carbon atoms to a hydroxyl group and include hydroxymethyl (-CH 2 OH), 1-hydroxyethyl [-CH 2 (OH)CH 3 ] and 2-hydroxyethyl (-CH 2 CH 2 OH).
  • aminoalkyl refers to linear chain alkyl radical containing 1 to 2 carbon atoms attached through available carbon atoms to a primary, secondary, or tertiary amino group and include aminomethyl (-CH 2 NR 2 ), 1-aminoethyl [-CH 2 (NR 2 )CH 3 ] and 2-aminoethyl (-CH 2 CH 2 NR 2 ) where R is a hydrogen atom or methyl or ethyl group.
  • the compounds of formula I, II or III can be present as salts, in particular pharmaceutically acceptable salts. If the compounds of formula I, II or III have, for example, at least one basic center, they can form acid addition salts. These are formed, for example, with strong inorganic acids, such as mineral acids, for example sulfuric acid, phosphoric acid or a hydrohalic acid, with strong organic carboxylic acids, such as alkanecarboxylic acids of 1 to 4 carbon atoms which are unsubstituted or substituted, for example, by halogen, for example acetic acid, such as saturated or unsaturated dicarboxylic acids, for example oxalic, malonic, succinic, maleic, fumaric, phthalic or terephthalic acid, such as hydroxycarboxylic acids, for example ascorbic, glycolic, lactic, malic, tartaric or citric acid, such as amino acids, (for example aspartic or glutamic acid or lysine or arginine), or benzoic
  • Corresponding acid addition salts can also be formed having, if desired, an additionally present basic center.
  • the compounds of formula I, II or III having at least one acid group can also form salts with bases.
  • Suitable salts with bases are, for example, metal salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium or magnesium salts, or salts with ammonia or an organic amine, such as morpholine, thiomorpholine, piperidine, pyrrolidine, a mono-, di- or tri-lower alkylamine, for example ethyl-, tert-butyl-, diethyl-, diisopropyl-, triethyl-, tributyl- or dimethyl-propylamine, or a mono-, di- or trihydroxy lower alkylamine, for example mono-, di- or triethanolamine.
  • Corresponding internal salts may furthermore be formed. Salts which are unsuitable for pharmaceutical uses but which can be
  • Preferred salts of the compounds of formula I, II or III which include a basic group include monohydrochloride, hydrogensulfate, methanesulfonate, phosphate or nitrate.
  • Preferred salts of the compounds of formula I, II or III which include an acid group include sodium, potassium and magnesium salts and pharmaceutically acceptable organic amines.
  • the compounds in the invention contain at least one chiral center and therefore exist as optical isomers.
  • the invention therefore comprises the optically inactive racemic (rac) mixtures (a one to one mixture of enantiomers), optically enriched scalemic mixtures as well as the optically pure individual enantiomers.
  • the compounds in the invention also may contain more than one chiral center and therefore may exist as diastereomers.
  • the invention therefore comprises individual diastereomers as well as mixtures of diastereomers in cases where the compound contains more than one stereo center.
  • the compounds in the invention also may contain acyclic alkenes or oximes and therefore exist as either the E (ent ought) or Z (zusammen) isomers.
  • the invention therefore comprises individual E or Z isomers as well as mixtures of E and Z isomers in cases where the compound contains an acylic alkene or oxime funtional group. Also included within the scope of the invention are polymorphs, hydrates, and solvates of the compounds of the instant invention.
  • the present invention includes within its scope prodrugs of the compounds of this invention.
  • prodrugs will be functional derivatives of the compounds of this invention which are readily convertible in vivo into the required compound.
  • the term “administering” shall encompass the treatment of the various conditions described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the patient.
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example in "Design of Prodrugs” ed. H. Bundgaard, Elsevier, 1985, which is incorporated by reference herein in its entirety. Metabolites of the compounds includes active species produced upon introduction of compounds of this invention into the biological milieu.
  • the present invention also relates to pharmaceutical compositions comprising the compounds of the present invention and a pharmaceutically acceptable carrier.
  • the present invention also relates to methods for making the pharmaceutical compositions of the present invention.
  • the present invention also relates to methods for treating or preventing disorders elated to estrogen functioning, bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, autoimmune disease, lung, colon, breast, uterus, or prostate cancer, hot flashes, cardiovascular disease, impairment of cognitive function, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity and incontinence in a mammal in need thereof by administering the compounds and pharmaceutical compositions of the present invention.
  • the present invention also relates to methods for reducing bone loss, lowering LDL cholesterol levels and eliciting a vasodilatory effect, in a mammal in need thereof by administering the compounds and pharmaceutical compositions of the present invention.
  • novel compounds of the present invention can be prepared according to the procedure of the following Schemes and examples, using appropriate materials and are further exemplified by the following specific examples.
  • the compounds illustrated in the examples are not, however, to be construed as forming the only genus that is considered as the invention.
  • the following examples further illustrate details for the preparation of the compounds of the present invention. Those skilled in the art will readily understand that known variation of the conditions and processes of the following preparative procedures can be used to prepare these compounds.
  • the compounds of the present invention of formulae I and II are prepared according to the general methods outlined in Schemes 1-4, and according to the related methods described.
  • Those of formula III are prepared according to general methods outlined in Schemes 5-6 and according to the related methods described. All temperatures are degrees in Celsius unless otherwise noted.
  • step 1 aryl iodide 1 is coupled with an homoallylic alcohol 2a or 2b under the influence of a palladium catalyst, to give 3a or 3b respectively.
  • step 2 cyclized under acidic or basic conditions in step 2, to provide the tetrahydro-phenanthrone derivative 4 or 5 respectively.
  • Representative protocols for step 1 (method A) and step 2 (method B or method C) in Scheme 1 are as follows:
  • This DCM solution is then filtered through a short plug of silica gel that is further eluted with EtOAc before concentration of the combined filtrates in vacuo (approximately 10 mmHg/60 °C) to provide a crude material.
  • the crude material from method A is taken up in DCM ("N” mL) and treated with cone. HC1 (aq., “O” mL) at “P” °C, and for "Q” h. The mixture is then first washed with saturated aqueous Sodium bicarbonate and then with water. Back extraction of the combined aqueous phases is done with EtOAc. The combined organic phases are then dried over anhydrous sodium sulfate and concentrated in vacuo to yield the crude product.
  • the homoallylic alcohols 2a and 2b which are used as starting materials in Scheme 1 could, when not commercially available, be prepared by known methods such as the allylation of aldehydes (see Wada, et al, Tetrahedron Lett. 1997, 38, 8045-8048 and references cited therein).
  • a general method Employing Mg / BiCl 3 as reagents for this purpose, is outlined in Scheme 2.
  • the primary homoallylic alcohol 2a is formed.
  • the secondary homoallylic alcohol 2b is formed in an analogous way by reaction with aldehyde 7.
  • a representative protocol for the reaction shown in Scheme 2 (method D) is as follows:
  • the allylic bromide 6a or 6b (Scheme 2, 1.0 eq.) is added to a suspension of bismuth trichloride (1.1 eq.) and magnesium turnings (2.4 eq.) in a THF-H 2 O (4:1) mixture.
  • the aldehyde formaldehyde 7 (Scheme 2, "J” eq.) is added in one portion.
  • the resulting mixture is then stirred for "K" h before quenching with l.OM HCl.
  • the organic materials are extracted with diethyl ether, the combined organic extracts washed with water and saturated aqueous NaCl, dried over anhydrous sodium sulfate, and concentrated in vacuo to furnish the crude product.
  • the substituted benzylideneacetones 1 used as starting material in Scheme 1, can be prepared from the corresponding aromatic aldehyde 8 in a conventional way by aldol condensation with ketones 9 as shown in Scheme 3.
  • ketone 9 is unsymmetric (i.e., when R ⁇ and R ra are different)
  • the reacting site can be controlled by varying the reaction conditions according to known methods (see Irie, et al, Bull. Chem. Soc. Jpn. 1980, 53, 1366-1371 and Iranpoor, et al, Tetrahedron 1998, 55, 9475-9480 and references cited therein).
  • R 1 in 8 is hydrogen, a non-hydrogen protecting group can be introduced on 1 after the aldol condensation.
  • the 4a,9,10,10a-teti'ahydro- ⁇ H-phenanthren-3-ones 4 can be further modified by employment of known methods for the reactions of enone and carbonyl functionalities as shown in Scheme 4.
  • a non-hydrogen R VI -substituent in (10) can be introduced by treatment of 4 with an organocopper reagent carrying the R VI -substituent (see Lipshuts B. ⁇ . "Synthetic Procedures Involving Organocopper Reagents" in "Organometallics in Synthesis", Schlosser M. (ed.), John Wiley & Sons 1994).
  • a representative protocol (method E) for the introduction of a non-hydrogen R VI -substituent is as follows:
  • the carbonyl group of ketone 10 can be altered using traditional carbonyl chemistry to generate derivatives 11, where the R w - and R ⁇ -substituents has been introduced.
  • the thioketal can be prepared from 10 by treatment with a thiol, or dithiol, under acidic conditions.
  • the R ⁇ - and R m -substituents of 10 can be separately changed from hydrogen to non-hydrogen by alkylation of the corresponding enolates of 10.
  • a non-hydrogen R m -substituent can be introduced by alkylation of 10 (enolate A)
  • a non-hydrogen R ⁇ -substituent can be introduced by alkylation of 10 (enolate B).
  • Deprotection i.e., to change the R'-substituent from a non-hydrogen to hydrogen
  • step 5 A general route for the construction of the tetrahydro-phenanthrone nucleus of formulae III is shown in Scheme 5. This methodology is based on the chemistry described by Fetizon and Delobelle, CR. Hebd. Seances Acad. Sci, 1957, 245; 850-852 and by Howell and Taylor, J Chem. Soc, 1958, 1248-1253.
  • tetralone 12 is formed by oxidation of enone 11 by mCPBA. Robinson-type annulation of tetralone 12 with enone 13 results in phenantrone 14.
  • Representative protocols for step 1 (method L) and step 2 (method M) in Scheme 5 are as follows:
  • Deprotection i.e., to change the R I -substituent from a non-hydrogen to hydrogen
  • the 3,4,4a,9,10,10a-hexahydro-7H-phenanthren-2 ⁇ ones 14 can by further modified by employment of known methods for the reactions of enone and carbonyl functionalities as shown in Scheme 6.
  • a non-hydrogen R IV -substituent in (20) can be introduced by treatment of 14 with and organocopper reagent carrying the R IV -substituent (see Lipshuts B. ⁇ . "Synthetic Procedures Involving Organocopper Reagents" in "Organomettalics in Synthesis", Schlosser M.
  • step step 2 of Scheme 6 the carbonyl functionality of 14 can be reduced using traditional carbonyl chemistry.
  • a representative protocol (method R) for the reduction of carbonyl groups is as follows:
  • the carbonyl group of ketone 7 can be altered using traditional carbonyl chemistry to generate derivatives 19 and 20.
  • thioketal 19 can be prepared from 17 by treatment with a dithiol under acidic conditions
  • Examples 1-54 relate to compounds of formulae I and II
  • Examples 55-75 relate to compounds of formula III.
  • Step 1 2-Iodo-4-methoxy-benzaldehyde.
  • m-iodo-anisole 47.2 g, 202 mmol
  • DMF 20 mL
  • POCl 3 1.1 eq.
  • the mixture was then heated at 100 °C for 12 h before sequential addition of further portions of DMF (12 mL) and POClj (0. 5eq.), and then again stirred for another 12 h at 100 °C.
  • the dark mixture was then poured onto 500 mL of 2.0M NaOH before extraction with diethyl ether and DCM.
  • Step 3 (rac)-(4aR,10aS)-7-Methoxy-4a,9,10,10a-tetrahydro-4H-phenanth ⁇ en-3-one and (r ⁇ c)-(4 ⁇ S, 10 ⁇ S)-7-Metb xy-4a,9, 10, 10a-tetrahydro- H-phenanthren-3 -one.
  • Step 4 (r ⁇ c)-(4 ⁇ S, 1 O ⁇ S) - -Mexboxy- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3-one.
  • Step 5 (rac)-(4aS, 1 OaS) -7 -By dxoxy- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3-one.
  • Step 1 (r c -2-Butyl-but-3-en-l-ol.
  • a crude product was obtained. This was purified by distillation (79-81 °C/65 nimHg) to yield (r ⁇ c)-2-butyl-but-3-en-l-ol as a colorless oil.
  • Example 5 Synthesis of frgc)-t7S'. aS.10flS)-l-butyl-7-hvdroxy-1.4.4a > 9.10.10a- hexahvdro- H-phenanthren-3- onerE5a):andt -gc)- ⁇ iR. ⁇ g ⁇ S'.i ⁇ ?fl t ->')-l-butyl-7-hydroxy- l 4a-,9 0J0a-hexahvdro- H-phenanthren-3-one (E5b).
  • the crude product consisted of a mixture of (rac)-(lS,4aS, 10dS)-l-butyl-7-methoxy-l, 4,4a,9,10,10a -hexahydro-2H-phenanthren-3-one and (rac)-(lR, 4aS, 10aS)- ⁇ -butyl-7-methoxy- 1 , 4,4a,9,10,10a-hexahydro-2H-phenanthren-3-one that was used in the next step (step 2).
  • Example 6 Synthesis of (rac)-(lSAaS.lOaS)- l-butyl-3,3-ethanediyldimercap to-7-hvdroxy-1.2,3.4.4a,9,10.10a-octahvdro-phenanthrene; (E6a ⁇ and c)- i -. flS.i ⁇ ⁇ S ) - l-butyl-3.3-ethanediyldimercapt o-7-hvdroxy-l,2,3,4,4a.9.10.10a- octahydro-phenanthrene (E6b .
  • Example 7 Synthesis of " c ) -t-?S'. aS' 0flS')-l-butyl-7-hvdroxy-10a- methyI-l,4.4a,9,10,10a-hexahydro-2H-phenanthren-3-one (E7).
  • Example 8 Synthesis of (rac)-aS.4aS.10aS)-l- butyI-3.3-ethanediyldimercapto-7-hvdroxy- l ⁇ a-methyl-l.2.3,4. 4a,9 -,10.10a -octahvdro-phenanthrene (E8 .
  • Example 10 Synthesis of ⁇ c)-( ⁇ flS , .i ⁇ ?gR)-10a-ethyl-7-hydroxy-3-methyl-4a. 9,10,10a-tetrahydro- ⁇ H-phenanthren-l-one (ElOa : and frac)-f4aR 0aR)-10a-ethyl-7-h ⁇ droxy-3-methyl-4a. 9.10.10a-tetrahvdro- H- phenanthren-1-one (ElOb).
  • Step 1 (rac)-(2R,3R)-(rac)-(2S,3R)-3- ⁇ I yl- ⁇ ent-4-en-2-ol.
  • the crude product was purified by silica gel flash chromatography using EtOAc :r ⁇ -heptane (3:7) as eluent, to yield (rac)-(2R, 3R)-(rac)-(2S, 5RJ-3-ethyI-pent-4-en-2-ol as an oil.
  • Example 11 Synthesis of (r ⁇ c)-(lR.2S.4 ⁇ S.10 ⁇ S)-l-bx ⁇ t ⁇ l-7- vdroxy- 2-methyl-1. 4.4a.9.10.10a-hexahvdro- H-phenanthren-3-one (Ella): (r ⁇ c)- (lR.2R.4 ⁇ S.10 ⁇ S)- l-butyl-7-hvdroxy-2- methyl-1, 4,4a,9,10,10a-hexahydro- H-phenanthren-3-one ( ⁇ ll ): and (r ⁇ c)- (lS.4R.4 ⁇ RJ0 ⁇ S)-l-b tyl-7-h ⁇ droxy-4- methyl-1.4.4a.9.10. 10a-hexahydro--?H-phenanthren-3-one (Ellc).
  • Step 2 (rac)-(lR, 2S, 4aS, 1 OaS) A -Butyl-7-hydroxy-2-methyl- 1 ,4,4a,9, 10,10a-hexahydro-2H-phena nthren-3-one and (rac)-(lR, 2R, 4aS, 1 OaS) A -Butyl-7-hydroxy-2-methyl- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3-one and (rac)-(lS,4R,4aR,10aS)A- Butyl-7-hydroxy- 4-methyl-l,4,4a,9,10, 10a-hexahydro-2H-phenanthren-3-one.
  • Example 12 Synthesis of (rac)-(lR.2R.4aS.10aS)A-butyl-33-e thanediyldimercapto -7-hydroxy-2-methyl-1.2.3.4,4a.9.10.10a-octahvdro-phenanthrene (E12a ⁇ : and (rac)- (lR.2S.4aS.10aS)A-butyl-33- ethanediyldimercapto-7-hvdroxy -2-methyl-1.2.3.4.4a. 9.10.10a-octahvdro-phenanthrene rE12fr..
  • reaction mixture was then washed with l.OM HCl (aq, 3 x 100 mL), water (200 mL), saturated Sodium bicarbonate (100 mL), and saturated NH 4 C1 (100 mL) before drying over anhydrous magnesium sulfate and concentration in vacuo.
  • the crude product thus obtained was purified by silica gel flash chromatography, using EtOAc :n-heptane (1:9, 2:8, 3:7, stepwise gradient) as eluent, to yield pure 2-iodo-4-(4-methoxy-benzyloxy)-benzaldehyde in the first eluted fraction as a yellowish solid, together with a mixture of unconsumed 4-hydroxy-2-iodo-benzaldehyde and pure 2-iodo-4-(4-methoxy-benzyloxy)-benzaldehyde in the second.
  • Step 2 4-[2-Iodo-4-(4-methoxy-benzyloxy)-phenyl]-but-3-en-2-one.
  • 2-iodo-4-(4-methoxy-benzyloxy)-benzaldehyde (14.7 g, 39.9 mmol) in a water:acetone mixture (150 mL, 1:2) was added aqueous NaOH (16.0M, 1.2 eq.) before heating at reflux for 10 min.
  • the first eluted fraction contained a mixture of (rac)-(4aR,10aS)- 7-hydroxy- 10a-methyl-4a,9, 10, 1 Oa-tetrahydro- ⁇ H-phenanthren-3-one and (rac)-(4aS, 10aS)-7- hydroxy-10a-methyl-4a,9,10,10a-tetrahydro- ⁇ H-phenanthren-3-one, and the second also a mixture but with different proportions.
  • Example 14 Synthesis of (rac)- (lS.4aS,10aS)-33- ethanedivdimercapto -7-hvdroxy-l- (3-methyl-butyr)- 10a-methyl-l,2.3.4.4a,9.10. lOa-octahvdro- phenanthrene (E14).
  • Example 15 Synthesis of (rac)-(lS.4aSJ0aS)-7-hvdroxy-10a-methylA- phenethyl-l,4.4a.9,10 0a-hexahydro- H-phenanthren-3-one ( ⁇ 15).
  • the crude product was purified by silica gel flash chromatography, using EtOAc: ⁇ -heptane (1:9, 15:85, 2:8, v:v; stepwise gradient) as eluent, followed by P ⁇ PLC to yield (rac)-(lS,4aS,10aS)-7-bydxoxy- ⁇ Oa-methyl- 1- ⁇ henethyl- l,4,4a,9,10,10a-hexahydro-2H-phenanthren-3-one together with unconsumed (rac)-(4aS, 1 OaS) - -by dxoxy- 10a-methyl-4a,9, 10, 10a-tetrahydro- H-phenanthren-3-one.
  • Example 16 Svnthesis of (rac)-(lS.2S.4aS.10aS)-7- ⁇ droxy-2 ⁇ 0a- dimethyl-1- r3-methvI-butyl)-l,4.4a.9.10.10a-hexahvdro- H-phenanthren-3-one fE16a ⁇ : and (rflc -( S.2R. a ⁇ ⁇ / S , )-7-Hydro ⁇ y-2. 10a-dimethyl-l-(3-methyl-butvn-1. 4.4a.9. 10,10a-hexahvdro- H-phenanthren-3-one fE16b).
  • Step 1 4-Benzyloxy-2-iodo-benzaldehyde.
  • Step 2 4-(4-Benzyloxy-2-iodo-phenyl)-but-3-en-2-one.
  • 4-benzyloxy-2-iodo-benzaldehyde 17.73 g, 52.4 mmol
  • aqueous NaOH 16.0M, 1.2 eq.
  • the second eluted material contained a mixture of (rac)-(4aS,10aS)-7-benzyloxy- 10a-methyl-4a,9,10, lOa-tetrahydro- 4H- phenanthren-3-one and (rac)-(4aS, 10aR)-7 -benzyloxy- 10a-methyl-4a,9,10, lOa-tetrahydro- ⁇ H-phenanthren-3 -one.
  • the crude product was purified using PHPLC to yield a mixture of (rac)-(lS,2S,4aS, 10aS)-7-bydxoxy-2, 1 Oa-dimethyl- 1 -(3-methyl-butyl)- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3 -one and (rac)-(lS, 2R, 4aS, 1 OaS) -7 -by dxoxy-2, 1 Oa-dimethyl- 1 -(3-methyl-butyl)- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3-one as a colorless glass.
  • Example 19 Synthesis of t flcJ-( bS ⁇ R.gfl>y)-8a-methyl-8-(3-methvI-butvn-4b.5.6.7.8.8a. 9.10-octahvdro- phenanthren-2-ol (E19a : and (rac)-(4bS.6R.8S.8aS)-6-et ylsul ⁇ anyl-8a-met ⁇ l-&- (3-methyl-butyl)-4b.5.6.7.8.8a.9,10-octahvdro-phenanthren-2-oi rE19b).
  • the crude product was first purified on PHPLC, followed by fractionation on chromatotron, using EtOAc : ⁇ .-heptane (2:8, 3:7, v:v, stepwise gradient) as eluent, to yield (rac)-(4bS,8R,8aS)- 8a-methyl-8-(3-methyl-butyl)-4b,5,6,7,8,8a, 9,10-octahydro-phenanthren-2-ol as a colorless glass in the first eluted fraction and (rac)-(4bS,6R,8S,8aS)-6-etbyls ⁇ xlfanyl ⁇ 8a-xnetbyl- 8-(3-methyl-butyl)-4b,5,6,7,8,8a,9,10-octahydro-phenanthren-2-ol (1.3 mg) in the second.
  • Example 20 Synthesis of (rac)-(lS,4aS,10aS)-33-(propane-l. 3-diyldimercapto)-7-hydroxy-l-(3-methyl-butyI)- lOa-methyl- 1.2.3,4,4a,9., 10.10a-octahydro-phenanthrene (E20 .
  • Example 21 Synthesis of (rac) ⁇ (4as.l0as)-7-hvdroxy-10a- methyl-1.4.4a. 9.10. 10a-hexahvdro-2H-phenanthren-3-one (E21).
  • Example 22 Synthesis of (mc)- flS' flflS)-3.3-ethanediyldimercapto-7- hydroxy-10a-methyl-l,2,3,4.4a,9.10.10a-octahydro-phenanthrene (E22 .
  • Example 23 Synthesis of (rac)-(4aS.10aS)- 10a-ethvI-7-hvdroxy-1.4.4a.9.10. lOa-hexahvdro- 2H-phenanthren-3-one (E23).
  • Step 1 (rac)-2-Ethyl-but-3 ⁇ en-l-ol.
  • a crude product was obtained. This was purified by distillation (68-70 °C/80 mmHg) to yield (rac)-2-ethyl-but-3-en-l-ol as a colorless oil.
  • Step 3 (rac)-(4aS,l OaS) AOa-Eihyl-7-bydxoxy l,4,4a,9,10,10a-hexahydro-2H-phenanthren -3 -one.
  • the crude product was purified on chromatotron, using EtOAc: ⁇ --heptane (1 :9) as eluent.
  • the main fraction contained (r ⁇ c)-(4 ⁇ S, 10 ⁇ S)A 0a-ethyl-7-hydroxy- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3-one.
  • Example 24 Synthesis of c)- ⁇ gS 0 ⁇ S')-3.3-ethanediyldimercapto-10a -ethyI-7-hvdroxy -1.2.3.4.4a,9,10, 10a- octahvdro-phenanthrene (E24 .
  • the first eluted fraction was then further fractionated using P ⁇ PLC to yield (r ⁇ )-( ⁇ S,70 ⁇ )-3,3-ethanediyldimercapto- 10a- ethyl-7-hydroxy-l,2,3,4,4a,9,10,10a-octahydro-phenanthrene (white solid).
  • Example 25 A pharmaceutical formulation comprising ⁇ rae)- (lR,2R,4aS.10aS) -l-butyl-3. 3-ethanediyldimercapto-7-hvdroxy-2-methyl-1.2.3.4.4a.9. 10. lOa-octahvdro-phenanthrene.
  • Step 1 The enone
  • Example 27 Synthesis of (lS aSJOaS) -7-hydroxy-10a-methyl-l- (3-methyl-hutvn-1.4.4a.9.10.10a-hexahvdro-2H-phenanthren-3-one nE27 ⁇ .
  • Step 1 The racemic mixture of (IS, 4 aS,l OaS) -7-benzyloxy-l Oa-methyl- 1- (3-methyl-butyl)-l,4,4a,9,10,10a-hexahydro-2H-phenanthren-3-one from Example 13 was purified by chiral ⁇ PLC to afford two pure enantiomers (17 and 21 mg), (lR,4aR, lOaR) -7-benzyloxy- 1 Oa-methyl- 1 -(3-methyl-butyl)- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3 -one resp. (lS,4aS,10aS) -7-benzyloxy- 10a- methyl- 1- (3-methyl-butyl)- 1, 4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3 -one.
  • Step 2 The reaction was carried out on 17mg (lR,4aR, lOaR) -7-benzyloxy- 1 Oa-methyl- 1 - (3-methyl-butyl)- l,4,4a,9,10,10a-hexahydro-2H-phenanthren-3-one for 20 h according to method F using T ⁇ F (4.0 mL) as solvent, and 10% Pd/C (33.0 mg) as catalyst.
  • Example 28 Synthesis of (lR.4aRS.10aR) -7-benzvIoxy-10a-methyl-l- (3-methyl-butvD-1.4.4a. 9.10. 10a-hexahvdro-2H-phenanthren-3-one (E28).
  • reaction was carried out on 21 mg (lS,4aS,10aS) -7-hydroxy-l Oa-methyl- 1- (3-methyl-butyl)-l,4,4a,9,10,10a-hexahydro-2H-phenanthren-3-one for 20 h according to method F using T ⁇ F (4.0 mL) as solvent, and 10% Pd/C (33.0 mg) as catalyst.
  • Example 29 Synthesis of (rac)-(lS.4aS.10aS)A-(3-met xl-butv ⁇ )-3. 3-ethanediyldimercapto-7- hydroxy-1.4,4a, 9.10.10a-octahvdrophenanthrene (E29).
  • Example 30 Synthesis of ⁇ • gc)-( aR.10flR)-7-hydroxy-4a,lOa-dimethyl -3,4.4a.9,10.10a-hexahvdro-iH-phenanthren-2-one fE30 .
  • Step 1 7-Methoxy-4-methyl-l,2-dihydro-naphthalene: A solution of 31.8 g (180 mmol, 1.0 eq.) of 6-methoxy-l -tetralone in dry THF (100 mL) was added dropwise while stirring to a solution of methyl lithium (1.6 M in diethyl ether, 2.3 eq.) during approximately 1 h. Stirring was continued for another 2 h before slow addition of 200 mL of 5.0 M aqueous HCl. The phases were separated after vigorous stirring for 3 h. The aqueous phase was extracted with diethyl ether (4 x 100 mL) and the combined organic phases were dried over anhydrous sodium sulfate.
  • Step 2 (r ⁇ c -6-Methoxy-l-methyl-3,4-dihydro-7H-naphthalen-2-one: The reaction was carried out on 24.8 g (142 mmol) of 11, dissolved in 600 mL DCM according to method L to give r c -6-Methoxy-l-methyl-3,4-dihydro-iH-naphthalen-2-one as a yellowish oil after purification of the crude product by silica gel flash chromatography, using EtOAc :n-heptane (1:9, 2:8, stepwise gradient) as eluent.
  • Step 3 (r ⁇ c)-7-Methoxy-4a-methyl-4,4a,9,10-tetrahydro-5H-phenanthren-2-one: Coupling of a solution of (7- ⁇ c)-6-Methoxy-l-methyl-3,4-dihydro-7H-naphthalen-2-one (2.10 g, 11.0 mmol) dissolved in toluene (10 mL) with but-3-en-2-one in accordance with method M after purification of the crude product by silica gel flash chromatography using EtOAc :r ⁇ -heptane (3:7) as eluent, afforded (rac -7-Methoxy-4a-methyl-4,4a, 9,10-tetrahydro-5H-phenanthren-2-one as a yellowish solid.
  • Step 4 7-Methoxy-4a, 10a-dimethyl-3,4,4a,9, 10, 10a-hexahydro-7H-phenanthren-2-one: The reaction was carried out on 200 mg (0.83 mmol) of (r ⁇ -7-Methoxy-4a-methyl-4, 4a,9,10-tetrahydro-3H-phenanthren-2-one dissolved in T ⁇ F (10 mL), according to method Q using the following conditions: Titanium (IN) isopropoxide (1.3 eq, suspension in 3 mL T ⁇ F), methylmagnesium chloride (3M solution in T ⁇ F, 1.3 eq.), nickel(II)acetylacetonate (0.05 eq.), reaction-time and temperature (1 h from -15°C to 0 °C, quenching at r.t.).
  • Example 31 Synthesis of (rac)-(lS,4aS,10aS) -7-hydroxy-10a-methyl-4-phenyl- 1.4.4a,9,10.10a-hexahydro-2H-phenanthren-3-one (E31).
  • Step 1 (2)-5-(4-Benzyloxy-2-iodo-phenyl)-4-phenyl-pent-4-en-2-one.
  • the crude product was purified by flash chromatography using EtOAc :n-heptane (2:8) as eluent to yield (Z)-5-(4-Benzyloxy-2-iodo-phenyl)-4-phenyl-pent-4-en-2-one as a yellowish oil.
  • Example 33 Synthesis of ⁇ mc)-fiS. ffS flg ')-3,3-(ethane-l,2-divIdimercapto)- 7- hydroxy- l-(2-phenylethylV10a-methyl-1.2.3.4.4a.9.10.10a-octahydro-phenanthrene
  • the crude product was purified by MPLC, using C ⁇ 2 C1 2 : MTBE (100:0, 90:10, v:v) as eluent to yield colorless glasses of (rac)-(4aS,10aS)-3,3- ethanediyldioxy-7-hydroxy- 1 Oa-methyl- 1 ,2,3 ,4,4a,9, 10, 1 Oa-octahydro-phenanthrene (E34a), contaminated with 10% of E34b and (rfl ⁇ )-( ⁇ S, 0 R -3,3-ethanediyldioxy -7-hydroxy- 1 Oa-methyl- 1 ,2,3,4,4a,9, 10, 1 Oa-octahydro-phenanthrene (E 101 b), contaminated with 10% of ElOla.
  • Example 35 Synthesis of (rac)-(3S,4aS J0aS)-7- vdroxy-3-Oentyl-10a-metkyl ⁇ l. 2,3,4.4a,9.10.10a-octahvdro-phenanthrene (E35a) and (rac)-(3R.4aS.10aS) -7-hydroxy-3-pentvI-10a-methvI-l, 2,3,4,4a,9.1,10a-octahydro-phenanthrene (E35h).
  • Step2 Crae -(3S ⁇ S ) i0 ⁇ S -7-benzyloxy-3- hydroxy-3-(l-pentyl)-10a-methyl-l,2,3,4, 4a,9, 10,1 Oa-octahydro-phenanthrene and (rac)-(3S,4aR,10aS)-7 - benzyloxy-3 -hydroxy-3 -( 1 -pentyl-5-en)- 1 Oa-methyl- 1 ,2,3 ,4,4a,9, 1 , 1 Oa-octahydro- phenanthrene.
  • Step 3 (rac)-(3S,4aS,10aS)-7-bydxoxy-3-( -pentyl)- 1 Oa-methyl- 1, 2,3 ,4,4a,9, 10,10a- octahydro-phenanthrene.
  • the crude material from step 2 was treated with phosphoric acid (85%) at 140 °C for 1 hour, followed by extraction with EtOAc/ ⁇ 2 O and dried with anhydrous sodium sulphate.
  • the crude product is purified on chromatotron using EtOAc/n-heptane (1:9, v:v) as eluent, followed by PHPLC to yield a mixture of (rac)-(3S,4aS,10aS)-7 -bydxoxy- 3-(l-pentyl)-10a-methyl-l, 2,3,4,4a,9,10, 1 Oa-octahydro-phenanthrene (E35a) and (rac)-(3R,4aS,10aS)-7 -bydxoxy- 3-(l -pentyl) -1 Oa-methyl- 1, 2,3, 4,4a,9, 10,1 Oa-octahydro-phenanthrene.
  • Example 36 Synthesis of (rac) ⁇ (lS.2R.4aS.10aS)-2 ⁇ 0a-dimethyl-33- fethane-1. 2-diyldimercapto) -7-hvdroxy-l-(3-methyl-butyl-1.2.3.4.4a. 9.10. 10a- octahydro-phenanthrene E36).
  • Example 37 Synthesis of (rac) ⁇ (lS.4aSJ0aS)- 7-Hvdroxy-l- G'-methyl-butyf. -1.4. 4a.9.10.10a-hexahvdro-2H-phenanthren-3-one (E37).
  • Step 1 (r c ( ⁇ S,i0-.S 7-Benzyloxy-4a,9,10,10a-tefrahydro- ⁇ H-phenanthren-3-one.
  • Step 2 '-methyl-butyl)- 1 ,4,4a,9, 10, 1 Oa-hexahy- dro-2H-phenanthren-3-one.
  • the enone (rac)-(4aS,10aS)-7-benzyloxy-4a_9,lO, 10a-tetrahydro- ⁇ H-phenanthren-3-one (50 mg) dissolved in T ⁇ F (5.0 mL), was treated according to method E ("J” lithium 2-thienylcyanocuprate (Aldrich, no.
  • Step 3 (rac)-(lS, 4aS, 10aS)- -Bydxoxy- 1 -(3 '-methyl-butyl)- 1 ,4,4a,9, 10, 1 Oa-hexahy- dro-2H-phenanthren-3-one.
  • Example 38 Synthesis of (rac)-(4aS.10aS)-33-(propane-l, 3-diyldimercaptoV7-hydroxy-1.2.3,4,4a.9.10.10a-octahvdro-phenanthrene (E38).
  • Example 39 (rac)-(lS,4S.4aSJ0aS)-7-Jivdrox ⁇ -l-butyl-4 ⁇ 0a-dimeth ⁇ l 1.4. 4a.9. 10. 10a-hexahvdro-2H-phenanthren-3-one (E39).
  • Step 1 (rac)-(4R, 4aS, 70 ⁇ S 7-Benzyloxy-4,10 -dimethyl-4a,9, 10, lOa-tetrahydro- ⁇ H-phenanthren-3-one and (rac)-(4S, 4aS,10aS)-7-benzyloxy-4, 10 ⁇ -dimethyl-4a, 9,10, 10a-tetrahydro- H-phenanthren-3-one.
  • Step 2 (rac)-(lS,4S,4aS,10aS)-7-BenzyloxyA-butyl-4, 1 Oa-dimethyl- 1,4,4a, 9, 10,10a-hexahydro-2H-phenanthren-3-one.
  • Step 3 (rac)-(lS,4S,4aS,10aS)-7-Bydxoxy- l-butyl-4, 1 Oa-dimethyl- l,4,4a,9, 10, 10a- hexahydro-2H-phenanthren-3-one.
  • Example 40 Synthesis of fmc)-t S. flS.i0aS ) -3,3-ethanediyldimercapto-7-hvdroxy-4. 10a-dimethyl-1.2,3.4.4a.9.10.10a-octahvdro-phenanthrene (E40
  • Step 1 (rac)-(4S,4aS,10aS)- -Bydxoxy-4, 1 Oa-dimethyl- l,4,4a,9, 10,10a- hexahydro -2H-phenanthren-3-one.
  • Step 2 (rac)-(4S, 4aS, 10aS)-3, 3 -ethanediyldimercapto-7- hydroxy-4, 1 Oa-dimethyl- 1, 2,3 ,4,4a,9, 10, 1 Oa-octahydro-phenanthrene.
  • the crude product was purified using P ⁇ PLC to yield (rac)-(4S,4aS,10aS)-3, 3 -ethanediyldimercapto-7-hydroxy-4, 1 Oa-dimethyl- 1 ,2,3 ,4,4a,9, 10, 10a- octahydro- phenanthrene as a glass.
  • Example 41 (rac)-(4S.4aS.10aS)-7- ⁇ .vdroxy-4-benzyl- lOa-methyl-1 . 4.4a.9.1 0. 10a-hexahydro- H-phenanthren-3-one (E41a) and (rac)-(4aS 0aS)-7- vdrox ⁇ -4A-dibenzyl-10a- methyl-1.4,4a.9. 10.10a- hexahydro -2H -phenanthren-3-one (E41b).
  • Step 1 r c -( S, ⁇ S,i0 ⁇ S 7-Benzyloxy-4-benzyl-10a-methyl-l, 4,4a,9, 10, 10a- hexahydro-2H-phenanthren-3-one and (rac)-(4aS,10aS)-7-benzyloxy-4, 4-dibenzyl- 1 Oa-methyl- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3 -one.
  • Step 2 raeA ⁇ S 10 ⁇ S 7-hydroxy-4-benzyl- 1 Oa-methyl- l,4,4a,9, 10, lOa-hexahydro - 2H-phenanthren-3-one.
  • Step 3 fr c -( S 0 S 7-Hydroxy-4,4-dibenzyl-l Oa-methyl- l,4,4a,9, 10, lOa-hexahydro -2H-phenanthren-3-one.
  • Example 43 Synthesis of (rac)-(4aS.10aS)-33-ethanediyl -7-hydroxy -10a- methyl-1. 2.3,4, 4a,9.10, lOa-octahydrophenanthrene (E43 .
  • Example 44 Synthesis of c)-t3R. «S'.i0gS')-l , .2 , .3 , .4 , -tetrachloro-7-hvdro ⁇ y-10a- methyl-1.2,3,4,4a,9.10.10a-octahvdrospiro[phenanthrene-3,6'-cyclohexane -l f .3 / -diene fE44 ⁇ .
  • Example 46 Synthesis of (rac)-(3S.4aS.10aS)-7-hvdroxy-10a-v ⁇ ethyl- 23 ⁇ a.9. 10,10a-octahydrospiro[phenanthrene-3,2'-cvcIobutanej-r-one fE46a) and (r ⁇ c)-(3R.4 ⁇ S.10 ⁇ S)-7- vdroxy-10a-met v ⁇ A .2.3.4.4a.9.10. lOa-octahvdrospiro [phenanthrene-3,2 , -cyclobutane -l'-one (E46b
  • Example 47 Synthesis of tr ⁇ c)- ⁇ iS, ⁇ S.i0tfS')-l',l'-ethanediyldimercapto-7- hvdroxy-10a-methvI-1.2.3.4.4a.9.10.10a-octah y dros p iro phenanthrene-3.2 '-cvclobutanel (E41).
  • Example 48 Synthesis of (r ⁇ c)-(4 ⁇ S.l fl ⁇ S)-7-hvdroxy-10a-methyl-1.2.3.4.4a.9.10. 10a-octahvdrospiro[phenanthrene-3.1'-cyclobutane] E48).
  • Example 49 Synthesis of frac)- ⁇ £iflgS')-3-(l-cvclopenten-l-vf)-7- hvdroxy-10a-methyl-l,4,4a,9,10,10a-hexahydrophenanthrene ( ⁇ 49 .
  • Step 1 (r- ⁇ )- S,70 ⁇ 5 ⁇ )-3,7-dihydroxy-10a-methyl-3- [l-(phenylsulphinyl) cyclopentyl] -l,2,3,4,4a,9,10,10a-octahydrophenanthrene (mixture of diastereomers).
  • r ⁇ -BuLi (1.60 mL of 1.6 M solution in hexanes, 2.40 mmol) was added to a solution of cyclopenthylphenylsulphoxide (466 mg, 2.40 mmol) in THF (15 mL) under cooling to -70°C. The reaction mixture was allowed to warm to r.t. and then was cooled to 0°C.
  • Step 2 (rac)-(4aS, 10aS)-3-(l-cyclopenten-l-y ⁇ )-7-bydxoxy- 1 Oa-methyl- l,4,4a,9, 10, lOa-hexahydrophenanthrene.
  • Example 50 Synthesis of (rac)-(3S.4aS.10aS)- -hvdroxy-lOa-methyl-l.2.3. 4.4a.9.10,10a.2',3'.4'.5'- dodecahvdrospiro[phenanthrene-3.2'-furanl (E50a) and trac)-t3R. S.i0 S')-7-hvdroxy-10a-methyl-1.2.3.4.4a.9.10. 10a.2'.3'. 4'.5'-dodecahvdrospiro[phenanthrene-3.2'-furan] (E50b).
  • Step 2 (racA ⁇ S J i0 ⁇ S 3,7-dihydroxy-3-(3-hydroxy ⁇ ropyl)- 1 Oa-methyl- 1,2,3, 4,4a,9,10, 1 Oa-octahydrophenanthrene (mixture of diastereomers).
  • Step 3 (rac)-(3S,4aS,10aS)-3, -dibydxoxy-3-[3-[ (4-methylphenyl) sulphonyloxy] propyl] - 1 Oa-methyl- 1 ,2,3,4,4a,9, 10, 1 Oa-octahydrophenanthrene and (rac)-(3R, 4aS,10aS)-3, 7-dihydroxy-3- [3 -[(4-methylphenyl) sulphonyloxy]propyl]- 1 Oa-methyl- 1,2, 3,4,4a,9,10, 1 Oa-octahydrophenanthrene.
  • Step 4 (rac)-(3S,4aS,l 0aS)-7-bydxoxyA0a-methylA,2,3,4,4a,9, 10,10a,2',3',4',5' -dodecahydrospiro [phenanthrene-3 ,2'-furan].
  • Step 5 (r ⁇ c)-(3R, 4 ⁇ S,10 ⁇ S)-7 -by dxoxy AOa-xne bylA, 2,3, 4,4a,9,10, 10a,2',3',4',5'-dodecahydrospiro[phenanthrene-3,2'-furan].
  • Example 51 Synthesis of (rac)-(3S,4aS 0aS)-7-hvdroxy-10a- ethyl- 23 ⁇ , 4a,9,10,10a,3',4',5'.6'-dodecahvdrospiro[phenanthrene-3,2'-2H-pyran] E51a) and tr ⁇ c)-riR. ⁇ S.i0 S)-7-hvdroxy-10a- methyl-1.2.3.4.4a.9.10.10a.3'.4'.5 , .6'- dodecahv drospiro [phenanthrene-3,2'-2H-pyran] (E51b>.
  • Step 2 (rac)-(3S,4aS,10aS)-3,7-dibydxoxy- 1 Oa-methyl-3- [4- [ (4-methylphenyl) -sulphonyloxy]butyl]- 1 ,2,3 ,4,4a,9, 10,1 Oa-octahydrophenanthrene.
  • Step 3 (rac)-(3S,4aS,10aS)- -bydxoxy A0a- methyl- 1, 2,3, 4,4a,9, 10,10a,3',4',5',6'-dodecahydrospiro[phenanthrene-3,2'-2H-pyran].
  • Step 4 (racA3R ⁇ S70 ⁇ S 3,7-dihydroxy-10a-methyl-3- [4- [(4-methylphenyl) sulphonyloxy]butyl]- 1 ,2,3 ,4,4a,9, 10,1 Oa-octahydrophenanthrene.
  • Step 5 (rac (3R, ⁇ S70 ⁇ S -7-hydroxy-10a-methyl-l,2,3,4,4a,9,10,10a,3',4',5',6'- dodecahydrospiro [phenanthrene-3 ,2 '-2H-pyran].
  • Example 52 Synthesis of (rac)-(lS R aS.lOaS)- 7-hvdroxy- lOa-methyl-1- (3-methylbutyr>-1.2.3.4.4a.9.10. 10a.2'.3'.4'.5'- dodecahydrospiro fphenanthrene -3.2'-furan1 fE52 .
  • Step 1 (rac)-(lS,3R,4aS,10aS)-3,7-dibydxoxyA0a-xnetbylA- (3-methylbutyl)-3- [3-(phenylmethoxy)propyl]- 1 ,2,3 ,4,4a,9, 10, 1 Oa-octahydrophenanthrene.
  • Step 2 (r ⁇ c)-(lS,3R,4 ⁇ S,10 ⁇ S)-3,7-dibydxoxy-3- (3 -hydroxypropyl)- 10a-methyl-l- (3 -methylbutyl)- 1 ,2,3 ,4,4a,9, 10,1 Oa-octahydrophenanthrene.
  • Step 3 (rac)-(lS,3R,4aS,10aS)-3,7-dibydxoxy- 1 Oa-methyl-1 -(3 -methylbutyl)- 3-[3-[(4-methylphenyl)sulphonyloxy]propyl]-l ,2,3,4,4a,9, 10, 1 Oa-octahydrophenanthrene.
  • Step 4 (r ⁇ c (7S5R, ⁇ S,i0 ⁇ S -7-hydroxy-10a-methyl-l-(3-methylbutyl)-l,2,3,4,4a,9,10, 10a,2',3',4',5'-dodecahydros ⁇ iro[phenanthrene-3,2'-furan].
  • Step 1 (rac)-(lS,3R,4aS,10aS)-3,7-dibydxoxyA0a-metbylA- (3-methylbutyl)-3- [ 1 -(phenylthio)cyclopropyl]- 1 ,2,3 ,4,4a,9, 10, 1 Oa-octahydrophenanthrene.
  • Step 3 (rac)-(lS, 4aS, 1 OaS) A', I '-ethanediyldimercapto-7-hydroxy- 1 Oa-methyl- 1 - (3 -methylbutyl)- 1 ,2,3 ,4,4a,9, 10, 1 Oa-octahydrospiro [phenanthrene-3 ,2'-cyclobutane] (mixture of diastereomers).
  • Step 4 (rac)-(lS,4aS, 70 ⁇ S 7-hydroxy-10a-methyl-l-(3-methylbutyl)-l,2,3,4,4a,9,10, 1 Oa-octahydrospiro [phenanthrene-3 , 1 '-cyclobutane] .
  • Example 54 Synthesis of t ⁇ rflc - ⁇ i>S', ⁇ S' 0 S')-7-hydroxy-3-(3-hydroxypropylV c)- >S'.iS'. gS'.10gS)-7-hvdro ⁇ y-10a-methyl-l-r3-methylbutvIV1.2.3.4.4a.9.10. 10a,2',3',4 f ,5'-dodecahydrospirofphenanthrene-3.2'-furan] (E54bV
  • Step l (r ⁇ c ⁇ R,i0 ⁇ R -10a-Butyl-7-methoxy-4a-methyl-3,4,4a,9,10, 10a-hexahydro-jH-phenanthren-2-one: The reaction was carried out on 200 mg (0.83 mmol) of r c)-7-methoxy-4a-methyl-4,4a 5 9, 10-tetrahydro-5H-phenanthren-2-one dissolved in diethylether (3 mL), according to method P except that Cul was used instead of CuCN employing the following conditions; Cul (1.2 eq, suspension in 10 mL diethyl ether), alkyl lithium (n-BxxLi [1.6M solution in hexanes], 2.2 eq.), reaction-time and temperature (30 min.
  • Step 2 (rac)-(4aR, 1 OaR) A 0a-Butyl-7-hydroxy-4a-methyl-3,4,4a,9,l 0,
  • Example 58 rgc>-7-Hydroxy-l,4a-dimethyl-4,4a,9,10-tetrahvdro-iH-phenanthren-2-one E58).
  • Stepl r c -7-Methoxy- 1 ,4a-dimethyl-4,4a,9, 10-tetrahydro-5H ⁇ phenanthren-2-one: Coupling of 200 mg (1.05 mmol) of 6-methoxy-l-methyl-3,4-dihydro- iH-naphthalen -2-one, dissolved in toluene (2.0 mL) with pent- l-en-3 -one in accordance to method M gave (r ⁇ c -7-Methoxy- 1 ,4a-dimethyl-4,4a,9, 10-tetrahydro-3H-phenanthren-2-one which was used without further purification in the next step.
  • Step 2 (rac -7- ⁇ ydroxy- 1 ,4a-dimethyl-4,4a,9, 10-tetrahydro-5H-phenanthren-2-one (E58): The reaction was carried out on crude Cra ⁇ -7-Methoxy-l,4a-dimethyl-4,4a,9, 10-tetrahydro-5H-phenanthren-2-one dissolved in 2.0 mL DCM, using 3.5 eq. of BBr 3 for 16 h according to method O. A V* portion of the crude product was purified using P ⁇ PLC to yield E58 as a yellow solid.
  • the reaction was carried out on a % portion of the crude (r ⁇ c -7-hydroxy-l, 4a-dimeti yl-4,4a,9,10-tefrahydro-3H-phenanthren-2-one (max. 0.262 mmol) dissolved in a mixture of acetonitrile and DCM (2.0+2.0 mL) according to method R (0.20 mL of trifluoro acetic acid was used).
  • the crude product was purified on a chromatotron using EtOAc:rc-heptane (15:85) as eluent followed by P ⁇ PLC, to yield E59.
  • Example 60 Synthesis of fmc)-4b.8-dimethyl-4b,5,6.7.9. 10-hexahydro -phenanthren-2-ol (E60a. E60b. E60c. E60d .
  • Example 61 Synthesis of mc)-t3S'. flR)-7-hydroxy-3,4a-dimethvI-4,4a.9. 10-tetrahvdro-5H-phenanthren-2-one (E61).
  • Step 1 (rac)-(3S,4aR)-7-Metboxy-3,4a-dimetbyl-4,4a,9, 10-tetrahydro-3H- phenanthren-2-one: Coupling of 200 mg (1.05 mmol) of (r ⁇ )-6-methoxy-l-methyl-3, 4-dihydro-7H-naphthalen-2-one dissolved in toluene (2.0 mL) with 3-methyl-but-3-en- 2-one in accordance to method M gave crude (rac)-(3S,4aR)- -M.exboxy-3, 4a-dimethyl-4,4a,9,10-tetrahydro-3H-phenanthren-2-one which was used without further purification in the next step.
  • Step2 (rac)-(3S, ⁇ R 7-Hydroxy-3,4a-dimethyl-4,4a,9, 10-tetrahydro-JH- phenanthren-2-one (28): The reaction was carried out on crude (rac)-(3S,4aR)- 7-Methoxy-3,4a-dimethyl-4,4a,9,10-tetrahydro-3H-phenanthren-2-one using 3.3 eq. of BBr 3 for 16 h according to method O. The crude product was purified using P ⁇ PLC to yield E61.
  • Step 1 (rac)-(4S, ⁇ R ⁇ -7-Methoxy-4a-methyl-4-propyl-4,4a,9,10-tefrahydro-3H-phenanthren-2-one: Coupling of 200 mg (1.05 mmol) of r ⁇ )-6-Methoxy-l-methyl-3,4-dihydro-iH-naphthalen-2-one dissolved in toluene (2.0 mL) with hept-3-en-2-one in accordance to method M gave crude (rac)-(4S, ⁇ R -7-Methoxy-4a-methyl-4-propyl-4,4a,9, 10-tetrahydro-3H-phenanthren-2-one which was used without further purification in the next step.
  • Step 2 (rac)-(4S, R)-7- ⁇ ydroxy-4a-methyl-4-propyl-4,4a,9, 10-tetrahydro-3H-phenanthren-2-one (E62): The reaction was carried out on crude (rac)-(4S, ⁇ R -7-Methoxy-4a-methyl-4-propyl-4,4a, 9, 10-tetrahydro-3H- phenanthren-2-one using 3.3 eq. of BBr 3 for 16 h according to method O. The crude product was purified using P ⁇ PLC to yield E62.
  • Example 63 Synthesis of fmc)-t ⁇ Jg. ffR)-7-Hydroxy-4,4a-dimethyl-4,4a.9. 10-tetrahydro-3H-phenanthren-2-one (E63a) and (rac)-(4S.4aR)-7-Ilvdroxy-4. 4a-dimethyl-4,4a,9,10-tetrahvdro-iH-phenanthren-2-one (E63b).
  • Step 1 (r ⁇ c)-(4R,4aR)-7-Methoxy-4,4a-dimethyl-4,4a,9,
  • Step 2 (rac)-(4R,4aR)-7 -Bydxoxy-4,4a-dixnetbyl-4,4a,9, 10-tetrahydro- 3H-phenanthren- 2-one (E63a) and (rac)-(4S,4aR)- -Bydxoxy-4, 4a-dimethyl-4,4a,9, 10-tetrahydro -JH-phenanthren-2-one (E63b): The reaction was carried out on the crude mixture of (r ⁇ c)-(4R,4aR)-7-Methoxy-4,4a-dimethyl-4,4a,9, 10-tetrahydro-3H-phenanthren-2-one and (rac)-(4S, R)-7-Methoxy-4,4a-dimethyl-4,4a,9, 10-tetrahydro-3H-phenanthren-2-one using 3.3 eq.
  • Example 64 Synthesis of gc)-l-EthyI-7-hvdroxy-4a-methyl-4,4a ,9. 10-tetrahvdro-jH-phenanthren-2-one (E64).
  • Step 1 (rac) A -Ethyl-7-methoxy-4a-methyl-4,4a,9, 10-tetrahydro-3H-phenanthren-2-one.
  • Coupling of 569 mg (2.99 mmol) of (r ⁇ -6-methoxy-l-methyl-3,4-dihydro- /H-naphthalen-2-one dissolved in toluene (5.0 mL) with hex-l-en-3-one in accordance to method M gave crude (rac)- l-Ethyl-7-methoxy-4a-methyl-4,4a, 9,10-tetrahydro-3H- phenanthren-2-one, which was used without fiirther purification in the next step.
  • Step 2 (rac) A -Ethyl-7-hydroxy-4a-methyl-4,4a,9, 10-tetrahydro-3H-phenanthren-2-one.
  • the reaction was carried out on crude (r ⁇ -l-Ethyl-7-methoxy-4a-methyl-4,4a, 9,10-tetrahydro-3H-phenanthren-2-one (max. 2.99 mmol) dissolved in 6.0 mL DCM, using 3.0 eq. of BBr 3 for 5 h according to method O.
  • the crude product was purified on a chromatotron using EtOAc: «-heptane (3:7, 6:5, 5:5, v:v, stepwise gradient) as eluent to yield E64.
  • ES-MS m/z 257.2 (pos, M+ ⁇ ), 255.4 (neg, M- ⁇ ); ' ⁇ MR (CD 3 OD) ⁇ 7.1-7.2 (m, 1 ⁇ ), 6.10 (dd, 1 ⁇ ), 6.55 (d, 1 ⁇ ), 2.25-3.00 (m, 10 ⁇ ), 1.55 (s, 3 ⁇ ), 1.25 (t, 3H).
  • Example 65 Synthesis of trac)-8-Ethyl-4b-methyI-4b,5,6.7.9. 10-hexahvdro- phenanthren-2-ol (E65V
  • Example 66 Synthesis of ⁇ • c ) -( ⁇ R 0aR S')-l-Ethyl-7-hvdroxy-4a-methyl-1.4.4a.9. 10,10a-hexahydro-3H-phenanthren-2-one (E66).
  • Step 1 (rac)- 1 -Butyl-7-methoxy-4a-methyl-4,4a,9, 10-tetrahydro-3H-phenanthren-2-one: Coupling of 220 mg (1.16 mmol) of (r ⁇ c -6-methoxy-l-methyl-3, 4-dihydro-iH-naphthalen-2-one dissolved in toluene (2.0 mL) with oct-l-en-3-one in accordance to method M gave, after purification of the crude product by silica gel flash chromatography using EtOAc:r ⁇ -heptane (3:7) as eluent, (rac) A -Butyl-7-xnetboxy- 4a-methyl-4,4a,9,10-tetrahydro-3H-phenanthren-2-one as a yellowish oil.
  • Step 2 (rac) A -Butyl-7-hydroxy-4a-methyl-4,4a,9, 10-tetrahydro-3H-phenanthren-2-one (40).
  • the reaction was carried out on 220 mg of (r ⁇ -l-Butyl-7-methoxy-4a- methyl-4,4a,9,10-tetrahydro-3H-phenanthren-2-one dissolved in 5.0 mL DCM using 3.5 eq. of BBr 3 for 4 h according to method O.
  • the crude product was purified on a chromatotron, using EtOAc :r ⁇ -heptane (3:7,v:v) as eluent to yield E67 as a yellowish oil.
  • Example 68 Synthesis of fmc)-8-Butyl-4b-methyl-4b. 5.6.7.9. 10-hexahvdro-phenanthren-2-oHE68 .
  • Example 69 Synthesis of (rac)-(8R.4bR.8aR)-8- utyl-4b- methyl-4b.5.6.7. 8.8a.9. lO-octahvdro-phenanthren-2-ol flE69a): and (rac)-(8S.4bR.8aR)-8-Butyl-4b- methyl-4b.5.6.7,8,8a,9.10-octahvdro-phenanthren-2-oI ( ⁇ 69bV
  • the reaction was carried out on 25 mg of (r ⁇ c)-8-butyl-4b-methyl-4b,5,6,7, 9, lO-hexahydro-phenanthren-2-ol for 12 h according to method S except that the reaction was run under pressure (6.0 bar) using methanol (2.0 mL) as solvent, and 5% Pd/C (12 mg) as catalyst.
  • the crude product was fractionated using PHPLC to E69a as the first eluted material and E69b as the second.
  • E69a ES-MS m/z: 273.1 (pos, M+H) 271.0 (neg, M-H); ⁇ NMR (CDC13) ⁇ 7.10 (d, IH), 6.60 (dd, IH), 6.55 (d, IH), 2.70-2.75 (m, IH), 2.55-2.65 (m, IH), 2.30 (d, IH), 2.00-2.05 (m, IH), 1.80-1.85 (m, IH), 1.65-1.70 (m, IH), 1.45-1.50 (m, 2H), 1.05-1.35 (m, 10H), 1.10 (s, 3H), 0.95-1.00 (m, IH), 0.90 (t, 3H).
  • E69b ES-MS m/z: 273.1 (pos, M+H), 271.0 (neg, M-H); 'H NMR (CDC13) ⁇ 7.10 (d, IH), 6.60 (dd, IH), 6.50 (d, IH), 2.80 (dd, 2H), 2.25 (d, IH), 1.90-2.00 (m, IH), 1.65-1.75 (m, 2H), 1.60-1.75 (m, IH), 1.60-1.65 (m, 2H), 1.50-1.60 (m, IH), 1.45-1.50 (m, IH), 1.25-1.45 (m, 8H), 1.10 (s, 3H), 0.90 (t, 3H).
  • Example 70 Synthesis of frac)-4a-Butyl-7-hvdroxy-l-methyl-4,4a,9. 10-tetrahydro-3H-phenanthren-2-one (E70).
  • Step 1 4-Butyl-7-methoxy-l,2-dihydro-naphthalene: A solution of 5.29 g (30 mmol, 1.0 eq.) of 6-methoxy-l -tetralone in dry THF (25 mL) was added dropwise while stirring, to a mixture of butyl lithium (1.6 M solution in hexanes, 2.1 eq.) and THF (40 mL) during approximately 30 min. Stirring was continued for another 30 min. before slow addition of 2.0 M aqueous HCl (150 mL). The phases were separated after vigorous ⁇ stirring for 2 h.
  • the aqueous phase was extracted with diethyl ether (3 x 50 mL) and the combined orgranic phases were dried over anhydrous sodium sulfate.
  • the crude product obtained upon concentration of the extract in vacuo, was purified by silica gel flash cliromatography using EtOAc: ⁇ .-heptane (0:10, 1:9, stepwise gradient) as eluent, to give 4-Butyl-7-methoxy-l, 2-dihydro-naphthalene as a yellowish oil.
  • Step 2 (r ⁇ c -l-Butyl-6-methoxy-3,4-dihydro-/H-naphthalen-2-one: The reaction was carried out on 1.28 g (5.92 mmol) of 4-Butyl-7-methoxy-l,2-dihydro-naphthalene dissolved in 50 mL DCM according to method L to afford (rac)- l-Butyl-6-methoxy-3, 4-dihydro-iH-naphthalen-2-one as a yellowish oil after purification of the crude product by silica gel flash cliromatography, using EtOAc :n-heptane (5:95, 2:8, stepwise gradient) as eluent.
  • Step 3 (rac) -4a-Butyl-7-methoxy- 1 -methyl-4,4a,9, 10-tetrahydro-3H-phenanthren-2-one : Coupling of 100 mg (0.43 mmol) of (r ⁇ c -l-Butyl-6-methoxy-3,4-dihydro- /H-naphthalen-2-one dissolved in benzene (1.0 mL) with pent- l-en-3 -one according to method M, gave after purification of the crude product by silica gel flash chromatography using EtOAc :o-heptane (1:99, 1:9, stepwise gradient) as eluent r ⁇ c -4a-butyl-7-methoxy-l -methyl-4,4a,9,10-tetrahydro-5H-phenanthren-2-one.
  • Step 4 (r ⁇ c -4a-Butyl-7-hydroxy-l-me1nyl-4,4a,9,l0-tetrahydro-3H-phenanthren-2-one (E70).
  • the reaction was carried out on 13mg (r ⁇ c)-4a-butyl-7-methoxy- l-methyl-4,4a, 9,10-tetrahydro-3H-phenanthren-2-one dissolved in 2.0 mL DCM, using 3.0 eq. of BBr 3 for 4 h according to method O.
  • the crude product was purified on a chromatotron, using EtOAc:n-heptane (3:7,v:v) as eluent to afford E70.
  • Step 1 ( ⁇ c)-4a-Butyl-7-methoxy-4,4a,9,10-tetrahydro-3H-phenantl ⁇ ren-2-one: Coupling of 100 mg (0.43 mmol) of (r«cJ-l-butyl-6-methoxy-3,4-dihydro-iH-naphthalen-2-one dissolved in benzene (1.0 mL) with but-3-en-2-one in accordance to method M gave, after purification of the crude product by silica gel flash chromatography using EtOAc: «-heptane (1 :99, 2:8, stepwise gradient) as eluent, (r c -4a-Butyl-7-methoxy-4, 4a,9, 10-tetrahydro -3H-phenanthren-2-one.
  • Step2 r ⁇ c -4a-Butyl-7-hydroxy-4,4a,9,10-tetrahydro-3H- ⁇ henanthren-2-one (E71).
  • the reaction was carried out on 33 mg of (r ⁇ c -4a-Butyl-7-methoxy-4,4a,9, 10-tetrahydro-3H-phenanthren-2-one dissolved in 2.0 mL DCM, using 3.0 eq. of BBr 3 for 4 h according to method O.
  • the crude product was purified on a chromatotron, using EtOAc :n-heptane (3:7,v:v) as eluent to yield E71 as a yellowish solid.
  • Example 72 Synthesis of (rac)-(4aR.10aR-)4a-Butyl- 7-hvdroxy-3.4.4a.9..0. 10a-hexahydro-JH-phenanthren-2-one (E72a); and (r ⁇ c)-(4 ⁇ R.10 ⁇ S)- 4a-Butyl-7-hydroxy-3,4,4a,9, 10,10a-hexahydro- JH-phenanthren-2-one (E72b ⁇ .
  • E72a ES-MS m/z: 273.4 (pos, M+ ⁇ ), 271.3 (neg, M- ⁇ ); ⁇ NMR (CD 3 OD) ⁇ 7.15 (d, 1 ⁇ ), 6.60 (dd, 1 ⁇ ), 6.50 (d, 1 ⁇ ), 1.60-2.80 (m, 13 ⁇ ), 1.20-1.25 (m, 2H), 0.85 (t, 3H); E72b: ES-MS m/z: 273.4 (pos, M+H), 271.3 (neg, M-H); 'HNMR (CD 3 OD) ⁇ 7.10 (d, IH), 6.55 (dd, IH), 6.50 (d, IH), 1.50-2.80 (m, 13H), 1.20-1.25 (m, 2H), 0.85 (t, 3H).
  • Step 1 ra ⁇ )-7-Hydroxy-4a-methyl-4,4a,9,10-tetrahydro-3H-phenanthren-2-one: The reaction was carried out on 570 mg (2.35 mmol) of (r ⁇ c -7-Methoxy-4a-methyl-4, 4a,9,10-tetrahydro-3H-phenanthren-2-one, dissolved in 10.0 mL DCM, using 3.5 eq. of BBr 3 for 20 h according to method O.
  • Step 2 (rac)-(4aR, 10aS)-7-Bydxoxy-4a- etbyl-3,4,4a,9, 10,10a-hexahydro- ZH-phenanthren-2-one (E73):
  • the reaction was carried out on 133.0mg (0.58 mmol) ( ⁇ cJ-7-hydroxy-4a-memyl-4,4a,9,10-tefrahydro-3H-phenanthren-2-one for 2 h according to method S using T ⁇ F (6.0 mL) as solvent, and 10% Pd/C (133.0 mg) as catalyst.
  • the crude product was purified by P ⁇ PLC to yield E73 (81 mg) as a white solid.
  • Example 74 Synthesis of «c>- R.itfff ')-2.2-ethanediyldimercapto-7-hvdroxy-4a- methyl-1.2.3,4.4a,9.10.10a-octahvdrophenanthrene (E74).
  • Example 76 A pharmaceutical formulation comprising (mc)-4b.8-dimethyl-4b. 5.6.7.9.10-hexahydro-phenanthren-2-ol.
  • the scintistrip assay differs from a traditional hormone binding assay by not requiring the removal of free tracer prior to the measurement of receptor bound tracer.
  • the scintillating agent is in the polystyrene forming the incubation vial and thus a radioactive molecule in the close proximity to the surface will induce scintillation of the plastic.
  • [H]- ⁇ -Estradiol hereafter referred to as [H]-E2 was purchased from New England Nuclear, Boston, MA.
  • Human estrogen receptors (hER) alpha and beta were extracted from the nuclei from SF9-cells infected with a recombinant baculovirus transfer vector containing the cloned hER genes. Recombinant baculovirus was generated utilizing the BAC-TO-BAC expression system (Life Technonlogies) in accordance to instruction from the supplier.
  • the hER coding sequences were cloned into a baculovirus transfer vector by standard techniques.
  • the recombinant baculoviruses expressing hER were amplified and used to infect SF9 cells. Infected cells were harvested 48 hr post infection. A nuclear fraction was obtained as described in 2 and the nuclei were extracted with a high-salt buffer (17 mM K-2HPO4, 3 mM KH 2 PO 4 , 1 mM MgCl 2 , 0.5 mM EDTA, 6 mM MTG, 400 mM KC1, 8.7% Glycerol).
  • the concentration of hER' s in the extract was measured as specific [ 3 H]-E2 binding with the G25-assay 3 and was determined to contain 400 pmols specific bound [3H]-E2/mL nuclear extract in the case of hER-alpha and 1000 pmols/mL nuclear for hER-beta.
  • the total concentration of proteins (as determined with Bradford Reagent, Bio-Rad according to instructions from manufacturer) in the nuclear extracts were ⁇ 2 mg/mL.
  • K d The equilibrium binding constant for [ 3 H]-E2 to hER in solution was determined to 0.05 nM for hER-alpha and to 0.07 nM for hER-beta with the G25-assay for highly diluted extracts (hER ⁇ 0.1 nM). The extracts were aliquoted and stored at -80°C.
  • the scintistrip assay In brief; the nuclear extracts were diluted (50 fold for hER-alpha and 110 fold for hER-beta) in coating buffer (17 mM K 2 HPO 4 , 3 mM KH 2 PO 4 , 40 mM KC1, 6 mM MTG). The diluted extracts were added to Scintistrip wells (200 ⁇ L/well) and incubated 18-20 hr. at ambient room temperature (22-25 °C). The estimated final concentration of immobilized hER in all experiments was ⁇ nM. All incubations were performed in 17 mM K 2 HPO 4 , 3 mM KH 2 PO 4 , 140 mM KC1, 6 mM MTG (buffer A). The wells were washed twice after hER coating with 250 ⁇ L buffer prior to addition of the incubation solution. All steps were carried out at ambient room temperature (22-25 °C).
  • the equilibrium binding constants were determined to 0.15 - 0.2 nM for both hER subtypes.
  • IC 50 -value the concentration required to inhibit 50% of the binding of 3 [H]-E2
  • b ((b ra ax-bmm)/(l+(I/IC 5 o) s ))+b m i n
  • I added concentration of binding inhibitor
  • IC 50 is the concentration of inhibitor at half maximal binding
  • S is a slope factor. 1
  • the Microbeta-instrument generates the mean cpm (counts per minute) value / minute and corrects for individual variations between the detectors thus generating corrected cpm values. It was found that the counting efficiency between detectors differed with less than five percent.
  • the compounds of Examples 1-48 exhibit binding affinities to the estrogen receptor ⁇ -subtype in the range of ICso 3 to 10,000 nM and to the estrogen receptor ⁇ -subtype in the range of IC 5 - 3 to 10,000 nM.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant inventive are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restinosis, gynecomastia, autoimmune disease, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer of the lung, colon, breast, uterus, and prrostate.

Description

Novel Estrogen Receptor Ligands and Methods I
Field of Invention
This invention relates to novel compounds which are estrogen receptor ligands and are preferably selective for either the estrogen receptor α or β isoforms, to methods of preparing such compounds and to methods for using such compounds such as for estrogen hormone replacement therapy and for diseases modulated by the estrogen receptor such as osteoporosis, elevated blood triglyercide levels, atherosclerosis, endometriosis, cognitive disorders, urinary incontinence, autoimmune disease, and cancer of the lung, colon, breast, uterus and prostate.
Background of Invention
The estrogen receptor (ER) is a ligand activated mammalian transcription factor involved in the up and down regulation of gene expression. The natural hormone for the estrogen receptor is β-17-estradiol (E2) and closely related metabolites. Binding of estradiol to the estrogen receptor causes a dimerization of the receptor and the dimer in turn binds to estrogen response elements (ERE's) on DNA. The ER/DNA complex recruits other transcription factors responsible for the transcription of DNA downstream from the ERE into mRNA which is eventually is translated into protein. Alternatively the interaction of ER with DNA may be indirect through the intermediacy of other transcription factors, most notably fos and jun. Since the expression of a large number of genes is regulated by the estrogen receptor and since the estrogen receptor is expressed in many cell types, modulation of the estrogen receptor through binding of either natural hormones or synthetic ER ligands can have profound effects on the physiology and pathophysiology of the organism.
Estrogens are critical for sexvial development in females. In addition, estrogens play an important role in maintaining bone density, regulation of blood lipid levels, and appear to have neuroprotective effects. Consequently decreased estrogen production in post-menopausal women is associated with a number of diseases such as osteoporosis, atherosclerosis, and cognitive disorders. Conversely certain types of proliferative diseases such as breast and uterine cancer and endometriosis are stimulated by estrogens and therefore antiestrogens (t'.e., estrogen antagonists) have utility in the prevention and treatment of these types of disorders.
In addition to women suffering from breast cancer, men afflicted with prostatic cancer can also benefit from anti-estrogen compounds. Prostatic cancer is often endocrine sensitive and androgen stimulation fosters tumor growth, while androgen suppression retards tumor growth. The administration of estrogen is helpful in the treatment and control of prostatic cancer because estrogen administration lowers the level of gonadotropin and consequently androgen levels.
The use of natural and synthetic estrogens in hormone replacement therapy has been shown to markedly decrease the risk of osteoporosis. In addition, there is evidence that hormone replacement therapy has cardiovascular and neuroprotective benefits. However hormone replacement therapy is also associated with an increase risk of breast and uterine cancer. It is known that certain types of synthetic ER ligands display a mixed agonist/antagonist profile of activity showing agonist activity in some tissues and antagonist activity in other tissues. Such ligands are referred to as selective estrogen receptor modulators (SERMS). For example tamoxifen and raloxifene are known to be agonists in bone (and therefore prevent osteoporosis) while displaying antagonistic properties in breast (and therefore lowers the risk of breast cancer). However neither tamoxifen nor raloxifene is ideal for hormone replacement therapy as neither of these SERMS are as efficacious as estradiol in preventing bone loss. Furthermore the use of tamoxifen is still associated with an increased risk of uterine cancer and both tamoxifen and raloxifene are known to aggravate hot flashes.
Historically it has been believed there was only one estrogen receptor. However recently a second subtype (ER-β) has been discovered. While both the "classical" ER-α and the more recently discovered ER-β are widely distributed in different tissues, they nevertheless display markedly different cell type and tissue distributions. Therefore synthetic ligands which are either ER-α or ER-β selective may preserve the beneficial effects of estrogen while reducing the risk of undesirable side effects.
What is needed in the art are compounds that can produce the same positive responses as estrogen replacement therapy without the negative side effects. Also needed are estrogen-like compounds that exert selective effects on different tissues of the body.
The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive function, cerebral degenerative disorders, restinosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, autoimmune disease and cancer of the lung, colon, breast, uterus, and prostate.
Description of Invention
In accordance with the present invention, compounds are provided which are estrogen receptor ligands and have the general formula I, II, or III
I II III
wherein the bond between the CI and C2 carbon atoms (of compounds of general formula I) or the bond between C2 and C3 (of compounds of general formula II) or the bond between CI and CIO (of compounds of general formula III) is either a single or double bond; Ri (of compounds of general formula I or III) is an RΛ group other than a phenyl group;
RA is selected from the group hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, aryl or arylalkyl;
Rα and Rβ (of compounds of general formula II) are the same or are different and each is an RA group;
Ra (of compounds of general formula I or II) is a hydroxyl or RA group or is a hydroxyalkyl or aminoalkyl group of 1 to 2 carbon atoms;
R3α and R3β (of compounds of general formula I) may together be a single oxygen or sulfur atom; or R3α and R3β may together be a single nitrogen atom which in turn is bonded to a group selected from RA or ORA; or R3α and R3β may together be a single carbon atom (i.e., an exo methylene carbon atom) which in turn is bonded to two RA groups which may be the same or are different; or R3α and R3β may be the same or are different and each may be selected from RA, ORA, SRA, or N(RA)2 wherein the individual RA groups may be the same or are different and may be taken together with any attached and intervening atoms to form a 3-8 membered ring;
R2α and R2β (of compounds of general formula III) may together be a single oxygen or sulfur atom; or R3α and Rsβ may together be a single nitrogen atom which in turn is bonded to a group selected from RA or ORA; or R2 and R2β may together be a single carbon atom which in turn is bonded to two RA groups which may be the same or are different; or R2α and R2β may be the same or are different and each may be selected from hydroxyalkyl, aminoalkyl, RA, ORA, SRA, or N(RA)2 wherein the individual RA groups may be the same or are different and may optionally be taken together with any attached and intervening atoms to form a 3-8 membered ring;
R3 (of compounds of general formula II or III) is an RA group; Rt is an RA group;
Rt„ is a hydrogen atom or a methyl or ethyl group in compounds of formula I or II, or a methyl or ethyl group in compounds of formula III.;
R7 is a hydrogen atom or a linear or branched alkyl or cycloalkyl group or acyl group of 1 to 4 carbon atoms;
R10a is an RA group;
with the proviso that not all of R]5 R2, R3 and R( are hydrogen in compounds of formula I or II, and that ι is not hydrogen in compounds of formula III. and pharmaceutically acceptable salts and stereoisomers thereof.
Detailed Description of Invention
The present invention relates to compounds useful as estrogen receptor modulators and have the general formula I, II or III as described above.
One embodiment of the present invention relates to compounds according to the general formula I, II or III wherein the substituents R4, and R10a have a trans relative stereochemistry.
Another embodiment of the present invention relates to compounds according to the general formula I or III, wherein the substituent Ri is RB and RB is selected from hydrogen, /.-propyl, 2-propenyl, 2-propynyl, ra-butyl, 2-butenyl, 3-butenyl, 2-butynyl, 3-butynyl, 72-pentyl, 3-methylbutyl, 3 -methyl- 1-butenyl, 3-methyl-2-butenyl, 3-methylρentyl, 3-ethylpentyl, cyclopropylethyl. cyclopentylethyl, cyclohexylethyl, cycloheptylethyl, cyclopropylpropyl, cyclopentylpropyl, benzyl, and phenethyl. Another embodiment of the present invention relates to compounds according to the general formula II, wherein Ri is RB (where RB is defined as above) and Riβ is a hydrogen atom or methyl group.
Another embodiment of the present invention relates to compounds according to the general formula I, II or III wherein Rιoa is RB.
Another embodiment of the present invention relates to compounds according to the general formula I or II, wherein R2 is a hydrogen atom or a methyl, ethyl, or hydroxymethyl group.
Another embodiment of the present invention relates to compounds according to the general formula III, wherein R2 and R-β may be the same or are different and each may be selected from hydroxyalkyl, RA, ORA or SRA where the individual RA groups (where RA is defined as above) may be the same or are different and may optionally be taken together with any attached and intervening atoms to form a 3-8 membered ring.
Another embodiment of the present invention relates to compounds with the general formula I, wherein R3α and R3β may be the same or are different and each may be selected from RA ORA, or SRA where the individual RA groups (where RA is defined as above) may be the same or are different and may optionally be taken together with any attached and intervening atoms to form a 3-8 membered ring.
Another embodiment of the present invention relates to compounds with the general formula I, II or III wherein ( is a hydrogen atom or methyl or ethyl group.
Another embodiment of the present invention relates to compounds with the general formula I, II or III wherein R7 is hydrogen atom or an acyl group of 1 to 4 carbon atoms. Another embodiment of the present invention relates to compounds with the general formula I or III wherein Ri is selected from the group hydrogen, methyl, or ethyl and Rioa is RB.
Another embodiment of the present invention relates to compounds with the general formula I or III wherein Ri is RB and Rι0a is selected from hydrogen, methyl, or ethyl.
Another embodiment of the present invention relates to compounds with the general formula III wherein R2α and R2β may be the same or are different and each may be selected from hydroxyalkyl, R\ ORA, or SRA where the individual RA groups (where RA is defined as above) may be the same or are different and may optionally be taken together with any attached and intervening atoms to form a 3-8 membered ring.
Another embodiment of the present invention relates to compounds with the general formula II, wherein R^ is RB and Rι0a is selected from hydrogen, methyl, or ethyl.
Another embodiment of the present invention relates to compounds with the general formula II, wherein Riα is selected from hydrogen, methyl, or ethyl and Rι0a is RB.
Compounds of the invention include, but are not limited to, the following:
(rac)-(4aS, 10αS)-7-hydroxy- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3 -one (El);
(rac)-(4aS, 10aS)-3,3 -ethanediyldimercapto-7-hydroxy- 1 ,2,3 ,4,4a,9, 10, 1 Oa-octahydro-phena nthrene (E2);
(rac)-(4aR, 10α -7-hydroxy- 10a-methyl-4a,9, 10, 1 Oa-tetrahydro-^H-phenanthren-3-one
(E3a);
(rac)-(4aS, 1 Oα^-7-hydroxy- 10a-methyl-4a,9, 10, 1 Oa-tetrahydro-^H-phenanthren-3-one
(E3b);
(rac)-(4aS, 10aS)-\ 0a-butyl-7-hydroxy-4a,9, 10, 1 Oa-tetrahydro-^H-phenanthren-3-one (E4);
(rac)-(lS, 4aS, 10aS)-\ -butyl-7-hydroxy- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3 -one
(E5a); (rac)-(lR, 4aS, 1 OaS)- 1 -butyl-7-hydroxy- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3 -one
(E5b);
(rac)-(lS, 4aS, 10aS)-\ -butyl-3 ,3 -ethanediyldimercaρto-7-hydroxy- 1 ,2,3 ,4,4a,9, 10,1 Oa-octah ydiO-phenanthrene (E6a);
(rac)-(lR,4aS,10aS)-
1 -butyl-3 ,3-ethanediyldimercapto-7-hydroxy- 1 ,2,3 ,4,4a,9, 10, 1 Oa-octahydro-phenanthrene
(E6b);
(rac)-(lS, 4aS, 1 OaS)- 1 -butyl-7-hydroxy- 1 Oa-methyl- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenant hren-3-one (E7);
(rac)-(lS, 4aS, 1 OaS)- 1 -butyl-3,3-ethanediyldimercapto-7-hydroxy-l Oa-methyl-1 ,2,3,4,4a,9,
10,1 Oa-octahydro-phenanthrene (E8);
(rac)-(lS, 4aS, 10aS)-\ -butyl-7-hydroxy- 1 Oa-methyl- 1 ,2,3,4,4a,9, 10, 1 Oa-octahydro-phenant hrene (E9);
(rac)-(4aS, 10aR)-\ 0a-ethyl-7-hydroxy-3-methyl-4a,9, 10, 1 Oa-tetrahydro-^H-phenanthren- 1 - one (ElOa);
( ' c (^αR,/(9αR)-10a-ethyl-7-hydroxy-3-me yl-4a,9,10,10a-tefrahydro-^H-phenanthren-l
-one (ElOb);
(rac)-(lR, 2S, 4aS, 1 OaS) -I -butyl-7-hydroxy-2-methyl- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenan thren-3-one (Ella);
(rac)-(lR, 2R, 4aS, 10aS)-\ -butyl-7-hydroxy-2-methyl- 1 ,4,4a,9, 10,10a-hexahydro-2H-phena nthren-3-one(Ellb);
(rac)-(ls, 4R, 4aR, 1 OaS)- 1 -butyl-7-hydroxy-4-methyl- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenan thren-3-one (Ellc);
(rac)-(lR, 2R, 4aS, 10aS)-l -butyl-3 ,3 -ethanediyldimercapto-7-hydroxy-2-methyl- 1 ,2,3 ,4,4a,9
, 10, 1 Oa-octahydro-phenanthrene (E12a);
(rac)-(lR, 2S, 4aS, 10aS)-\ -butyl-3, 3 -ethanediyldimercapto-7-hydroxy-2-methyl-l ,2,3, 4,4a,9
, 10, 1 Oa-octahydro-phenanthrene (E12b);
(rac)-(lS, 4aS, 1 fozS 7-hydroxy- 1 Oa-methyl- 1 -(3-methyl-butyl)- 1 ,4,4a,9, 10, 1 Oa-hexahydro-
2H-ρhenanthren-3-one (E13);
(rac)-(lS, 4aS, 10aS)-3 ,3 -ethanediyldimercapto-7-hydroxy- 1 -(3-methyl-butyl)- 1 Oa-methyl- 1 , ,3,4,4a,9, 10, 1 Oa-octahydro-phenanthrene (E14); (rac)-(lS, 4aS, 10 Sj-7-hydroxy- 1 Oa-methyl- 1 -phenethyl- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phe nanthren-3-one (E15);
(rac)-(lS, 2S, 4aS, 10αS 7-hydroxy-2, 1 Oa-dimethyl- 1 -(3-methyl-butyl)- 1 ,4,4a,9, 10, 1 Oa-hexa hydro-2H-phenanthren-3-one (E16a);
(rac)-(lS, 2R, 4aS, 1 OaS) -1 -hydroxy-2, 1 Oa-dimethyl- 1 -(3 -methyl-butyl)- 1 ,4,4a,9, 10, 1 Oa-hexa hydro--?H-phenanthren-3-one (E16b);
(rac)-(4bS, 8S, S S 6,6-dimethoxy-8a-methyl-8-(3-methyl-butyl)-4b,5,6,7,8,8a,9, 10-octahy dro-phenanthren-2-ol (E17a);
(rac)-(lS, 4aS, 10αSj-7-hydroxy- 1 Oa-methyl- 1 -(3 -methyl-butyl)- 1 ,4,4a,9, 10, 1 Oa-hexahydro-
2H-ρhenanthren-3-one (E17b);
(rac)~(lS, 4aS, 1 OaS) -3 ,3 -ethanediyldioxy-7-hydroxy- 1 -(3 -methyl-butyl)- 1 Oa-methyl- 1 ,2,3 ,4, 4a,9, 10, 1 Oa-octahydro-phenanthrene (E18);
(rac)-(4bS, 8R, SαSJ-8a-methyl-8-(3-methyl-butyl)-4b,5,6,7,8,8a,9,l O-octahydro-phenanthre n-2-ol (E19a);
(rac)-(4bS, 6R, 8S, SΩS 6-ethylsulfanyl-8a-methyl-8-(3-methyl-butyl)-4b,5,6,7,8,8a,9, 10-oct ahydro-ρhenanthren-2-oI (E19b);
(rac)-(lS, 4aS, 1 OaS) - ,3-(propane- 1 ,3 -diyldimercapto)-7-hydroxy- 1 -(3-methyl-butyl)- 1 Oa- methyl-1 ,2,3,4,4a,9, 10, 1 Oa-octahydro-phenanthrene (E20);
(rac)-(4aS, 10 -7-hydroxy- 1 Oa-methyl- 1 ,4,4a,9, 10, 10a-hexahydro-2Η-phenanthren-3-one
(E21);
(rac)-(4aS, 10aS)-3,3 -ethanediyldimercapto-7-hydroxy- 1 Oa-methyl- 1 ,2,3 ,4,4a,9, 10,1 Oa-octa hydro-phenanthrene (E22);
(rac)-(4aS, 10aS)-\ Oa-ethyl-7-hydroxy- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3 -one
(E23);
(rac)-(4aS, 10aS)-3 ,3 -ethanediyldimercapto- 1 Oa-ethyl-7-hydroxy- 1 ,2,3 ,4,4a,9, 10,1 Oa-octah ydro-phenanthrene (E24);
(mc)-(lS,4aS,10aS)-l-(3-methyl-butyl)-10a-Qlihyl-7- y
H-phenanthren-3-one (E26);
(lS,4aS,10aS)
-7-hydroxy- 1 Oa-methyl- 1 -(3 -methyl-butyl)- 1 ,4,4a,9, 10,10a-hexahydro-2H-phenanthren-3 -o ne (E27); (lR,4aRS 0aR)
-7-benzyloxy- 1 Oa-methyl- 1 -(3 -methyl-butyl)- 1 ,4,4a,9, 10,10a-hexahydro-2H-phenanthren-3
-one (E28);
(rac)-(lS, 4aS, 1 OaS)-l -(3 -methyl-butyl)-3 ,3 -ethanediyldimercapto-7-hydroxy- 1 ,4,4a,9, 10, 1
Oa-octahydrophenanthrene (E29);
(rac)-(4aR, 10αR)-7-hydroxy-4a, 10a-dimethyl-3 ,4,4a,9, 10, 1 Oa-hexahydro-iH-phenanthren-
2-one (E30);
(rac)-(lS,4aS,10aS)
-7-hydroxy- 10a-methyl-4-phenyl- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3 -one (E31);
(rac)-(4R,4aS, i(?α^-3,3-ethanediyldimercapto-7-hydroxy-10a-methyl-4-phenyl-l,4,4a,9,l
0,1 Oa-octahydro-phenanthrene (E32);
(rac)-(lS, 4aS, 10aS)-3 ,3 -(ethane- 1 ,2-diyldimercapto)-7-hydroxy- 1 -(2-phenylethyl)- 1 Oa-met hyl- 1 ,2,3 ,4,4a,9, 10, 1 Oa-octahydro-phenanthrene (E33);
(rac)-(lS, 4aS, 10aS)-3 ,3 -ethanediyldioxy-7-hydroxy- 1 Oa-methyl- 1 , 2,3 ,4,4a,9, 10, 1 Oa-octahydro-phenanthrene (E34a);
(rac)-(lS, 4aS, 10aR)-3 ,3-ethanediyldioxy-7-hydroxy- 1 Oa-methyl- 1 ,
2,3,4,4a,9,10,10a-octahydro-phenanthrene (E34b);
(rac)-(3S, 4aS, 10 -7-hydroxy-3-pentyl-l Oa-methyl- 1 ,
2,3 ,4,4a,9, 1 , 1 Oa-octahydro-phenanthrene (E35a);
("r ς)-(3R, S,i0αS;-7-hydroxy-3-pentyl-10a-methyl-l,
2,3 ,4,4a,9, 1 , 1 Oa-octahydro-phenanthrene (E35b);
(rac)-(lS, 2R, 4aS, 10aS)-2, 10a-dimethyl-3 ,3 -(ethane- 1 ,2-diyldimercaρto)-7-hydroxy- 1 -(3-m ethyl-butyl- 1 ,2,3 ,4,4a,9, 10, 1 Oa-octahydro-phenanthrene (E36);
(rac)-(lS, 4aS, 10αS 7-Ηydroxy- 1 -(3 '-methyl-butyl)- 1 ,4,4a,9, 10, 1 Oa-hexahy- dro-2H-phenanthren-3-one (E37);
(rac)-(4aS, 1 OaS) -3 ,3 -(propane- 1 ,3 -diyldimercapto)-7-hydroxy- 1 ,2,3 ,4,4a,9, 10, 1 Oa-octahydr o-phenanthrene (E38);
(rac)-(lS, 4S, 4aS, 1 S 7-Ηydroxy- 1 -butyl-4, 1 Oa-dimethyl- 1 ,4,4a,9, 10, 10a-hexahydro-2H- phenanthren-3-one (E39);
(rac)-(4S, 4aS, i0 S 3,3-ethanediyldimercapto-7-hydroxy-4,
1 Oa-dimethyl-1 ,2,3,4,4a,9, 10, 1 Oa-octaliydro-phenanthrene (E40); (rac)-(4S, 4aS, 1 <føS)-7-Hydroxy-4-benzyl- 1 Oa-methyl- 1 ,4,4a,9, 10,10a-hexahydro-2H-phena nthren-3-one (E41a);
(rac)-(4aS, 10αS 7-hydroxy-4,4-dibenzyl- 1 Oa-methyl- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phena nthren-3-one (E41b);
(rac)-(4aS, 1 forS 7-hydroxy-l 0a-methyl-3,3-methylene-l ,2,3,4,4a,9, 10, 1 Oa-octahydrophen anthrene (E42);
(rac) - (4aS, 1 OaS) -3 ,3 -ethanediyl-7-hydroxy- 1 Oa-methyl- 1 ,2,3 ,4,4a, 9, 10, 1 Oa-octahydrophen anthrene (E43);
(rac)-(3R, 4aS, 10aS)-\ ',2',3',4'-tetrachloro-7-hydroxy- 1 Oa-methyl- 1 ,2,3,4,4a,9, 10, 10a
-octahydrospiro [phenanthrene-3 ,6'-cyclohexane]- 1 ',3 '-diene (E44); frας)-f5S αSi0 S -3,7-dihydroxy-10a-methyl-3-[l-(phenylthio)cyclopropyl]-l,2,3,4,4a,9,
10, 1 Oa-octahydrophenanthrene (E45);
(rac)-(3S, 4aS, 1 OαS^-7-hydroxy- 1 Oa-methyl- 1 ,2,3 ,4,4a,9, 10, 1 Oa-octahydrospiro [phenanthre ne-3,2'-cyclobutane]-l'-one (E46a);
(rac)-(3R, 4aS, 10aS)-7- yάx y- 1 Oa-methyl- 1 ,2,3, 4,4a,9, 10, 10a-octahydrospiro[phenanthre ne-3,2'-cyclobutane]-l'-one (E46b);
(rac)-(3S, 4aS, 10aS)-V, 1 '-ethanediyldimercaρto-7-hydroxy- 1 Oa-methyl- 1 ,2,3,4,4a,9, 10, 10a
-octahydrospiro [phenanthrene-3 ,2'-cyclobutane] (E47);
(rac)-(4aS, 10aS)-7- yάxo y- 1 Oa-methyl- 1 ,2,3,4,4a,9, 10, 1 Oa-octahydrospiro [phenanthrene-
3,l'-cyclobutaneJ (E48);
(rac)-(4aS, 10aS)-3-(l -cyclopenten- 1 -yl)-7-hydroxy- 1 Oa-methyl- 1 ,4,4a,9, 10, 1 Oa-hexahydro phenanthrene (E49);
(rac)-(3S,4aS,10aS)-
7-hydroxy- 1 Oa-methyl- 1 ,2,3 ,4,4a,9, 10, 10a,2
',3',4',5'-dodecahydrospiro[phenanthrene-3,2'-furan] (E50a);
(rac)-(3R,4aS,10aS)-
7-hydroxy- 1 Oa-methyl- 1 ,2,3 ,4,4a,9, 10, 10a,2
',3',4',5'-dodecahydrospiro[phenanthrene-3,2'-furan] (E50b);
(rac)-(3S,4aS,10aS)-
7-hydroxy- 1 Oa-methyl- 1 ,2,3 ,4,4a,9, 10,10a,3
',4',5',6'-dodecahydrospiro[phenanthrene-3,2'-2H-pyran] (E51a); (rac)-(3R,4aS,10aS)-
7-hydroxy-l Oa-methyl- 1 ,2,3 ,4,4a,9, 10, 10a,3
',4',5',6'-dodecahydrospiro[phenanthrene-3,2'-2H-pyran] (E51b);
(rac)-(lS, 3R, 4aS, 1 OaS)-
7-hydroxy-10a-methyl-l-(3-methylbutyl)-l,2,3,4,4a,9,10,10a,2
',3 ',4',5'-dodecahydrospiro[phenanthrene-3,2'-furan] (E52);
(rac)-(lS, 4aS, 10αS 7-hydroxy-l Oa-methyl-1 -(3-methylbutyl)- 1 ,2,3,4,4a,9, 10, 1 Oa-octahydr ospiro [phenanthrene-3, 1 '-cyclobutane] (E53);
(rac)-(lS, 4aS, 10aS)-7- ydxoxy-3 -(3 -hydroxypropyl)- 1 Oa-methyl- 1 -(3 -methylbutyl)- 1 ,4,4a,
9, 10,1 Oa-hexahydrophenanthrene (E54a);
(rac)-(lS, 3S, 4aS, 1 OaS)-
7-hydroxy- 1 Oa-methyl- 1 -(3 -methylbutyl)- 1 ,2,3,4,4a,9, 10,10a,2
',3 ',4',5'-dodecahydrospiro [phenanthrene-3 ,2'-furan] (E54b);
(rac)-(4aR, 10aR)- 10a-Butyl-7-hydroxy-4a-methyl-3 ,4,4a,9, 10, 1 Oa-hexahydro-iH-phenanth ren-2-one (E55); rαςj-7-Ηydroxy-4a-methyI-4,4a,9, 10-tetrahydro- JH-phenanthren-2-one (E56);
(rac)-4b-methyl-4b,5,6,7,9, 10-hexahydro-phenanthren-2-ol (E57);
(rαc -7-Ηydroxy- 1 ,4a-dimethyl-4,4a,9, 10-tetrahydro-5H-phenanthren-2-one (E58);
^rαc^-4a,8-dimethyl-4b,5,6,7,9,10-hexahydro-phenanthren-2-ol (E59);
(rαc 4b,8-dimethyl-4b,5,6,7,9,10-hexahydro-ρhenanthren-2-ol (E60a, E60b, E60c,
E60d);
(rac)-(3S, αR)-7-hydroxy-3 ,4a-dimethyl-4,4a,9, 10-tetrahydro-3H-phenanthren-2-one
(E61);
(rac)-(4S, αR)-7-Ηydroxy-4a-methyl-4-propyl-4,4a,9, 10-tetrahydro-3H-phenanthren-2-one
(E62);
(rac)-(4R, αR -7-Ηydroxy-4,4a-dimethyl-4,4a,9, 10-tetrahydro-3H-phenanthren-2-one
(E63a);
(rac)-(4S, αR 7-Ηydroxy-4,4a-dimethyl-4,4a,9, 10-tetrahydro-3H-phenanthren-2-one
(E63b); frαc)-l-Ethyl-7-hydroxy-4a-methyl-4,4a,9,10-tetrahydro-3H-phenanthren-2-one (E64);
(rac 8-Ethyl-4b-methyl-4b,5,6,7,9, 10-hexahydro-phenanthren-2-ol (E65); (rαc (^αR,iC' R,/S -l-Ethyl-7-hydroxy-4a-methyl-l,4,4a,9,10,10a-hexahydro-3H-phenant hren-2-one (E66);
(rac)Λ -Butyl-7-hydroxy-4a-methyl-4,4a,9, 10-tetrahydro-3H-phenanthren-2-one (E67); (rαc 8~Butyl-4b-methyl-4b,5,6,7,9, 10-hexahydro-ρhenanthren-2-ol (E68); frαc («R,^bR,SαR 8-Butyl-4b-methyl-4b,5,6,7,8,8a,9,10-octahydro-phenanthren-2-ol (E69a);
(rac)-(8S, 4bR, SαR 8-Butyl-4b-methyl-4b,5,6,7,8,8a,9, 10-octahydro-phenanthren-2-ol (E69b);
^αcj-4a-Butyl-7-hydroxy-l-methyl-4,4a,9,10-tetrahydro-3H-phenanthren-2-one (E70); (r c -4a-Butyl-7-hydroxy-4,4a,9, 10-tetrahydro-3H-phenanthren-2-one (E71); (rac)-(4aR, 10αR- 4a-Butyl-7-hydroxy-3,4,4a,9, 10, 10a-hexahydro-/H-phenanthren-2-one (E72a);
(rac)-(4aR,10aS)-4a- utyl-7-]χydxoxy-3,4,4a,9, 10, 10a-hexalιydro-7H-phenanthren-2-one (E72b);
(rαc)-(4αR, 10 S 7-hydroxy-4a-methyl-3 ,4,4a,9, 10, 10a-hexahydro-iH-phenanthren-2-one (E73);
(rαc)-(4αR, 10^-2,2-ethanediyldimercaρto-7-hydroxy-4a-methyl- 1 ,2,3 ,4,4a,9, 10, 1 Oa-octah ydrophenanthrene (E74);
(rαc)-(4αR, 10α^)-7-hydroxy-4a-methyl-3 ,4,4a,9, 10,1 Oa-hexahydro-iH-phenanthren-2-one oxime (E75);
and pharmaceutically acceptable salts and stereoisomers thereof.
Another embodiment of the invention is a method of eliciting an estrogen receptor modulating effect in a mammal in need thereof, comprising administering to the mammal a therapeutically-effective amount of any of the compounds or any of the pharmaceutical compositions described above.
A class of this embodiment is the method wherein the estrogen receptor modulating effect is an agonizing effect. A first subclass of this class of embodiment is the method wherein the estrogen receptor is an ERα receptor.
A second subclass of this class of embodiment is the method wherein the estrogen receptor is an ERβ receptor.
A third subclass of this class of embodiment is the method wherein the estrogen receptor modulating effect is a mixed ERα and ERβ agonizing effect.
A second class of this embodiment is the method wherein the estrogen receptor modulating effect is an antagonizing effect.
A first subclass of this class of embodiment is the method wherein the estrogen receptor is an ERα receptor.
A second subclass of this class of embodiment is the method wherein the estrogen receptor is an ERβ receptor.
A third subclass of this class of embodiment is the method wherein the estrogen receptor modulating effect is a mixed ERα and ERβ antagonizing effect.
Another embodiment of the invention is a method of treating or preventing hot flashes in a mammal in need thereof by administering to the mammal a therapeutically effective amount of any of the compounds or pharmaceutical compositions described above.
Exemplifying the invention is a pharmaceutical composition comprising any of the compounds described above and a pharmaceutically acceptable carrier. Also exemplifying the invention is a pharmaceutical composition made by combining any two or more of the compounds described above and a pharmaceutically acceptable carrier. An illustration of the invention is a process for making a pharmaceutical composition comprising /combining any of the compounds described above and a pharmaceutically acceptable carrier. As one specific embodiment of this invention, 140 mg of
(rac)-(lR,2R, 4aS,10aS)-l-buty\-3,3
-ethanediyldimercapto-7-hydroxy-2-methyl- 1 ,2,3,4,4a,9, 10, 1 Oa-octahydro-phenanthrene is formulated with sufficient finely divided lactose to provide a total amount of 580 to 590 mg to fill a size 0, hard-gelatine capsule.
As one specific embodiment of this invention, 200 mg of (rας -4b,8-dimethyl-4b,5,6,7,9,10 -hexahydro-phenanthren-2-ol is formulated with sufficient finely divided lactose to provide a total amount of 580 to 590 mg to fill a size 0, hard-gelatine capsule.
Further exemplifying the invention is the use of any of the compounds described above in the preparation of a medicament for the treatment and/or prevention of osteoporosis in a mammal in need thereof. Still further exemplifying the invention is the use of any of the compounds described above in the preparation of a medicament for the treatment and/or prevention of bone loss, bone resorption, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restinosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, autoimmune disease, lung cancer, colon cancer, breast cancer, uterine cancer, prostate cancer, and/or disorders related to estrogen functioning.
The present invention is also directed to combinations of any of the compounds or any of the pharmaceutical compositions described above with one or more agents useful in the prevention or treatment of osteoporosis. For example, the compounds of the instant invention may be effectively administered in combination with effective amounts of other agents such as an organic bisphosphonate or a cathepsin K inhibitor. Nonlimiting examples of said organic bisphosphonates include adendronate, clodronate, etidronate, ibandronate, incadronate, minodronate, neridronate, risedronate, piridronate, pamidronate, tiludronate, zoledronate, pharmaceutically acceptable salts or esters therof, and mixtures thereof. Preferred organic biphosphonate include alendronate and pharmaceutically acceptable salts and mixtures thereof. Most preferred is alendronate monosodium trhihydrate. The precise dosage of the bisphonate will vary with the dosing schedule, the oral potency of the particular bisphosphonate chosen, the age, size, sex and condition of the mammal or human, the nature and severity of the disorder to be treated, and other relevant medical and physical factors. Thus, a precise pharmaceutically effective amount cannot be specified in advance and can be readily determined by the caregiver or clinician. An appropriate amount can be determined by routine experimentation from animal models and human clinical studies. Generally, an appropriate amount of bisphosphonate is chosen to obtain a bone resorption inhibiting effect, i.e. a bone resorption inhibiting amount of the bisphonsphonate is administered. For humans, an effective oral dose of bisphosphonate is typically from about 1.5 to about 6000 μg/kg of body weight and preferably about 10 to about 2000 μg/kg of body weight.
For human oral compositions comprising alendronate, pharmaceutically acceptable salts thereof, or pharmaceutically acceptable derivatives thereof, a unit dosage typically comprises from about 8.75 mg to about 140 mg of the alendronate compound, on an alendronic acid active weight basis, i.e. on the basis of the corresponding acid.
The compounds of the present invention can be used in combination with other agents useful for treating estrogen-mediated conditions. The individual components of such combinations can be administer separately at different times during the course of therapy or concurrently in divided or single combination forms. The instant invention is therefore to be understood as embracing all such regimes of simultaneous or alternating treatment and the term "administering" is to be interpreted accordingly. It will be understood that the scope of combinations of the compounds of this invention with other agents useful for treating estrogen-mediated conditions includes in principle any combination with any pharmaceutical composition useful for treating disorders related to estrogen functioning.
The compounds of the present invention can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powder, granules, elixirs, tinctures, suspensions, syrups and emulsions. Likewise, they may also be administered in intravenous (bolus or infusion), intraperitoneal, topical (e.g., ocular eyedrop), subcutaneous, intramuscular, or transdermal (e.g., patch) form, all using forms well known to those of ordinary skill in the pharmaceutical arts.
The dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex, and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed. An ordinarily skilled physician, veterinarian or clinician can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
Oral dosages of the present invention, when used for the indicated effects, will range between about 0.01 mg per kg of body weight per day (mg/kg/day) to about 100 mg/kg/day, preferably 0.01 mg per kg of body weight per day (mg/kg/day) to 10 mg/kg/day, and most preferably 0.1 to 5.0 mg/kg/day. For oral administration, the compositions are preferably provided in the form of tablets containing 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. A medicament typically contains from about 0.01 mg to about 500 mg of the active ingredient, preferably from about 1 mg to about 100 mg of active ingredient. Intravenously, the most preferred doses will range from about 0.1 to about 10 mg/kg/minute during a constant rate infusion. Advantageously, compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily. Furthermore, preferred compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches will known to those of ordinary skill in the art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen. In the methods of the present invention, the compounds herein described in detail can form the active ingredient, and are typically administered in admixture with suitable pharmaceutical diluents, exipients or carriers (collectively referred to herein as "carrier" materials) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.
For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms includes sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include without limitation starch, methylcellulose, agar, bentonite, xanthan gum and the like.
The compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed form a variety of phospholipids, such as 1,2-dipalmitoylphosphatidylcholine, phosphatidyl ethanolamine (cephalin), or phosphatidylcholine (lecithin).
The following definitions apply to the terms as used throughout this specification, unless otherwise limited in specific instances. The term "estrogen receptor ligand" as. used herein is intended to cover any moiety which binds to a estrogen receptor. The ligand may act as an agonist, an antagonist, a partial agonist or a partial antagonist. The ligand may be either ERα or ERβ selective or display mixed ERα and ERβ activity.
The term "aliphatic hydrocarbon(s)" as used herein refers to acyclic straight or branched chain groups which include alkyl, alkenyl or alkynyl groups.
The term "aromatic hydrocarbon(s)" as used herein refers to groups including aryl groups as defined herein.
Unless otherwise indicated, the term "lower alkyl", "alkyl", or "alk" as employed herein alone or as part of another group includes both straight and branched chain hydrocarbons, containing 1 to 12 carbon atoms (in the case of alkyl) in the normal chain and preferably 1 to 6 carbons, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, or isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl.
The term "cycloalkyl" as employed herein alone or as part of another group refers to 3- to 7-membered fully saturated mono cyclic ring system and include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
The term "cycloalkylalkyl" as employed herein alone or as part of another group refers to an cycloalkyl group containing 3 to 7 carbon atoms attached through available carbon atoms to a straight or branched chain alkyl radical containing 1 to 6 carbon atoms and include but are not limited to cyclopropylmethyl (-CH2 H5), cyclobutylethyl (-CH2CH2C4H7), and cyclopentylpropyl (-CH2CH2CH2C5H9).
The term "aryl" as employed herein alone or as part of another group refers to monocyclic and bicyclic aromatic groups containing 6 to 10 carbons in the ring portion and include but are not limited to phenyl, 1-naphthyl, and 2-naphthyl and may be optionally substituted through available carbon atoms with 1, 2, or 3 groups selected from hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, amino, trifluoromethyl, trifluoromethoxy, alkynyl, hydroxy, nitro, cyano, or carboxy.
The term "arylalkyl" as employed herein alone or as part of another group refers to an aryl group containing 6 to 10 carbon atoms attached through available carbon atoms to a straight or branched chain alkyl radical containing 1 to 6 carbon atoms and include but are not limited to benzyl (-CH2Ph), phenethyl (-CH2CH2Ph), phenpropyl (-CH2CH2CH2Ph), and 1-napthylmethylene (-CH2CιoH7).
Unless otherwise indicated, the term "lower alkenyl" or "alkenyl" as used herein by itself or as part of another group refers to straight or branched chain radicals of 2 to 12 carbons, preferably 2 to 6 carbons, in the normal chain, which include one to six double bonds in the normal chain, such as vinyl, 2-propenyl, 3-butenyl, 2-butenyl, 4-pentenyl, 3-pentenyl, 2-hexenyl, 3-hexenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 3-octenyl, 3-nonenyl, 4-decenyl, 3-undecenyl, 4-dodecenyl, and the like.
Unless otherwise indicated, the term "lower alkynyl" or "alkynyl" as used herein by itself or as part of another group refers to straight or branched chain radicals of 2 to 12 carbons, preferably 2 to 6 carbons, in the normal chain, which include one triple bond in the normal chain, such as 2-propynyl, 3-butynyl, 2-butynyl, 4-pentynyl, 3-pentynyl, 2-hexynyl, 3-hexynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 3-octynyl, 3-nonynyl, 4-decynyl, 3-undecynyl, 4-dodecynyl and the like.
The term "halogen" or "halo" as used herein alone or as part of another group refers to chlorine, bromine, fluorine, and iodine as well as CF3.
The term "acyl" as employed herein alone or as part of another group refers to a carbonyl group (C=O) which in turn is bonded a linear or branched alkyl group of from 1 to 4 carbon atoms and includes but is not limited to acetyl [-(C=O)CH3], propionyl [-(C=O)CH2CH3], and butyryl [-(C=O)CH2CH2CH3]. The term "hydroxyalkyl" as employed herein alone or as part of another group refers to linear chain alkyl radical containing 1 to 2 carbon atoms attached through available carbon atoms to a hydroxyl group and include hydroxymethyl (-CH2OH), 1-hydroxyethyl [-CH2(OH)CH3] and 2-hydroxyethyl (-CH2CH2OH).
The term "aminoalkyl" as employed herein alone or as part of another group refers to linear chain alkyl radical containing 1 to 2 carbon atoms attached through available carbon atoms to a primary, secondary, or tertiary amino group and include aminomethyl (-CH2NR2), 1-aminoethyl [-CH2(NR2)CH3] and 2-aminoethyl (-CH2CH2NR2) where R is a hydrogen atom or methyl or ethyl group.
The compounds of formula I, II or III can be present as salts, in particular pharmaceutically acceptable salts. If the compounds of formula I, II or III have, for example, at least one basic center, they can form acid addition salts. These are formed, for example, with strong inorganic acids, such as mineral acids, for example sulfuric acid, phosphoric acid or a hydrohalic acid, with strong organic carboxylic acids, such as alkanecarboxylic acids of 1 to 4 carbon atoms which are unsubstituted or substituted, for example, by halogen, for example acetic acid, such as saturated or unsaturated dicarboxylic acids, for example oxalic, malonic, succinic, maleic, fumaric, phthalic or terephthalic acid, such as hydroxycarboxylic acids, for example ascorbic, glycolic, lactic, malic, tartaric or citric acid, such as amino acids, (for example aspartic or glutamic acid or lysine or arginine), or benzoic acid, or with organic sulfonic acids, such as (Cj-C4)-alkyl- or aryl-sulfonic acids which are unsubstituted or substituted, for example by halogen, for example methane- or p-toluene-sulfonic acid. Corresponding acid addition salts can also be formed having, if desired, an additionally present basic center. The compounds of formula I, II or III having at least one acid group (for example COOH) can also form salts with bases. Suitable salts with bases are, for example, metal salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium or magnesium salts, or salts with ammonia or an organic amine, such as morpholine, thiomorpholine, piperidine, pyrrolidine, a mono-, di- or tri-lower alkylamine, for example ethyl-, tert-butyl-, diethyl-, diisopropyl-, triethyl-, tributyl- or dimethyl-propylamine, or a mono-, di- or trihydroxy lower alkylamine, for example mono-, di- or triethanolamine. Corresponding internal salts may furthermore be formed. Salts which are unsuitable for pharmaceutical uses but which can be employed, for example, for the isolation or purification of free compounds I or their pharmaceutically acceptable salts are also included.
Preferred salts of the compounds of formula I, II or III which include a basic group include monohydrochloride, hydrogensulfate, methanesulfonate, phosphate or nitrate.
Preferred salts of the compounds of formula I, II or III which include an acid group include sodium, potassium and magnesium salts and pharmaceutically acceptable organic amines.
The compounds in the invention contain at least one chiral center and therefore exist as optical isomers. The invention therefore comprises the optically inactive racemic (rac) mixtures (a one to one mixture of enantiomers), optically enriched scalemic mixtures as well as the optically pure individual enantiomers. The compounds in the invention also may contain more than one chiral center and therefore may exist as diastereomers. The invention therefore comprises individual diastereomers as well as mixtures of diastereomers in cases where the compound contains more than one stereo center. The compounds in the invention also may contain acyclic alkenes or oximes and therefore exist as either the E (entgegen) or Z (zusammen) isomers. The invention therefore comprises individual E or Z isomers as well as mixtures of E and Z isomers in cases where the compound contains an acylic alkene or oxime funtional group. Also included within the scope of the invention are polymorphs, hydrates, and solvates of the compounds of the instant invention.
The present invention includes within its scope prodrugs of the compounds of this invention. In general, such prodrugs will be functional derivatives of the compounds of this invention which are readily convertible in vivo into the required compound. Thus, in the methods of treatment of the present invention, the term "administering" shall encompass the treatment of the various conditions described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the patient. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example in "Design of Prodrugs" ed. H. Bundgaard, Elsevier, 1985, which is incorporated by reference herein in its entirety. Metabolites of the compounds includes active species produced upon introduction of compounds of this invention into the biological milieu.
The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention and a pharmaceutically acceptable carrier.
The present invention also relates to methods for making the pharmaceutical compositions of the present invention.
The present invention also relates to methods for treating or preventing disorders elated to estrogen functioning, bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, autoimmune disease, lung, colon, breast, uterus, or prostate cancer, hot flashes, cardiovascular disease, impairment of cognitive function, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity and incontinence in a mammal in need thereof by administering the compounds and pharmaceutical compositions of the present invention.
The present invention also relates to methods for reducing bone loss, lowering LDL cholesterol levels and eliciting a vasodilatory effect, in a mammal in need thereof by administering the compounds and pharmaceutical compositions of the present invention.
The novel compounds of the present invention can be prepared according to the procedure of the following Schemes and examples, using appropriate materials and are further exemplified by the following specific examples. The compounds illustrated in the examples are not, however, to be construed as forming the only genus that is considered as the invention. The following examples further illustrate details for the preparation of the compounds of the present invention. Those skilled in the art will readily understand that known variation of the conditions and processes of the following preparative procedures can be used to prepare these compounds. The compounds of the present invention of formulae I and II are prepared according to the general methods outlined in Schemes 1-4, and according to the related methods described. Those of formula III are prepared according to general methods outlined in Schemes 5-6 and according to the related methods described. All temperatures are degrees in Celsius unless otherwise noted. The following abbreviations, reagents, expressions or equipment, which are amongst those used in the descriptions below, are explained as follows: 20-25°C (room temperature, r.t.), molar equivalent (eq.), dimethyl formamide, (DMF) dichloromethane (DCM), ethyl acetate (EtOAc), tetrahydrofuran (THF), lithium diisopropylamide (LDA), methyl t-butyl ether (MTBE), rotating glass sheet coated with a silica gel-gypsum mixture used for chromatographic purification (chromatotron), preparative liquid chromatography with a C8 stationary phase and ammonium acetate acetonitrile- water buffer as mobile phase (PHPLC), electrospray mass spectroscopy (ES/MS).
A general route for the construction of the tetrahydro-phenanthrone nucleus of formulae I and II is shown in Scheme 1. This methodology is based on the chemistry described by Dyker, et al, J. Org. Chem. 1998, 63, 6043-6047. In step 1, aryl iodide 1 is coupled with an homoallylic alcohol 2a or 2b under the influence of a palladium catalyst, to give 3a or 3b respectively. Compound 3a or 3b is then cyclized under acidic or basic conditions in step 2, to provide the tetrahydro-phenanthrone derivative 4 or 5 respectively. Representative protocols for step 1 (method A) and step 2 (method B or method C) in Scheme 1 are as follows:
Method A
To a mixture of the aryl iodide 1 (Scheme 1, 1.0 eq.), the homoallylic alcohol "J" (2 in Scheme 1, "K" eq.), ethyl diisopropylamine ("L" eq.), and LiCl (1.0 eq.) in DMF ("M" mL/mmol of aryl iodide) is added Pd(OAc)2 (0.05 eq.). This mixture is then stirred in a sealed tube under a nitrogen atmosphere at 80°C for "N" h before being added to DCM. This DCM solution is then filtered through a short plug of silica gel that is further eluted with EtOAc before concentration of the combined filtrates in vacuo (approximately 10 mmHg/60 °C) to provide a crude material.
Method B
The crude material from method A is taken up in DCM ("N" mL) and treated with cone. HC1 (aq., "O" mL) at "P" °C, and for "Q" h. The mixture is then first washed with saturated aqueous Sodium bicarbonate and then with water. Back extraction of the combined aqueous phases is done with EtOAc. The combined organic phases are then dried over anhydrous sodium sulfate and concentrated in vacuo to yield the crude product.
Method C
The crude material from method A is dissolved in EtOAc ("N" mL) to which 1/3 of this volume saturated HCl/EtOAc is added followed by stirring at r.t. for "Q" h. The crude product is obtained by concentrating this solution in vacuo.
The homoallylic alcohols 2a and 2b which are used as starting materials in Scheme 1 could, when not commercially available, be prepared by known methods such as the allylation of aldehydes (see Wada, et al, Tetrahedron Lett. 1997, 38, 8045-8048 and references cited therein). A general method Employing Mg / BiCl3 as reagents for this purpose, is outlined in Scheme 2. When either of the allylic bromides 6a or 6b is reacted with formaldehyde under these conditions, the primary homoallylic alcohol 2a is formed. The secondary homoallylic alcohol 2b is formed in an analogous way by reaction with aldehyde 7. A representative protocol for the reaction shown in Scheme 2 (method D) is as follows:
Method D
While stirring at room temperature, the allylic bromide 6a or 6b (Scheme 2, 1.0 eq.) is added to a suspension of bismuth trichloride (1.1 eq.) and magnesium turnings (2.4 eq.) in a THF-H2O (4:1) mixture. After additional stirring for 20 min., the aldehyde formaldehyde 7 (Scheme 2, "J" eq.) is added in one portion. The resulting mixture is then stirred for "K" h before quenching with l.OM HCl. The organic materials are extracted with diethyl ether, the combined organic extracts washed with water and saturated aqueous NaCl, dried over anhydrous sodium sulfate, and concentrated in vacuo to furnish the crude product.
Scheme 1: A general route to tetrahydrophenanthren-3-one (4) and tetrahydro-phenantren-
Scheme 2: Synthesis of homoallylic alcohols by allylation of aldehydes.
The substituted benzylideneacetones 1 used as starting material in Scheme 1, can be prepared from the corresponding aromatic aldehyde 8 in a conventional way by aldol condensation with ketones 9 as shown in Scheme 3. When ketone 9 is unsymmetric (i.e., when Rπ and Rra are different), the reacting site can be controlled by varying the reaction conditions according to known methods (see Irie, et al, Bull. Chem. Soc. Jpn. 1980, 53, 1366-1371 and Iranpoor, et al, Tetrahedron 1998, 55, 9475-9480 and references cited therein). When R1 in 8 is hydrogen, a non-hydrogen protecting group can be introduced on 1 after the aldol condensation.
Scheme 3: Synthesis of substituted benzylideneacetone derivatives.
The 4a,9,10,10a-teti'ahydro-^H-phenanthren-3-ones 4 (Scheme 1), can be further modified by employment of known methods for the reactions of enone and carbonyl functionalities as shown in Scheme 4. For example, in step 1 of Scheme 4, a non-hydrogen RVI-substituent in (10) can be introduced by treatment of 4 with an organocopper reagent carrying the RVI-substituent (see Lipshuts B.Η. "Synthetic Procedures Involving Organocopper Reagents" in "Organometallics in Synthesis", Schlosser M. (ed.), John Wiley & Sons 1994). A representative protocol (method E) for the introduction of a non-hydrogen RVI-substituent (step 1 of Scheme 4) is as follows:
Method E
To a cool (dry ice / acetone bath) mixture of the copper(I)-reagent "J" ("K" eq.) in (additional) "L" mL of the solvent "M" is added while stirring, a solution of the organometallic reagent "N" ("O" eq.). The mixture is then allowed to come to 0 °C for 15 min., before again cooling (dry-ice / acetone bath). A solution of the enone 4 (Scheme 4, 1.0 eq.) is then added dropwise. Stirring is continued at "P" °C for "Q" h, before quenching with saturated aqueous NΗ4C1. The organic materials are then taken up in EtOAc. This solution is dried over anhydrous sodium sulfate and filtered through a short plug of silica gel before concentration in vacuo to yield the crude product. Another example is the introduction, in step 1 of Scheme 4, of hydrogen as RVI-substituent in (10) by hydrogenation of (4). A representative protocol (method F) for hydrogenation/hydrogenolysis is as follows: Method F
A flask, containing a mixture, in the solvent "J" ("K" mL), of the substrate (1.0 eq.) to be hydrogenated/hydrogenolyzed, and a catalyst "L" ("M" mg), is evacuated and filled with hydrogen three times before stirring at room temperature and atmospheric pressure for "N" h. Workup is done by filtering the mixture through a short plug of celite®, followed by concentration of the filtrate in vacuo to obtain the crude product.
In step 2 of Scheme 4, the carbonyl group of ketone 10 can be altered using traditional carbonyl chemistry to generate derivatives 11, where the Rw- and R^-substituents has been introduced. For example, the thioketal can be prepared from 10 by treatment with a thiol, or dithiol, under acidic conditions. A representative protocol (method G) for the preparation of thioketals (11, Rvπ, Rvm= S-alkyl) from 10 is as follows:
Method G
To a cool (dry ice / acetone bath) solution of the ketone 10 (Scheme 4, 1.0 eq.) in dry DCM ("J" mL) is added the thiol or dithiol "K" ("L" eq.), followed by BF3OEt2 (1.5 eq.), while stirring. The mixture is then allowed to slowly come to room temperature, and stirred there for another "M" h before quenching with saturated aqueous Sodium bicarbonate. The organic materials are then taken up in EtOAc. This solution is dried over anhydrous sodium sulfate before passage through a short plug of silica gel and concentration in vacuo to give the crude product.
Another example is the preparation of ketals of the general formula 11 (Rvπ, Rvm= O-alkyl) from 10. A representative protocol (method H) is as follows:
Method H
A mixture of the ketone 10 (Scheme 4, 1.0 eq.), the alcohol or diol "J" ("K" mL), Amberlyst 15® ("L" mg), and DCM ("M" mL) is stirred at "N" °C for "O" h before filtration through celite®. The celite®-bed is then washed with DCM, and the combined filtrates washed with water, dried over anhydrous sodium sulfate and filtered through a short plug of silica gel. The crude product is obtained by concentrating this filtrate in vacuo.
The Rπ- and Rm-substituents of 10 (Scheme 4) can be separately changed from hydrogen to non-hydrogen by alkylation of the corresponding enolates of 10. Thus, a non-hydrogen Rm-substituent can be introduced by alkylation of 10 (enolate A), while a non-hydrogen Rπ-substituent can be introduced by alkylation of 10 (enolate B). Enolate 10 (enolate A) can for example be prepared from (4) (Rm= H) by 1,4-addition of a negatively charged nucleophile to the enone moiety. Other general methods for the generation of enolates involves treatment of the corresponding ketone with a strong base such as LDA. When the Rvπ- and Rvm-substituents of 11 are attached via a sulfur atom (i.e., R , Rvm= S-alkyl) as in thioketals, one or both of RVE and Rvm can be exchanged to hydrogen by treatment with a desulfurizing agent, such as Raney-Ni. Two representative protocols (method I and method J) for the desulfurization of 11 (Scheme 4) are as follows:
Method I
To a stirred solution of the thioketal 11 (Scheme 4, Rvπ, Rw= S-alkyl, 1.0 eq.) in abs. ethanol ("J" mL) is added Raney-Ni ("K" mg). The weight of the Raney-Ni is measured as the weight of the wet material that is obtained on a flat spatula after picking from a sedimented suspension in abs. ethanol. This mixture is then rapidly stirred at "L" °C for "M" h, before filtration through celite® and successive washing with abs. ethanol and EtOAc. The crude product is obtained by concentrating the combined filtrate and washings in vacuo.
Method J
To a stirred mixture of the thioketal 11 (Scheme 4, Rvπ, Rvm= S-alkyl, 1.0 eq.) and Al-Ni-alloy (Aldrich no. 22,165-1, "J" mg).in abs. EtOH ("K" mL), is slowly added 3.0M NaOH (aq., "L" drops) at room temperature. Another portion of abs. EtOH ("M" mL) is added after "N" h of stirring, before filtration through celite®. The filtrate is then partitioned between aqueous ammonium acetate and MTBE. The organic phase is dried over anhydrous sodium sulfate and filtered through a short plug of silica gel, before concentration in vacuo, to provide the crude product.
Scheme 4: Introduction of further substituents on and synthetic modifications of 4a,9, 10, 10a-tetrahydro-¥H-phenanthren-3 -ones.
(10 enolate A) (10 enolate B)
Deprotection (i.e., to change the R'-substituent from a non-hydrogen to hydrogen) can be done by several different known methods depending on the nature of the R'-substituent. For example, when RI= CΗ2Ph deprotection can be done by hydrogenolysis (for a representative protocol see method F), and when R'= CH3 deprotection can be done by treatment with BBr3 (for a representative protocol see method K).
Method K
To a cool (dry-ice / acetone bath) and stirred solution of the aryl methyl ether substrate (1.0 eq.) in dry DCM ("J" mL) is added BBr3 (l.OM sol in DCM, "K" eq.). The mixture is then allowed to come to "L" °C, and kept at that temperature for "M" h before quenching with saturated aqueous sodium bicarbonate. The organic materials are then taken up in EtOAc. This solution is dried over anhydrous sodium sulfate before passage through a short plug of silica gel and concentration in vacuo to furnish the crude product.
A general route for the construction of the tetrahydro-phenanthrone nucleus of formulae III is shown in Scheme 5. This methodology is based on the chemistry described by Fetizon and Delobelle, CR. Hebd. Seances Acad. Sci, 1957, 245; 850-852 and by Howell and Taylor, J Chem. Soc, 1958, 1248-1253. In step 1, tetralone 12 is formed by oxidation of enone 11 by mCPBA. Robinson-type annulation of tetralone 12 with enone 13 results in phenantrone 14. Representative protocols for step 1 (method L) and step 2 (method M) in Scheme 5 are as follows:
Method L
To a cooled solution (~5 °C) of 1.0 eq. the olefin in DCM was added in portions while stirring mCPBA (50 weight % dispersion in water, 1.2 eq.) at such a rate that the temperature never exceeded 10 °C. The mixture was then stirred at 5-10 °C for 12 h before filtration through celite® and washing of the filtrate with saturated aqueous sodium bicarbonate, water, and saturated aqueous NaCl. To the solution thus obtained was added PPTS (0.05 eq.) before heating at reflux for 2.5 h. Concentration in vacuo then followed to yield the crude product.
Method M
To a stirred solution of the tetralone (1.0 eq.) in toluene or benzene, was first added the enone coupling partner (1.2 eq.), followed by the pTsOH catalyst (0.05 eq.). The mixture was, after being heated at 85 °C for 20 h, then filtered through a short plug of silica gel. Elution of this plug with enough of MTBE to totally deliver all of the desired material, followed by concentration of the eluate in vacuo, furnished the crude product.
Scheme 5: A general route to tetrahydrophenanthren-2-one derivatives 4
Deprotection (i.e., to change the RI-substituent from a non-hydrogen to hydrogen) can be done by several different known methods depending on the nature of the R'-substituent. For example when RI= CH3, deprotection can be done by treatment with BBr (for a representive protocol see, method O).
Method O
To a cool (dry-ice / acetone bath) and stirred solution of the aryl methyl ether (1.0 eq.) in dry DCM was added BBr3 (l.O M sol in DCM). The mixture was then allowed to come to -20°C, and kept at that temperature for the time indicated before quenching with saturated aqueous Sodium bicarbonate. The organic materials were then taken up in EtOAc. This solution was dried (anhydrous sodium sulfate) before passage through a short plug of silica gel and concentration in vacuo to furnish the crude product.
The 3,4,4a,9,10,10a-hexahydro-7H-phenanthren-2~ones 14 (Scheme 5) can by further modified by employment of known methods for the reactions of enone and carbonyl functionalities as shown in Scheme 6. For example, a non-hydrogen RIV-substituent in (20) can be introduced by treatment of 14 with and organocopper reagent carrying the RIV-substituent (see Lipshuts B.Η. "Synthetic Procedures Involving Organocopper Reagents" in "Organomettalics in Synthesis", Schlosser M. (ed.), John Wiley & Sons 1994), or by treatment of 4 with an organotitaniumate complex (see Flemming, S. et.al, Tet. Lett 1994, 35 (33), 6075-6078 and Kabbara, S. et.al, Liebigs Ann.1995, 401-406. A protocol for the introduction of a non-hydrogen RIV-substituent (method P and Q, step 1 of Scheme 6) is as follows:
Method P
To a cool (dry ice / acetone bath) suspension of CuCN in diethylether was added while stirring, a solution of the alkyl lithium. The mixture was then allowed to come to 0 °C, before cooling again (dry-ice / acetone bath). A solution of 1.0 eq. of the enone was then added dropwise. Stirring was continued at that temperature, and for the time indicated, before quenching with saturated aqueous NΗ4C1. The organic materials were thereafter taken up in EtOAc. This solution was dried (anhydrous sodium sulfate) and filtered through a short plug of silica gel before concentration in vacuo, to yield the crude product. Method Q
To a cool (-30 °C) suspension of titanium (IN) isopropoxide in anhydrous THF was added while stirring, a solution of the alkyl magnesium chloride. The mixture was then allowed to come to 0 °C, before again cooling (dry-ice / acetone bath). A solution of Νickel(II) acetylacetonate (0.05 eq.) and the enone (1.0 eq.) in anhydrous THF was then added dropwise. Stirring was continued at -15 °C for 30 min., and the mixture was then stirred at r.t overnight. The mixture was diluted with diethyl ether and quenched with water. After stirring for 1 hour, the precipitate was filtered of and the residue was concentrated in vacuo to yield the crude product.
In step step 2 of Scheme 6, the carbonyl functionality of 14 can be reduced using traditional carbonyl chemistry. A representative protocol (method R) for the reduction of carbonyl groups is as follows:
Method R
To a cool (-40 °C) solution of the enone (1.0 eq.) in acetonitrile was added while stirring sodium borohydride (5.0 eq.), followed by trifluoro acetic acid (1/4 of the volume of acetonitrile). The remaining mixture was thereafter allowed to come to room temperature in approximately 1 h, and then stirred at that temperature for another 2 h before quenching with saturated aqueous Sodium bicarbonate. The organic material was talcen up in EtOAc, dried (anhydrous sodium sulfate), and filtered through a short plug of silica gel before concentration in vacuo to give the crude product.
Another example is the introduction of hydrogen as RIV-substituent in (10) by hydrogenation of 4 or 6 (step 3 and 4 of Scheme 6). A representative protocol (methods for hydrogenation is as follows:
Method S
A flask containing a solution of the substrate (1.0 eq.) and a palladium catalyst, was evacuated and filled with hydrogen three times before stirring the mixture at room temperature and atmospheric pressure for the time indicated. Workup was done by filtering the mixture through a short plug of celite®, followed by concentration of the filtrate in vacuo to obtain the crude product.
In step 5 and 6 of Scheme 6, the carbonyl group of ketone 7 can be altered using traditional carbonyl chemistry to generate derivatives 19 and 20. For example, thioketal 19 can be prepared from 17 by treatment with a dithiol under acidic conditions, N-oxime 20 (RVII= Ν) can be prepared from 17 by treatment with hydroxylamine and thioketone 10 (RVII:= S) can be prepared from 17 by treatment with Lawesson's reagent. Representative protocols (methods T and U) for the preparation of thioketals ((19), Rv, RVI = S-alkyl) and N-oximes from 17 are as follows:
Method T
To a cool (dry ice/ acetone bath) solution of the ketone 17 (Scheme 6, 1.0 eq.) in dry DCM is added the dithiol (2.0 eq.) followed by BF3OEt2 (1.5 eq.) while stirring. The mixture is then allowed to slowly come to room temperature, and stirred there for the time indicated before quenching with saturated aqueous Sodium bicarbonate. The organic phases are then taken up in EtOAc. This solution is dried over anhydrous sodium sulfate before passage through a short plug of silica gel and concentration in vacuo to give the crude product.
Method U
A mixture of the ketone, ΝH2OHΗC1 (lOeq.) and sodium acetate (10 eq.) is stirred in methanol under N2 atmosphere at r.t. during 3 days. Water is added and the organic materials are then talcen up in EtOAc. This solution is dried over anhydrous sodium sulfate before passage through a short plug of silica gel and concentration in vacuo to give the crude product.
Method V
5-Bromo-l-pentene in anhydrous THF is added to magnesium in anhydrous THF, at such speed that the mixture gently refluxed (an I2 crystal is added to start the reaction). After addition, the reaction mixture is heated at 70 °C for 30 minutes and allowed to cool to room temperature.
To a stirred solution of the above described Grignard reagent (4.0 eq.) is added ketone 20, Scheme 4 (leq.) at room temperature and the reaction mixture is stirred for 20 minutes before quenching with saturated aqueous NH4C1. The organic materials are then taken up in EtOAc. This solution is dried over anhydrous sodium sulphate and filtered through a short plug of silica gel to yield the crude product.
Scheme 6: Modifications of the tetraliydrophenanthren-2-one 14 at position 10.
The following examples represent preferred, but non-limiting embodiments of the invention. Examples 1-54 relate to compounds of formulae I and II, and Examples 55-75 relate to compounds of formula III.
Example 1: Synthesis of
Step 1: 2-Iodo-4-methoxy-benzaldehyde. To a stirred mixture of m-iodo-anisole (47.2 g, 202 mmol) and DMF (20 mL) was added POCl3 (1.1 eq.) dropwise. The mixture was then heated at 100 °C for 12 h before sequential addition of further portions of DMF (12 mL) and POClj (0. 5eq.), and then again stirred for another 12 h at 100 °C. The dark mixture was then poured onto 500 mL of 2.0M NaOH before extraction with diethyl ether and DCM. The combined extracts were dried over anhydrous sodium sulfate before concentration in vacuo, to yield the crude product as a dark syrup, that was purified using silica gel flash chromatography twice with EtOAc/rø-heptane (8:2, v:v) as eluent. 2-Iodo-4-methoxy-benzaldehyde was obtained as white needles by gently concentrating the solution obtained after the chromatography. Another portion of 2-iodo-4-methoxy-benzaldehyde was obtained from the mother liquid. 'H NMR (270 MHz, CDC13) δ 9.90 (s, 1H), 7.85 (d, 1H), 7.40 (d, 1H), 6.95 (ddd, 1H), 3.85 (s, 3H); I3C NMR (CDC13) δ 195.05, 165.5, 131.75, 128.75, 125.60, 114.95, 102.30, 55.70. Step 2: 4-(2-Iodo-4-methoxy-phenyl)-but-3-en-2-one. To a stirred suspension of 2-iodo-4-methoxy-benzaldehyde (558 mg, 2.13 mmol) in a water-acetone mixture (6.0 mL, 3:2), was added aqueous NaOH (16.0M, 1.2 eq.) before heating at reflux for 10 min. The yellow precipitate formed upon cooling to r.t. was collected, washed with water, and dried over P2O5 to give 4-(2-iodo-4-methoxy-phenyl)-but-3-en-2-one. 'H NMR (270 MHz, CDC13) δ 7.70 (d, IH), 7.50 (d, IH), 7.40 (d, IH), 6.90 (DD, IH), 6.45 (d, IH), 3.80 (s, 3H), 2.40 (s, 3H).
Step 3: (rac)-(4aR,10aS)-7-Methoxy-4a,9,10,10a-tetrahydro-4H-phenanthιen-3-one and (rαc)-(4αS, 10αS)-7-Metb xy-4a,9, 10, 10a-tetrahydro- H-phenanthren-3 -one. The aryl iodide 4-(2-iodo-4-methoxy-phenyl)-but-3-en-2-one (362 mg) was treated according to method A ("J" = but-3-en-l-ol, "K" = 2.5, "L" = 8.0, "M" = 4, "N" = 3.5). The material obtained was then treated according to method B ("N" = 3 0, "O" = 0.3, "P" = 25, "Q" = 20). The crude product obtained was purified by silica gel flash chromatography using EtOAc:/2-heptane (2.5:97.5, 5:95, 1 :9, stepwise gradient) as eluent, followed by fractionation with PΗPLC. The first eluted fraction contained
(rαc)-(4αR, 10α -7-methoxy-4a,9, 10, 10a-tetrahydro- H-phenanthren-3 -one (yellowish solid), and the second
(rαc)-(4αS, 0αSJ-7-methoxy-4a,9,10,10a-tetrahydro- H-phenanthren-3-one (white solid). (rαc)-(4αR, 10αS 7-Methoxy-4a,9, 10, 10a-tetrahydro- H-phenanthren-3-one: ES/MS m/z: 229.3 (pos., M+Η); ΗNMR (270 MHz, CDC13) δ 6.95-7.05 (m, 2H). 6.75 (dd, IH), 6.65 (d, IH), 6.05 (dd, IH), 3.80 (s, 3H), 3.35-3.45 (m, IH), 2.85-2.95 (m, 2H), 2.55-2.75 (m, 3H), 1.70-2.00 (m, 2H).
(rαc)-(4αS, 7toS 7-Methoxy-4a,9,10,10a-tetrahydro-4H-phenanthren-3-one: ES/MS m/z: 229.3 (pos., M+Η); Η NMR (270 MHz, CDC13) δ 7.10 (d, IH), 6.95 (dd, IH), 6.75 (dd, IH), 6.70 (d, IH), 6.10 (dd, IH), 3.75 (s, 3H), 3.20 (dd, IH), 2.90-3.10 (m, 3H), 2.25-2.50 (m, 2H), 2.10-2.20 (m, IH), 1.65-1.80 (m, IH).
Step 4: (rαc)-(4αS, 1 OαS) - -Mexboxy- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3-one. The substrate (rαc)-(4αS, 10αS)-7-methoxy-4a,9, 10, 10a-tetrahydro- H-phenanthren-3 -one (30 mg) was treated according to method F ("J" = methanol, "K" = 5.0, "L" = 5% Pd/C,
"M" = 10, "N" = 24) to obtain m/z: 231.1 (pos., M+Η).
Step 5: (rac)-(4aS, 1 OaS) -7 -By dxoxy- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3-one. The substrate
(rac)-(4aS, 10aS)-7-met oxy- 1 ,4,4a,9, 10,10a-hexahydro-2H-phenanthren-3 -one (28 mg) was treated according to method K ("J" = 1.0, "K" = 3.0, "L" = - 20, "M" = 4.0). The crude product was purified on chromatotron using EtOAc:rø-heptane (3:7, v:v) as eluent to yield (rαc^-( S,i0α^-7-hydroxy-l,4,4a,9,10,10a-hexahydro-2H-phenanthren-3-one (white solid). ES/MS m/z: 217.0 (pos., M+Η), 215.2 (neg., M-Η); Η NMR (270 MHz, CDC13) δ 7.00 (d, IH), 6.65 (dd, IH), 6.60 (s, IH), 4.70 (s, IH), 3.05-3.15 (m, IH), 2.75-3.00 (m, 2H), 2.60-2.70 (m, IH), 2.35-2.55 (m, 2H), 2.25 (t, IH), 2.05-2.15 (m, IH), 1.95-2.05 (m, IH), 1.40-1.80 (m, 3H).
Example 2: Synthesis of
3,3-ethanediyldimercapto-7-hvdroxy-l,2,3<4.4a.9,10,10a-octahydro-phenanthrene
(E2).
The ketone (rac)-(4aS, 10aS)- -by dxoxy- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3-one (9.3 mg) was treated according to method G ("J" = 2.5, "K" = 1,2-ethanedithiol, "L" = 2.0, "M" = 12). The crude product was purified on chromatotron, using EtOAc:«-heptane (2:8, v:v) as eluent to yield
(rac)-(4aS, 10aS)-3 ,3 -ethanediyldimercapto-7-hydroxy- 1 ,2,3 ,4,4a,9, 10, 1 Oa-octahydro-phena nthrene (white solid). ES/MS m/z: 292.9 (pos., M+H), 290.8 (neg., M-H); Η NMR (270 MHz, CDC13) δ 7.10 (d, IH), 6.60 (dd, IH), 6.55 (d, IH), 4.50 (s, IH), 3.25-3.40 (m, 4H), 2.70-2.90 (m, 3H), 2.45-2.55 (m, IH), 2.20 (dq, IH), 2.00 (dt, IH), 1.75-1.90 (m, 3H), 1.40-1.60 (m, 2H), 1.20-1.35 (m, IH).
Example 3: Synthesis of
«c)-t «R.lflfflS)- 7-hydroxy-10a-methyl-4a,9J0J0a-tetrahvdro- H-phenanthren-3-one fE3a): and
7-hydroxy-10a-methyl-4a,9.10.10a-tetrahydro-^H-phenanthren-3-one fE3b).
Step 1:
(rac)-(4aR, 10 aS) - -Metboxy- 10a-methyl-4a,9, 10,10a-tetrahydro- H-phenanthren-3-one and
(rac)-(4aS, 1 OaS) -7 -Methoxy- 10a-methyl-4a,9, 10, 1 Oa-tetrahydro-^H-phenanthren-3-one.
The aryl iodide 4-(2-iodo-4-methoxy-phenyl)-but-3-en-2-one (325 mg) was treated according to method A ("J" = 2-methyl-but-3-en-l-ol, "K" = 2.5, "L" = 8.0, "M" = 10, "N" = 3.0). The material obtained was then treated according to method B ("N" = 25, "O" = 0.5, "P" = 40, "Q" = 4). The crude product obtained was fractionated on chromatotron using EtOAc :t--heptane (2:8, 9:1, slow stepwise gradient) as eluent. The first eluted fraction contained
(rac)-(4aS, 10aS)-7-xneihoxy- 10a-methyl-4a,9, 10,1 Oa-tetrahydro-^H-phenanthren-3 -one (solid), the second a mixture of
(rac)-(4aR, 10aS)-7-xn.ethoxy- 10a-methyl-4a,9, 10, 10a-tetrahydro- H-phenanthren-3 -one and
(rαc^-(^ S70αi9-7-memoxy-10a-methyl-4a,9,10,10a-tefrahydro-^H-phenanthren-3-one, and the third
(rac)-(4aR, 10aS)-7-xnet oxy- 10a-methyl-4a,9, 10, 10a-tetrahydro- H-phenanthren-3-one. (rac)-(4aS, 10aS)-7-Metboxy- 10a-methyl-4a,9, 10, 10a-tetrahydro-¥H-phenanthren-3-one: ES/MS m/z: 243.4 (pos., M+Η); Η NMR (270 MHz, CDC13) δ 7.00 (d, IH), 6.90 (d, IH), 6.75 (dd, IH), 6.70 (d, IH), 5.95 (d, IH), 3.80 (s, 3H), 3.20 (dd, IH), 3.05 (dd, IH), 2.90-3.00 (m, 2H), 2.40-2.55 (m, IH), 1.80-1.90 (m, 2H), 0.95 (s, 3H).
Step 2:
(rac)-(4aR, 1 OaS) -7 -Hydxoxy- 10a-methyl-4a,9, 10, 1 Oa-tetrahydro-^H-phenanthren-3 -one and
(rac)-(4aS, 10aS)-7-Hydxoxy- 10a-methyl-4a,9, 10, 10a-tetrahydro- H-phenanthren-3-one.
As substrate, a mixture of
(rac)-(4aR, 10αS)-7-methoxy- 10a-methyl-4a,9, 10, 1 Oa-tetrahydro-^H-phenanthren-3-one and
(rac)-(4aS, 10αS)-7-methoxy-l 0a-methyl-4a,9, 10, 1 Oa-tetral ydro-^H-ρhenanthren-3-one (43 mg, 3:2) was used according to method K ("J" = 3.0, "K" = 4.0, "L" = -20, "M" = 12).
The crude product thus obtained was purified on chromatotron, using EtOAc:/.-heptane
(3 :7) as eluent, followed by fractionation on PΗPLC. The first eluted fraction contained
(rαc^-(^αR,i0α-^-7-hydroxy-10a-methyl-4a,9,10,10a-tetrahydro-^H-phenanthren-3-one, and the second a mixture of
(rac)-(4aR, 10aS)-7-bydxoxy- 10a-methyl-4a,9, 10, 10a-tetrahydro-¥H-phenanthren-3 -one and
(rac)-(4aS, 10aS)-7-bydxoxy-l 0a-methyl-4a,9, 10, 10a-tetrahydro- H-phenanthren-3-one. (rac)-(4aR, 10aS)-l '-Hydroxy- 10a-methyl-4a,9, 10, 1 Oa-tetrahydro-^H-phenanthren-3-one: ES/MS m/z: 229.3 (pos., M+Η), 227.2 (neg., M-Η); Η NMR (270 MHz, CDC13) δ 6.95 (d, IH), 6.70 (d, IH), 6.65 (dd, IH), 6.60 (d, IH), 5.95 (d, IH), 5.00-5.30 (br. s, IH), 3.00 (dd, IH), 2.80-2.85 (m, 2H), 2.65 (dd, IH), 2.50 (dd, IH), 1.80-1.95 (m, IH), 1.60-1.70 (m, IH), 1.15 (s, 3H); 13C NMR (CDC13) δ
(rac)-(4aS, 1 O S -7-Hydroxy- 10a-methyl-4a,9, 10, 1 Oa-tetrahydro-^H-phenanthren-3-one: Η NMR (270 MHz, CDC13) δ 6.95 (d, IH), 6.90 (d, IH), 6.60-6.70 (m, 2H), 6.00 (d, IH), 3.20 (dd, IH), 3.05 (dd, IH), 2.90-3.00 (m, 2H), 2.45 (dd, IH), 1.80-1.90 (m, 2H), 0.95 (s, 3H); 13C NMR (CDCl3) δ 199.70, 161.05, 154.00, 136.95, 129.25, 127.35, 125.80, 115.55, 113.10, 42.50, 37.50, 35.45, 34.55, 25.90, 17.00.
Example 4: Synthesis of
^αc)-^flS' 0a-->')-10a-butyl-7-hvdroxy-4a,9,10.10a-tetrahydro-^H-phenanthren-3-one
(E4).
Step 1: (r c -2-Butyl-but-3-en-l-ol. Using the allylic bromide l-bromo-2-heptene (9.5 g) and the aldehyde formaldehyde (37% solution in water) as starting materials according to method D ("J" = 3.0, "K" = 18), a crude product was obtained. This was purified by distillation (79-81 °C/65 nimHg) to yield (rαc)-2-butyl-but-3-en-l-ol as a colorless oil. Η NMR (270 MHz, CDC13) δ 5.40-5.80 (m, IH), 4.90-5.20 (m, 2H), 3.85-4.05 (m, IH - OH), 3.55 (dd, IH), 3.40 (dd, IH), 1.90-2.25 ( , IH), 1.05-1.45 (m, 6H), 0.80 (t, 3H). Step 2:
(rac)-(4aS, 10aS)-\ 0a-Butyl-7-methoxy-4a,9, 10, 1 Oa-tetrahydro-^H-phenanthren-3-one. The aryl iodide 4-(2-iodo-4-methoxy-phenyl)-but-3-en-2-one (107 mg) was treated according to method A ("J" = (rac)-2-butyl-but-3-en-l-ol, "K" = 2.5, "L" = 8.0, "M" = 28, "N" = 72). The material obtained was then treated according to method B ("N" = 5.0, "O" = 0.5, "P" - 40, "Q" = 2). The crude (rac)-(4aS,10aS)-\0a- utyl-7-metboxy-4a,9,l0,\0a -tetrahydiO-^H-phenanthren-3-one obtained was used directly in step 3.
Step 3:
(rac)-(4aS, 10aS)- 10a-Butyl-7-hydroxy-4a,9, 10, 1 Oa-tefrahydro-^H-phenanthren-3-one. The substrate (rac)-(4aS, 1 OaS)- 10a-butyl-7-methoxy-4a,9, 10, 10a
-tetrahydro-^H-phenanthren-3-one (10 mg) was treated according to method K ("J" = 1.0, "K" = 4.0, "L" = -20, "M" = 12). The crude product was purified on chromatotron, using EtOAc:«-heptane (2:8) as eluent to yield (rac)-(4aS,10aS)-10a- utyl- 7-hydroxy-4a,9, 10,10a-tetrahydro-^H-phenanthren-3-one. ES/MS m/z: 271.3 (pos., M+Η), 268.9 (neg., M-Η); Η NMR (270 MHz, CDC13) δ 7.00 (dd, 2H), 6.70 (dd, IH), 6.6 (s, IH), 6.05 (d, IH), 3.25 (dd, IH), 3.05 (dd, IH), 2.85-2.90 (m, 2H), 2.55 (dd, IH), 2.10-2.15 (m, IH), 1.70-1.80 (m, IH), 1.15-1.50 (m, 6H), 0.85 (t, 3H).
Example 5: Synthesis of frgc)-t7S'. aS.10flS)-l-butyl-7-hvdroxy-1.4.4a>9.10.10a- hexahvdro- H-phenanthren-3- onerE5a):andt -gc)-^iR.^gιS'.i<?flt->')-l-butyl-7-hydroxy- l 4a-,9 0J0a-hexahvdro- H-phenanthren-3-one (E5b).
Step 1:
(rac)-(lS, 4aS,10aS)-\ -Butyl-7-methoxy- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3-one and
(rac)-(lR, 4aS,10aS)-l -ButyI-7-methoxy- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3-one . The enone (rac)-(4aS, 1 & S)-7-methoxy-4a,9, 10, 10a-tetrahydro-¥H-phenanthren-3-one (39 mg) from Example 1 dissolved in diethyl ether/TΗF (3.0 mL, 2:1), was treated according to method E ("J" = CuCN, "K" = 2.2, "L" = 2.0, "M" = diethyl ether, "N" = /--butyl lithium [1.6M solution in hexanes], "O" = 4.2, "P" = -78, "Q" = 0.5). The crude product consisted of a mixture of (rac)-(lS,4aS, 10dS)-l-butyl-7-methoxy-l, 4,4a,9,10,10a -hexahydro-2H-phenanthren-3-one and (rac)-(lR, 4aS, 10aS)-\ -butyl-7-methoxy- 1 , 4,4a,9,10,10a-hexahydro-2H-phenanthren-3-one that was used in the next step (step 2).
Step 2:
(rac)-(lS, 4aS, 10aS)-\ -Butyl-7-hydroxy- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3-one and (rac)-(lR, 4aS, 10aS)-\ -Butyl-7-hydroxy- 1 ,4,4a,9, 10, 10a-hexahydro-2H- phenanthren-3 -one. As substrate, a mixture (47 mg) of (rac)-(lS,4aS,10aS)-l-butyl-7-methoxy-l, 4,4a,9,10,10a-hexahydro-2H-phenanthren-3-one and (rac)-(lR,4aS,10aS)-l-bntyl-7- methoxy-l,4,4a,9,10,10a-hexahydro-2H-phenanthren-3-one from step 1 was treated according to method K ("J" = 1.0, "K" = 3.0, "L" = -20, "M" = 4.0). The crude product obtained was purified on chromatotron, using EtOAc:«-heptane (3:7, v:v) as eluent to yield a mixture of (rαcA7S^ S,70αS l-butyl-7-hydroxy-l, 4,4a,9,l 0,10a- hexahydro-2H- phenanthren-3 -one and (rac)-(lR, 4aS, 1 OaS)- 1 -butyl-7-hydroxy- 1 ,4,4a,9, 10, 10a- hexahydro-2H-phenanthren-3-one as a glass. ES/MS m/z (mixture): 273.1 (pos., M+Η), 271.0 (neg., M-Η); Η NMR (distinguishable signals of the mixture, 270 MHz, CDC13) δ 7.05 (d, H-C5, minor isomer), 7.00 (d, H-C5, major isomer), 4.57 (s, -OH, minor isomer), 4.55 (s, -OH, major isomer).
Example 6: Synthesis of (rac)-(lSAaS.lOaS)- l-butyl-3,3-ethanediyldimercap to-7-hvdroxy-1.2,3.4.4a,9,10.10a-octahvdro-phenanthrene; (E6a^ and c)- i -. flS.i< αS)- l-butyl-3.3-ethanediyldimercapt o-7-hvdroxy-l,2,3,4,4a.9.10.10a- octahydro-phenanthrene (E6b .
A mixture of the ketones
(rac)-(lS, 4aS, 1 OaS)- 1 -butyl-7-hydroxy- 1 ,4,4a,9, 10,10a-hexahydro-2H-ρhenanthren-3 -one and
(rac)-(lR, 4aS, 1 OaS)- 1 -butyl-7-hydroxy- 1 ,4,4a,9, 10,10a-hexahydro-2H-phenanthren-3 -one
(2: 1 or 1 :2, 10.5 mg) was treated according to method G ("J" = 2.5, "K" =
1,2-ethanedithiol, "L" = 2.0, "M" = 12). The crude product was purified on chromatotron, using EtOAc :«-heptane (2:8) as eluent to yield a mixture of (rac)-(lS,4aS,10aS)-l-butyl-3,
3-ethanediyldimercapto-7-hydroxy- 1 ,2,3, 4,4a, 9, 10, 1 Oa-octahydro-phenanthrene and (rac) -(1R, 4aS, 1 OaS)- 1 -butyl-3 ,3 -ethanediyldimercapto-7-hydroxy- 1 ,2,3 ,4,4a, 9,10,10a-octahydrophenanthrene as a colorless glass. ES/MS m/z (mixture): 349.3 (pos., M+Η), 347.2 (neg., M-Η); Η NMR (distinguishable signals of the mixture, 270 MHz, CDC13) δ 7.110 (d, H-C5, minor isomer), 7.120 (d, H-C5, major isomer), 4.505 (s, -OH, minor isomer), 4.495 (s, -OH, major isomer), 0.875 (t, CH3, minor isomer), 0.905 (t, CH3, major isomer).
Example 7: Synthesis of " c)-t-?S'. aS' 0flS')-l-butyl-7-hvdroxy-10a- methyI-l,4.4a,9,10,10a-hexahydro-2H-phenanthren-3-one (E7).
Step 1:
(rac)-(lS, 4aS,10aS)-\ -Butyl-7-methoxy- 1 Oa-methyl- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenan thren-3-one. The enone (rac)-(4aS, 10αS)-7-methoxy-10a-methyl-4a, 9,10,10a-tetrahydro -^H-phenanthren-3-one (39 mg) from Example 3 dissolved in diethyl ether (1.5 mL) was treated according to method E ("J" = CuCN, "K" = 2.0, "L" = 2.5, "M" = diethyl ether, "N" = «-but l lithium [1.6M solution in hexanes], "O" = 4.0, "P" = -78, "Q" = 0.5) to furnish crude (rac)-(lS,4aS,10aS)-l-butyl-7-metboxy-l0a-methyl-l, 4,4a,9,l 0,10a -hexahydro-2H-phenanthren-3-one that was used in the next step.
Step 2:
(rac)-(lS, 4aS, 10aS)-\ -Butyl-7-hydroxy- 1 Oa-methyl- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenant hren-3 -one. As substrate (rac)-(lS, 4aS, 1 OaS)- 1 -butyl-7-methoxy- 1 Oa-methyl- 1 ,4,4a, 9,10,10a-hexahydro-2H-phenanthren-3-one (49 mg) from the previous step was treated according to method K ("J" = 2.0, "K" = 3.5, "L" = -20, "M" = 5.0). The crude product thus obtained was purified on chromatotron, using EtOAc :«-heptane (2:8, 4:6, v:v; stepwise gradient) as eluent to yield (rac)-(lS,4aS,10aS)-\-bu yl-7-bydxoxy- 10a-methyl-l,4,4a,9,10,10a-hexahydro-2H-phenanthren-3-one. ES/MS m/z: 287.2 (pos., M+Η), 285.1 (neg., M-Η); Η NMR (270 MHz, CDC13) δ 6.90 (d, IH), 6.60-6.65 (m, 2H), 5.00 (br. s, IH), 3.00 (dd, IH), 2.70-2.95 (m, 4H), 2.45 (dt, IH), 2.30 (t, IH), 1.90-2.05 (m, IH), 1.70-1.80 (m, IH), 1.55-1.65 (m, IH), 1.40-1.50 (m, 2H), 1.10-1.35 (m, 4H), 1.05 (s, 3H), 0.90 (t, 3H); 13C NMR (CDC13) δ 14.00, 17.95, 22.70, 26.70, 27.95, 30.15, 32.55, 35.05, 38.60, 41.75, 41.85, 46.35, 112.85, 115.05, 126.25, 130.45, 137.25, 154.05, 212.40. Example 8: Synthesis of (rac)-aS.4aS.10aS)-l- butyI-3.3-ethanediyldimercapto-7-hvdroxy- lθa-methyl-l.2.3,4. 4a,9 -,10.10a -octahvdro-phenanthrene (E8 .
The ketone
(rac)-(lS, 4aS, 1 OaS)- 1 -butyl-7-hydroxy- 1 Oa-methyl- 1 ,4,4a,9, 10,10a-hexahydro-2H-phenant hren-3-one (11 mg) was treated according to method G ("J" = 2.0, "K" = 1,2-ethanedithiol, "L" = 2.0, "M" = 12). The crude product was purified purified on chromatotron using EtOAc:«-heptane (2:8, v:v) as eluent to yield
(rac)-(lS, 4aS, 1 OaS)- 1 -butyl-3 ,3-ethanediyldimercapto-7-hydroxy- 1 Oa-methyl- 1 ,2,3 ,4,4a,9, 10,1 Oa-octahydro-phenanthrene. ES/MS m/z: 363.4 (pos., M+Η), 361.3 (neg., M-Η); Η NMR (270 MHz, CDC13) δ 7.05 (d, IH), 6.50-6.65 (m, 2H), 4.65 (s, IH), 3.25-3.35 (m, 4H), 1.80-2.95 (m, 9H), 1.10-1.65 (m, 7H), 0.85 (t, 3H), 0.80 (s, 3H).
Example 9: Synthesis of
l-butyl-7-hydroxy-10a-methyI-l,23.4.4a,9.10.10a-octahydro-phenanthrene E9
The thioketal (rac)-(lS, 4aS, 10aS)-\ -butyl-3 ,3 -ethanediyldimercapto- 7-hydroxy-l Oa-methyl- 1, 2,3 ,4,4a,9, 10,1 Oa-octahydro-phenanthrene (6.2 mg) was treated according to method J ("J" = 100, "K" = 3.0, "L" = 5, "M" = 10, "N" = 96) to provide (rac)-(lS, 4aS, 1 OaS)-l -butyl -7-hydroxy- 1 Oa-methyl- 1 ,2,3 ,4,4a,9, 10, 1 Oa-octahydro- phenanthrene. ES/MS m/z: 273.4 (pos., M+H), 271.3 (neg., M-H); Η NMR (270 MHz, CDC13) δ 7.05 (d, IH), 6.60 (d, IH), 6.55 (d, IH), 3.0-4.0 (br. s, IH), 2.65-2.95 (m, 2H), 2.60 (dd, IH), 2.10 (dd, IH), 1.70-1.95 (m, 2H), 1.10-1.70 (m, 12H), 0.90 (t, 3H), 0.85 (s, 3H).
Example 10: Synthesis of ^ c)-(^flS,.i<?gR)-10a-ethyl-7-hydroxy-3-methyl-4a. 9,10,10a-tetrahydro-^H-phenanthren-l-one (ElOa : and frac)-f4aR 0aR)-10a-ethyl-7-hγdroxy-3-methyl-4a. 9.10.10a-tetrahvdro- H- phenanthren-1-one (ElOb).
Step 1: (rac)-(2R,3R)-(rac)-(2S,3R)-3-ΕI yl-ρent-4-en-2-ol. The allylic bromide l-bromo-2-pentene (2.49 g) and the aldehyde acetaldehyde was used as starting materials according to method D ("J" = 3.0, "K" = 18). The crude product was purified by silica gel flash chromatography using EtOAc :rø-heptane (3:7) as eluent, to yield (rac)-(2R, 3R)-(rac)-(2S, 5RJ-3-ethyI-pent-4-en-2-ol as an oil. Η NMR (270 MHz, DMSO-d6) δ 5.45-5.65 (m, IH), 4.95-5.20 (m, 2H)5 3.50-3.75 (m, IH), 1.30-2.00 (m, 3H), 1.10 (d, 3H), 0.85 (t, 3H).
Step 2:
(rac)-(4aS, 10aR)-l 0a-Ethyl-7-methoxy-3-methyl-4a,9, 10, 10a-tetrahydro- H-phenanthren- 1 -one and (rac)-(4aR,10aR)-10a-ethyl-7-meϋιoxy-3-methyl-4a,9,lO, lOa-tetrahydro-^H-phenanthren-1-one. The aryl iodide 4-(2-iodo-4-methoxy-phenyl)- but-3-en-2-one (51 mg) was treated according to method A ("J" = (rac)-(2R,3R)- (rac)-(2S3R)-3-ethyl-pent-4-en-2-ol, "K" = 2.5, "L" = 8.0, "M" = 44, "N" = 48). The residue obtained was dissolved in DCM (9.0mL) and stirred with 2.0 M aqueous KOΗ (1.0 mL) at reflux for 12 h before washing of this solution with water. Back extraction of the aqueous phase was done with EtOAc followed by drying over anhydrous sodium sulfate of the combined organic phases, and concentration of these in vacuo to yield a mixture of (rac) -(4aS, 1 OaR)- 10a-ethyl-7-methoxy-3-methyl-4a,9, 10, 10a- tetrahydro- H- phenanthren-1-one and (rac)-(4aR, 70αR -10a-ethyl-7-methoxy-3-methyl-4a, 9,10,10a-tetrahydro- H-phenanthren-l-one that was used in the next step. (rac)-(4aS, 10aR)-\ Oa-Ethyl-7- methoxy-3-methyl-4a,9, 10, 10a- tetrahydro- H-phenanthren -1-one: ES/MS m/z: 271.3 (pos., M+Η); ΗNMR (270 MHz, CDC13) δ 7.1 (d, IH), 6.55-6.75 (m, 2H), 5.75-5.90 (m, IH), 3.75 (s, 3H), 3.1-3.3 (m, IH), 2.7-2.9 (m, 3H), 2.3-2.5 (m, 2H), 1.8-2.1 (m, 3H), 1.0-1.7 (m, 3H), 0.6-0.9 (m, 3H). (rac)-(4aR,10aR)- 10a-Ethyl-7-methoxy-3 -methyl-4a,9, 10, 1 Oa-tetrahydro-^H-phenanthren- 1 -one: ES/MS m/z: 271.3 (pos, M+Η); Η NMR (270 MHz, CDC13) δ 7.20 (d, IH), 6.55-6.75 (m, 2H), 5.75-5.90 (m, IH), 3.75 (s, 3H), 3.1-3.3 (m, IH), 2.7-2.9 (m, 3H), 2.3-2.5 (m, 2H), 1.8-2.1 (m, 3H), 1.0-1.7 (m, 3H), 0.6-0.9 (m, 3H). Step 3:
(rac)-(4aS, 1 OaR)- 10a-Ethyl-7-hydroxy-3 -methyl-4a,9, 10, 1 Oa-tetrahydro- H-phenanthren- 1 -one and CracA R,i6>flR)-10a-Ethyl-7-hydroxy-3-methyl-4a,9,10,10a -tetrahydro-^H-phenantlιren-1-one. As substrate, a mixture of (rac)-(4aS,10aR)-\0a -ethyl-7-methoxy-3-methyl-4a,9, 10,10a-tetrahydro- H-phenanthren- 1 -one and (rαc)-(4αR, 1 OαR)- 10a-ethyl-7-methoxy-3 -methyl-4a,9, 10, 1 Oa-tetrahydro-^H-phenanthren- 1 -one (26 mg) was used according to method K ("J" = 2.5, "K" = 4.0, "L" = -20, "M" = 12). The crude product thus obtained was purified on a chromatotron using EtOAc-n-heptane (3:7) as eluent to yield a mixture of (rαc)-(4αS, 10αR)-10a-ethyl-7-hydxoxy-3- methyl-4a, 9, 10, 1 Oa-tetrahydro-^H-phenanthren- 1 -one and (rαc)-(4αR, 10αR)Λ Oa-ethyl-7-hydroxy -3 -methyl-4a,9, 10, 1 Oa-tetrahydro-^H-phenanthren- 1 -one. (rαc)- (4αS, 1 OαR) - 1 Oa-Ethyl -7-hydroxy- 3-methyl-4a,9,10, 10a-tetrahydro-¥H- phenanthren-l-one: ES/MS m/z: 257.2 (pos, M+Η), 255.1 (neg, M-Η); 'ΗNMR (500 MHz, CDC13) δ 7.00 (d, IH), 6.70 (d, IH), 6.60 (s, IH), 5.90 (s, IH), 4.95 (s, IH, OH), 3.15-3.25 (m, IH), 2.70-2.85 (m, 3H), 2.40-2.45 (m, 2H), 1.95 (s, 3H), 1.50-1.60 (m, IH), 1.35-1-45 (m, 2H), 0.80 (s, 3H). (rαc)-(4αR, 1 OαR) - 10a-Ethyl-7-hydroxy-3 -methyl-4a,9, 10, 10a-tetrahydro-^H- phenanthren-1-one: ES/MS m/z: 257.2 (pos, M+Η), 255.1 (neg, M-Η); ΗNMR (500 MHz, CDC13) δ 7.10 (d, IH), 6.70 (d, IH), 6.60 (s, IH), 5.85 (s, IH), 5.00 (s, H-OH), 3.15-3.25 (m, IH), 2.70-2.85 (m, 3H), 2.40-2.45 (m, 2H), 2.0 (s, 3H),1.50-1.60 (m, IH), 1.35-1-45 (m, 2H), 0.75 (s, 3H).
Example 11: Synthesis of (rαc)-(lR.2S.4αS.10αS)-l-bxιt\l-7- vdroxy- 2-methyl-1. 4.4a.9.10.10a-hexahvdro- H-phenanthren-3-one (Ella): (rαc)- (lR.2R.4αS.10αS)- l-butyl-7-hvdroxy-2- methyl-1, 4,4a,9,10,10a-hexahydro- H-phenanthren-3-one (Εll ): and (rαc)- (lS.4R.4αRJ0αS)-l-b tyl-7-h\droxy-4- methyl-1.4.4a.9.10. 10a-hexahydro--?H-phenanthren-3-one (Ellc).
Step 1:
(rac)-(lR, 2S, 4aS, 1 OaS) A -Butyl-7-methoxy-2-methyl- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phena nthren-3-one and (rac)-(lR,2R,4aS,10aS)A- Butyl-7-methoxy-2-methyl -l,4,4a,9,10, 10a-hexahydro-2H-phenanthren-3-one and (rac)-(lS,4R,4aR,10aS) -l-Butyl-7- methoxy-4-methyl- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3-one. The enone (rac)-(4aS, iO<atS)-7-methoxy-4a,9,10,10a-tetrahydro-^H-phenanthren-3-one (31 mg) from Example 1 dissolved in diethyl ether / TΗF (3.0 mL, 2:1), was treated according to method E ("J" - CuCN, "K" = 2.2, "L" = 2.0, "M" = diethyl ether, "N" = π-butyl lithium [1.6M solution in hexanes], "O" = 4.2, "P" = -78, "Q" = 0.5) with the following exception. Methyl iodide (65 eq.) was added to the reaction mixture, and stirring was continued for another 40 h at room temperature before quenching. The crude product was purified on chromatotron, using EtOAc:«-heptane (1:9, v:v) as eluent, to yield (rac)-(lR,2S,4aS,10aS) A- butyl-7-methoxy-2-methyl-l,4,4a,9,10, 1 Oa-hexahydro- 2H-phenanthren-3-one, (rac)-(lR,2R,4aS, 1 OaS) A-bλxty -7- methoxy-2-methyl-l,4,4a,9,l 0,10a -hexahydro- 2H- phenanthren-3 -one and (rac)-(lS, 4R, 4aR, 1 OaS) A -butyl-7-methoxy-4-methyl- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3-one as a mixture (colorless glass) that was used in the next step (step 2).
Step 2: (rac)-(lR, 2S, 4aS, 1 OaS) A -Butyl-7-hydroxy-2-methyl- 1 ,4,4a,9, 10,10a-hexahydro-2H-phena nthren-3-one and (rac)-(lR, 2R, 4aS, 1 OaS) A -Butyl-7-hydroxy-2-methyl- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3-one and (rac)-(lS,4R,4aR,10aS)A- Butyl-7-hydroxy- 4-methyl-l,4,4a,9,10, 10a-hexahydro-2H-phenanthren-3-one. As substrate, a mixture (22.5 mg) of (rac)-(lR, 2S, 4aS, 1 OaS)- 1 -butyl-7-methoxy-2-methyl- 1 ,4,4a,9, 10, 1 Oa-hexahydro- 2H-phenanthren-3-one, (rac)-(lR, 2R, 4aS, 1 OaS)- 1 -butyl-7-methoxy-2-methyl- 1 ,4,4a, 9,10, 10a-hexahydro-2H-phenanthren-3 -one and (rac)-(lS, 4R, 4aR, 1 OaS)- 1 -butyl-7-methoxy -4-methyl-l,4,4a,9,10,10a-hexahydro-2H-phenanthren-3-one from the previous step (step 1) was treated according to method K ("J" = 2.0, "K" = 3.0, "L" = -20, "M" = 20). The crude product thus obtained was purified on chromatotron, using EtOAc:rø-heptane (3:7) as eluent. This material was then further fractionated using PΗPLC. (rac)- (lS,4R,4aR,10aS) A- butyl-7-hydroxy-4-methyl- l,4,4a,9,10,10a-hexahydro-2H-phenanthren-3-one (3.5 mg) was obtained in the first eluted fraction, a mixture of (rac)-(lR, 2S, 4aS, 1 OaS)- 1 -butyl- 7-hydroxy-2-methyl-l,4,4a,9,10,10a-hexahydro-2H-phenanthren-3-one and (rac) - (lR,2R,4aS, WaS) -l-butyl-7-hydroxy-2-methyl-l,4,4a,9,10,10a-hexahydro -2H- phenanthren-3-one in the second, and (rac)-(lR,2R,4aS,l OaS) A-butyl-7-bydxoxy-2-methyl -l,4,4a,9,10,10a-hexahydro-2H-phenanthren-3-one in the third. (rac)-(lR,2R,4aS,10aS)- 1 -Butyl-7-hydroxy-2-methyl- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3-one: ES/MS m/z: 287.2 (pos, M+Η), 285.1 (neg, M-Η); 'ΗNMR (270 MHz, CDC13) δ 7.00 (d, IH), 6.65 (dd, IH), 6.60 (d, IH), 4.65 (br. s, IH), 2.80-3.05 (m, 4H), 2.70 (t, IH), 2.20 (t, IH), 1.95-2.10 (m, 2H), 1.65-1.90 (m, 2H), 1.00-1.40 (m, 6H), 1.05 (d, 3H, CH3-C2), 0.85 (t, 3H). (rac)-(lR, 2S, 4aS, 1 OaS)- 1 -Butyl-7-hydroxy- 2-methyl- 1 ,4,4a,9, 10, 1 Oa-hexahydro- 2H- phenantbren-3-one: 'H NMR (270 MHz, CDC13, selected signal) δ 1.25 (d, 3H, CH3-C2). (rac)-(lS, 4R, 4aR, 1 OaS) A - Butyl-7-hydroxy-4-methyl- 1 ,4,4a, 9, 10, 10a- hexahydiO-2H-phenanthren-3-one: ES/MS m/z: 287.2 (pos, M+Η), 285.1 (neg, M-Η); Η NMR (270 MHz, CDC13, selected signal) δ 0.95 (d, 3H, CH3-C4).
Example 12: Synthesis of (rac)-(lR.2R.4aS.10aS)A-butyl-33-e thanediyldimercapto -7-hydroxy-2-methyl-1.2.3.4,4a.9.10.10a-octahvdro-phenanthrene (E12a^: and (rac)- (lR.2S.4aS.10aS)A-butyl-33- ethanediyldimercapto-7-hvdroxy -2-methyl-1.2.3.4.4a. 9.10.10a-octahvdro-phenanthrene rE12fr..
A mixture (6.0 mg, 1:1) of the ketones (rac)-(lR,2S,4aS,10aS)A- butyl-7-hydroxy -2- methyl-1, 4,4a,9,10,10a-hexahydro-2H-phenanthren-3-one and (rac)- (lR,2R,4aS,10aS) - 1 -butyl-7-hydroxy-2-methyl- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3-one was treated according to method G ("J" = 2.5, "K" = 1,2-ethanedithiol, "L" = 2.0, "M" = 12). The crude product was fractionated using PΗPLC. (rac)-(lR, 2S, 4aS, 1 OaS) A - Butyl-3 , 3 -ethanediyldimercapto-7-hydroxy-2-methyl- 1 ,2,3 ,4,4a, 9, 10, 1 Oa-octahydro-phenanthrene was obtained from the first eluted fraction and (rac) -(lR,2R,4aS,l OaS) A-bxxtyl-3, 3- ethanediyldimercapto-7-hydroxy-2-methyl- 1 ,2,3 ,4,4a,9, 10,1 Oa-octahydro-phenanthrene from the second. (rac)-(lR,2S,4aS,10aS)A-Butyl-3,3-efaanediyldimexcapto-7 -hydroxy- 2-methyl-l,2,3,4,4a,9,10,10a-octahydro-phenanthrene: ES/MS m/z: 361.3 (neg, M-Η); 'Η NMR (270 MHz, CDC13) δ 7.10 (d, IH), 6.60 (dd, IH), 6.55 (d, IH), 3.5-4.5 (br. s, IH), 3.35-3.45 (m, 2H), 3.15-3.25 (m, 2H), 2.70-2.90 (m, 3H), 2.45-2.55 (m, 2H), 1.90-2.05 (m, IH), 1.70-1.90 (m, 2H), 1.50-1.70 (m, 4H), 1.10-1.50 (m, 4H), 1.30 (d, 3H), 0.90 (t, 3H). (rac)-(lR,2R,4aS,10aS) -1 -Butyl-3, 3 -ethanediyldimercapto -7-hydroxy-2-methyl-l, 2,3, 4,4a,9, 10,1 Oa-octahydro-phenanthrene: ES/MS m/z: 361.3 (neg, M-H); ΗNMR (270 MHz, CDC13) δ 7.15 (d, IH), 6.60 (dd, IH), 6.50 (d, IH), 3.5-4.0 (br. s, IH), 3.10-3.40 (m, 4H), 2.70-2.90 (m, 3H), 2.15-2.25 (m, IH), 1.80 (t, IH), 1.50-1.75 (m, 5H), 1.05-1.40 (m, 6H), 1.25 (d, 3H), 0.85 (t, 3H).
Example 13: Synthesis of t/fflc)-t-?S.^αS <?aS)-7-hvdroxy-10a-methyl-l- (3-methyl-butyl 1.4.4a.9.10.10a-hexahvdro- H-phenanthren-3-one (E13
Ste l: 2-Iodo-4-(4-methoxy-benzyloxy)-benzaldehyde. A mixture of 4-hydroxy-2-iodo-benzaldehyde (26.45 g, 106.6 mmol), p-methoxybenzyl chloride (1.3 eq.), ethyl diisopropylamine (1.4 eq.), and sodium iodide (0.1 eq.) in DCM (500 mL) was refluxed for 69 h. The reaction mixture was then washed with l.OM HCl (aq, 3 x 100 mL), water (200 mL), saturated Sodium bicarbonate (100 mL), and saturated NH4C1 (100 mL) before drying over anhydrous magnesium sulfate and concentration in vacuo. The crude product thus obtained, was purified by silica gel flash chromatography, using EtOAc :n-heptane (1:9, 2:8, 3:7, stepwise gradient) as eluent, to yield pure 2-iodo-4-(4-methoxy-benzyloxy)-benzaldehyde in the first eluted fraction as a yellowish solid, together with a mixture of unconsumed 4-hydroxy-2-iodo-benzaldehyde and pure 2-iodo-4-(4-methoxy-benzyloxy)-benzaldehyde in the second. 'H NMR (270 MHz, CDC13) δ 9.90 (s, IH), 7.85 (d, IH), 7.50 (d, IH), 7.35 (d, 2H), 7.00 (dd, IH), 6.90 (d, 2H), 5.05 (s, 2H), 3.80 (s, 3H).
Step 2: 4-[2-Iodo-4-(4-methoxy-benzyloxy)-phenyl]-but-3-en-2-one. To a stirred suspension of 2-iodo-4-(4-methoxy-benzyloxy)-benzaldehyde (14.7 g, 39.9 mmol) in a water:acetone mixture (150 mL, 1:2), was added aqueous NaOH (16.0M, 1.2 eq.) before heating at reflux for 10 min. The yellow precipitate formed after having added another portion of water (100 mL) and allowed to cool to room temperature was collected, washed with water, and dried over P2O5 to give 4-[2-iodo-4-(4-methoxy-benzyloxy)-phenyl] -but-3-en-2-one. ΗNMR (270 MHz, CDC13) δ 7.70 (d, IH), 7.50-7.55 (m, 2H), 7.30 (d, 2H), 6.95 (dd, IH), 6.90 (d, 2H), 6.45 (d, IH), 5.00 (s, 2H), 3.80 (s, 3H), 2.40 (s, 3H).
Step 3:
(rac)-(4aR, 10 aS) - -By dxoxy- 10a-methyl-4a,9, 10, 1 Oa-tetrahydro-^H-phenanthren-3-one and (rac)-(4aS, 70αS 7-Hydroxy-10a-methyl-4a, 9,10,10a-tetrahydro- H- phenanthren-3-one. The aryl iodide 4-[2-iodo-4-(4-methoxy-benzyloxy)- phenyl]-but-3- en-2-one (2.02 g) was treated according to method A ("J" = 2-methyl-but-3-en-l-ol, "K" = 1.5, "L" = 4.0, "M" = 2, "N" = 1.5). The material obtained was then treated according to method C ("N" = 100, "Q" = 12). The crude product obtained was fractionated by PΗPLC. The first eluted fraction contained a mixture of (rac)-(4aR,10aS)- 7-hydroxy- 10a-methyl-4a,9, 10, 1 Oa-tetrahydro-^H-phenanthren-3-one and (rac)-(4aS, 10aS)-7- hydroxy-10a-methyl-4a,9,10,10a-tetrahydro-^H-phenanthren-3-one, and the second also a mixture but with different proportions.
Step 4:
(rβc 7S, αS,70αS -7-Ηydroxy-10a-me l-l-(3-memyl-butyl)-l,4,4a,9,10,10a-hexahydro- 2H-phenanthren-3-one. To rapidly stirred magnesium turnings (6.25 eq.) covered with dry TΗF (1.0 mL), was added approximately 1/3 of the total amount of l-bromo-3-methylbutane. The rest of the l-bromo-3-methylbutane (totally 2.08 eq.) was then added in small portions, after having initiated the reaction with a small crystal of iodine, followed by heating at 60 °C for 30 min. Another portion of dry TΗF (3.0 mL) was then added before cooling (dry ice / acetone bath). To this cool mixture was added a suspension of Cul (0.5 eq.) in TΗF (1.0 mL) before allowing it to come to 0°C for 10 min. and again cooling (dry-ice / acetone bath). A solution of a mixture of the enones (rac)-(4aR, 10aS)-7-bydxoxy- 10a-methyl-4a,9, 10, 1 Oa-tetrahydro-^H-phenanthren-3-one and (rac)-(4aS, 10aS)-7 -by dxoxy A 0a-methyl-4a,9, 10, 1 Oa-tetrahydro-^H-phenanthren-3-one (220 mg, 1.0 eq.) in TΗF (2.0 mL) was then added dropwise. Stirring was continued at -78 °C for 2 h before quenching and workup as in method E. The crude product was purified on chromatotron using EtOAc :«-heptane (2:8, 3:7, 4:6, v:v; stepwise gradient) as eluent to yield (rac)-(lS,4aS,10aS)-7-bydxoxyA0a-metbyl-l- (3-methyl-butyl)- l,4,4a,9, 10, 10a-hexahydro-2H-ρhenanthren-3-one. ES/MS m/z: 299.2 (neg, M-Η); 'Η NMR (270 MHz, CD3OD) δ 6.90 (d, IH), 6.5-6.6 (m, 2H), 3.00 (dd, IH), 2.75-2.90 (m, 4H), 2.40 (t, 2H), 1.90-2.05 (m, IH), 1.65-1.80 (m, 2H), 1.40-1.60 (m, 2H), 1.25-1.40 (m, IH), 0.95-1.20 (m, 2H), 1.05 (s, 3H), 0.90 (t, 6H). Example 14: Synthesis of (rac)- (lS.4aS,10aS)-33- ethanedivdimercapto -7-hvdroxy-l- (3-methyl-butyr)- 10a-methyl-l,2.3.4.4a,9.10. lOa-octahvdro- phenanthrene (E14).
The ketone
(rac)-(lS, 4aS, 10aS)-7-bydxoxyA Oa-methyl- 1 -(3 -methyl-butyl)- 1 ,4,4a, 9, 10, 1 Oa-hexahydro- 2H-phenanthren-3-one (48.5 mg) was treated according to method G ("J" = 3.0, "K" = 1,2-ethanedithiol, "L" = 2.0, "M" = 12). The crude product was purified on chromatotron, using EtOAc :n-heptane (2:8, v:v) as eluent to yield (rac)-(lS,4aS,10aS)-3, 3- ethanediyldimercapto-7-hydroxy- 1 -(3 -methyl-butyl)- 1 Oa-methyl- 1 ,2,3,4, 4a,9, 10, 1 Oa-octahy dro-phenanthrene as a glass. ES/MS m/z: 377.2 (pos, M+Η), 375.1 (neg, M-Η); 'Η NMR (270 MHz, CD3OD) δ 7.00 (d, IH), 6.55 (dd, IH), 6.50 (d, IH), 3.20-3.40 (m, 4H), 2.55-2.90 (m, 4H), 2.50 (dd, IH), 2.25 (d, IH), 1.00-1.95 (m, 9H), 0.90 (dd, 6H), 0.85 (s, 3H).
Example 15: Synthesis of (rac)-(lS.4aSJ0aS)-7-hvdroxy-10a-methylA- phenethyl-l,4.4a.9,10 0a-hexahydro- H-phenanthren-3-one (Ε15).
To rapidly stirred magnesium turnings (24 eq.) covered with dry THF (1.0 mL), was added approximately 1/3 of the total amount of 2-bromoethylbenzene. The rest of the 2-bromoethylben zene (totally 2.08 eq. in 2.0 mL THF) was then added in small portions, after having initiated the reaction with a small crystal of iodine, followed by heating at 60 °C for 30 min. Another portion of dry THF (3.0 mL) was then added before cooling (dry ice / acetone bath). To this cool mixture was added a suspension of Cul (0.5 eq.) in THF (0.5 mL) before allowing it to come to 0°C for lOmin. and again cooling (dry-ice / acetone bath). A solution of a mixture of the enones (rac)-(4aR,10aS)-7- hydroxy-lOa- methyl-4a, 9,10,10a-tetrahydro- H-phenanthren-3-one and (rac)-(4aS,10aS)- -by dxoxy -10a- methyl-4a,9,10,10a-tetrahydro-^H-phenanthren-3-one (78 mg, 1.0 eq.) in TΗF (2.0 mL) from Example 3 was then added dropwise. Stirring was continued at -78 °C for 2 h before quenching and workup as in method E. The crude product was purified by silica gel flash chromatography, using EtOAc:π-heptane (1:9, 15:85, 2:8, v:v; stepwise gradient) as eluent, followed by PΗPLC to yield (rac)-(lS,4aS,10aS)-7-bydxoxy-\ Oa-methyl- 1-ρhenethyl- l,4,4a,9,10,10a-hexahydro-2H-phenanthren-3-one together with unconsumed (rac)-(4aS, 1 OaS) - -by dxoxy- 10a-methyl-4a,9, 10, 10a-tetrahydro- H-phenanthren-3-one. ES/MS m z: 335.2 (pos, M+Η), 333.4 (neg, M-Η); Η NMR (270 MHz, CD3CN) δ 7.10-7.30 (m, 5H), 6.90 (d, IH), 6.45-6.75 (m, 3H), 2.95 (dd, IH), 2.60-2.95 (m, 5H), 2.25-2.50 ( , 3H), 1.65-2.00 (m, 3H), 1.15-1.45 (m, 2H), 0.95 (s, 3H).
Example 16:Svnthesis of (rac)-(lS.2S.4aS.10aS)-7-Η\droxy-2Λ0a- dimethyl-1- r3-methvI-butyl)-l,4.4a.9.10.10a-hexahvdro- H-phenanthren-3-one fE16a^: and (rflc -( S.2R. a^ </ S,)-7-Hydroχy-2. 10a-dimethyl-l-(3-methyl-butvn-1. 4.4a.9. 10,10a-hexahvdro- H-phenanthren-3-one fE16b).
Step 1: 4-Benzyloxy-2-iodo-benzaldehyde. A mixture of 4-hydroxy-2-iodo-benzaldehyde (28.73 g, 248 mmol), benzyl bromide (1.3 eq.), ethyl diisopropylamine (1.4 eq.), and sodium iodide (0.1 eq.) in DCM (500 mL) was refluxed for 12 h. The remaining mixture was then washed with l.OM HCl (aq, 3 x 100 mL), water (200 mL), saturated Sodium bicarbonate (100 mL), and saturated NH4C1 (100 mL) before drying over anhydrous magnesium sulfate and concentration in vacuo. The crude product thus obtained was purified by silica gel flash chromatography using EtOAc :n-heptane (0:100, 1:9, 2:8, stepwise gradient) as eluent, to yield 4-benzyloxy-2-iodo-benzaldehyde as a yellow powder.
Step 2: 4-(4-Benzyloxy-2-iodo-phenyl)-but-3-en-2-one. To a stirred suspension of 4-benzyloxy-2-iodo-benzaldehyde (17.73 g, 52.4 mmol) in a wateπacetone mixture (150 mL, 1 :2), was added aqueous NaOH (16.0M, 1.2 eq.) before heating at reflux for 10 min. The yellowish precipitate formed after having added another portion of water (10 0 mL) and allowed to cool to room temperature was collected, washed with water, and dried over P2O5 to give 4-(4-benzyloxy-2-iodo-phenyl)-but-3-en-2-one as a yellow powder.
Step 3:
(rac)-(4aS, 10αR)-7-Benzyloxy- 10a-methyl-4a,9, 10, 10a-tetrahydro- H-phenanthren-3-one and (rac)-(4aS, i0-7S 7-Benzyloxy-10a-methyl-4a,9, 10,10a-tetrahydro -^H-phenanthren -3-one. The aryl iodide 4-(4-benzyloxy-2-iodo-phenyl)-but-3-en-2-one (6.175 g) was treated according to method A ("J" = 2-methyl-but-3-en-l-ol, "K" = 1.3, "L" = 4.0, "M" = 0.5, "N" = 1.5). The material obtained was then treated according to method C ("N" = 150, "Q" = 2). The crude product obtained was purified by silica gel flash chromatography using EtOAc :n-heptane (5:95, 1 :9, 2:8, stepwise gradient) as eluent, to yield (rac)- (4aS, 1 OaS) - -benzyloxy- 10a-methyl-4a,9, 10,1 Oa-tetrahydro-^H-phenanthren-3 -one (yellowish powder) as the first eluted material. The second eluted material contained a mixture of (rac)-(4aS,10aS)-7-benzyloxy- 10a-methyl-4a,9,10, lOa-tetrahydro- 4H- phenanthren-3-one and (rac)-(4aS, 10aR)-7 -benzyloxy- 10a-methyl-4a,9,10, lOa-tetrahydro- ¥H-phenanthren-3 -one.
Step 4:
(rac)-(lS, 2S, 4aS, 10aS)-7-Benzyloxy-2, 1 Oa-dimethyl- 1 -(3 -methyl-butyl)- 1 ,4,4a,9, 10, 1 Oa-he xahydro-2H-phenanthren-3-one and (rac)-(lS,2R,4aS,10aS)-7-Bexxzyloxy-2, 1 Oa-dimethyl- 1 -(3 -methyl-butyl)- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3 -one. The enone (rac)-(4aS,10aS)- -benzyloxy- 10a-methyl-4a,9,10, 10a-tetrahydro- H-phenanthren -3-one (70 mg) dissolved in TΗF (2.0 mL), was treated according to method E ("J" = lithium 2-thienylcyanocuprate [Aldrich, no. 32,417-5, 0.25M solution in TΗF], "K" = 2.0, "L" = 1.0, "M" = TΗF, "N" = 3-methyl-l-butyl magnesium bromide [0.5M solution in TΗF], "O" = 2.0, "P" = 0, "Q" = 0.5) with the following exception; Methyl iodide (16 eq. dissolved in 2.0 mL DMPU) was added to the reaction mixture, and stirring was continued for another 96 h at room temperature before quenching. The crude product was purified on PΗPLC to yield a mixture of (rac)-(lS,2S,4aS,10aS)-7-benzyloxy-2, 1 Oa-dimethyl- 1- (3 -methyl-butyl)- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3-one and (rac)-(lS,2R,4aS,10aS) -7-benzyloxy-2, 1 Oa-dimethyl- 1- (3 -methyl-butyl)- 1,4,4a, 9, 10, 10a-hexahydro-2H-phenanthren-3-one (white powder) that was used in the next step (step 5).
Step 5:
(rac)-(lS, 2S, 4aS, 10 aS) - -By dxoxy-2, 1 Oa-dimethyl-1 -(3 -methyl-butyl)- 1 ,4,4a,9, 10, 1 Oa-hex ahydro-2H-phenanthren-3-one and (rac)-(lS,2R,4aS,10aS)-7-Bydxoxy-2, 1 Oa-dimethyl-1- (3 -methyl-butyl)- 1 ,4,4a,9, 10,10a-hexahydro-2H-phenanthren-3 -one. As the substrate, a mixture of (rac)-(lS,2S,4aS,10aS)- 7-benzyloxy-2,l Oa-dimethyl-1- (3-methyl-butyl) - 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3-one and (rac)-(lS, 2R, 4aS,10aS)- 7-benzyloxy-2, 1 Oa-dimethyl- 1 -(3 -methyl-butyl)- 1 ,4,4a,9, 10,10a-hexahydro-2H-phenanthre n-3-one (29 mg) from the previous step (step 4) was treated according to method F ("J" = TΗF:ΗOAc [95:5], "K" = 3.0, "L" = 5% Pd/C, "M" = 10, "N" = 72). The crude product was purified using PHPLC to yield a mixture of (rac)-(lS,2S,4aS, 10aS)-7-bydxoxy-2, 1 Oa-dimethyl- 1 -(3-methyl-butyl)- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3 -one and (rac)-(lS, 2R, 4aS, 1 OaS) -7 -by dxoxy-2, 1 Oa-dimethyl- 1 -(3-methyl-butyl)- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3-one as a colorless glass. ES/MS m/z (mixture): 315.4 (pos, M+Η), 313.3 (neg, M-Η); 'Η NMR (270 MHz, CD3CN, selected signals of the mixture) δ 6.95 (d, H-C5, major isomer), 6.90 (d, H-C5, minor isomer), 6.10 (d, CH3-C2, major isomer), 0.95 (d, CH3-C2, minor isomer).
Example 17: Synthesis of
(rflc)-^bS.g>S'.gαS)-6,6-dimethoxy-8a-methyl-8-r3-methyl-butvn -4b.5.6.7.8.8a. 9.10-octahvdro-phenanthren-2-ol (Ε17a) and(rac)-(lS.4aS.10aS) -7-hvdroxy-10a-methyl-l- G-methyl-butvn-1.4.4a.9.10. 10a-hexahvdro-2H- phenanthren-3-one E17b .
Step 1:
(rac) -(IS, 4aS, 10aS)-7 -Benzyloxy- 1 Oa-methyl- 1 -(3 -methyl-butyl)- 1 ,4,4a,9, 10, 1 Oa-hexahydr o-2H-phenanthren-3 -one. The enone (rac)-(4aS, 10aS)-7 -benzyloxy- 10a-methyl-4a,9, 10, lOa-tetrahydro-^H-phenanthren-3-one (303 mg) from Example 16 dissolved in TΗF (4.0 mL), was treated according to method E ("J" = lithium 2-thienylcyanocuprate (Aldrich, no. 32,417-5, 0.25M solution in TΗF), "K" = 2.0, "N" = 3-methyl-l -butyl magnesium bromide (0.5M solution in TΗF), "O" = 2.0, "P" = 0, "Q" = 0.25). The crude product was purified on chromatotron, using EtOAc :«-heptane (1:9, 2:8, v:v, stepwise gradient) as eluent to yield (rac) -(IS, 4aS, 10aS)-7 -benzyloxy- 1 Oa-methyl- 1 -(3-methyl-butyl)- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3-one as a white powder.
Step 2:
(rac)-(lS, 4aS, 10aS)-7-BydxoxyA Oa-methyl- 1 -(3-methyl-butyl)- 1 ,4,4a,9, 10, 1 Oa-hexahydro- 2H-phenanthren-3-one and (rac)-(4bS,8S,8aS)-6,6-Di etboxy-8a-xnethyl-8- (3-methyl- butyl)-4b,5,6,7,8,8a,9,10-octahydro-phenanthren-2-ol. As the substrate, (rac)-(7S,^ Si0αS) -7-benzyloxy-10a-methyl-l-(3-methyl-butyl)-l,4,4a,9,10, 10a-hexahydro-2H-phenanthren-3-one was treated according to method F ("J" = methanoLEtOAc [7:3], "K" = 15, "L" = 5% Pd/C, "M" = 40, "N" = 16). The crude product was fractionated on chromatotron, using EtOAc.-rø-heptane (1:9, 2:8, 3:7, v:v, stepwise gradient) as eluent to yield (rαc)-(4bS,8S,8αS)-6,6- dimethoxy-8a-methyl-8- (3-methyl-butyl)-4b,5,6,7,8,8a,9, 10-octahydro-phenanthren-2-ol as a colorless glass in the first eluted fraction, and (rαc)-(lS,4αS, 10αS)-7-bydxoxyA Oa-methyl -1 -(3 -methyl-butyl)- 1, 4,4a,9,10,10a-hexahydro-2H-phenanthren-3-one (for an alternative synthetic method and spectroscopic data see earlier example) as a colorless glass in the second. (rαc)-(4bS, 8S, 5 S 6,6-Dimethoxy -8a-methyl-8-(3-methyl-butyl)- 4b,5,6,7,8,8a,9, lO-octahydro-phenanthren-2-ol: ES/MS m/z: 345.1 (neg, M-Η); 'ΗNMR (270 MHz, CD3OD) δ 7.05 (d, IH), 6.55 (dd, IH), 6.50 (d, IH), 3.25 (s, 3H), 3.15 (s, 3H), 2.60-2.90 (m, 3H), 2.50 (dt, IH), 2.10 (dt, IH), 1.85 (dt, IH), 1.75 (dd, IH), 1.25-1.60 (m, 7H), 1.05-1.15 (m, IH), 0.90 (dd, 6H), 0.85 (s, 3H); 13C NMR (CD3OD) δ 154.60, 137.25, 129.90, 126.00, 114.75, 112.65, 101.35, 46.45, 46.35, 44.60, 38.45, 35.50, 35.10, 33.80, 31.70, 29.65, 28.35, 26.65, 24.85, 22.30, 21.50, 17.55.
Example 18: Synthesis of
3,3-ethanediyldioxy-7-hvdroxy-l-(3-methyl-butyl)-10a-methyl-1.2.3,4,4a.9.10,10a-oc tahydro-phenanthrene (E18).
The ketone (rac)-(lS,4aS, 10aS)-7-bydxoxyA Oa-methyl- 1 -(3 -methyl-butyl)- 1, 4,4a,9, 10,10a-hexahydro-2H-phenanthren-3-one (10.4 mg) was treated according to method Η ("J" = 1,2-dihydroxyethane, "K" = 0.5, "L" = 50, "M" = 1.0, "N" = 22, "O" = 5). The crude product was purified on chromatotron, using EtOAc:«-heptane (2:8, 3:7, v:v, stepwise gradient) as eluent to yield (rac)-(lS,4aS, 10aS)- ,3-etbanediyldioxy- 7-hydroxy- 1 -(3 -methyl-butyl)- 1 Oa-methyl- 1 ,2,3 ,4,4a,9, 10,1 Oa-octahydro-phenanthrene as a colorless glass. ES/MS m/z: 345.4 (pos, M+Η), 343.3 (neg, M-Η); 'Η NMR (270 MHz, CDC13) δ 7.05 (d, IH), 6.55-6.65 (m, 2H), 4.60 (s, IH), 3.90-4.10 (m, 4H), 2.65-2.95 (m, 3H), 2.25 (dt, IH), 1.75-2.00 (m, 3H), 1.20-1.65 (m, 7H), 1.00-1.15 (m, IH), 0.90 (dd, 6H), 0.85 (s, 3H); 13C NMR (CDCl3) δ 153.15, 137.85, 131.90, 126.85, 115.15, 112.80, 110.20, 64.80, 63.80, 44.70, 38.35, 36.85, 35.25, 35.00, 33.60, 31.80, 28.40, 27.05, 24.95, 23.35, 22.35, 18.25. Example 19: Synthesis of t flcJ-( bS^R.gfl>y)-8a-methyl-8-(3-methvI-butvn-4b.5.6.7.8.8a. 9.10-octahvdro- phenanthren-2-ol (E19a : and (rac)-(4bS.6R.8S.8aS)-6-et ylsulϊanyl-8a-met \l-&- (3-methyl-butyl)-4b.5.6.7.8.8a.9,10-octahvdro-phenanthren-2-oi rE19b).
The substrate (rac)-(2S, αS,I S)-3,3-ethanediyldimercapto-7~ hydroxy-1- (3 -methyl-butyl)- 1 Oa-methyl- 1, 2,3, 4,4a,9, 10,1 Oa-octahydro-phenanthrene (14.7 mg) was treated according to method I ("J" = 1.0, "K" = 240, "L" = 22, "M" = 16). The crude product was first purified on PHPLC, followed by fractionation on chromatotron, using EtOAc :τ.-heptane (2:8, 3:7, v:v, stepwise gradient) as eluent, to yield (rac)-(4bS,8R,8aS)- 8a-methyl-8-(3-methyl-butyl)-4b,5,6,7,8,8a, 9,10-octahydro-phenanthren-2-ol as a colorless glass in the first eluted fraction and (rac)-(4bS,6R,8S,8aS)-6-etbyls\xlfanyl~8a-xnetbyl- 8-(3-methyl-butyl)-4b,5,6,7,8,8a,9,10-octahydro-phenanthren-2-ol (1.3 mg) in the second. (rac)-(4bS, 8R, SαS 8a-Methyl-8-(3-methyl-butyl) -4b,5,6,7,8,8a, 9, 10-octahydro- phenanthren-2-ol: ES/MS m/z: 287.2 (pos, M+H), 285.1 (neg, M-H); 'H NMR (270 MHz, CDC13) δ 7.10 (d, IH), 6.60 (dd, IH), 6.50 (d, IH), 4.40 (s, IH), 2.65-2.95 (m, 2H), 2.60 (dd, IH), 2.05-2.20 (m, IH), 1.70-2.00 (m, 2H), 1.00-1.70 (m, 11H), 0.875 (dd, 6H), 0.85 (s, 3H); 13C NMR (CDC13) δ 152.95, 138.00, 133.00, 126.75, 115.10, 112.60, 44.45, 38.90, 38.40, 35.45, 34.15, 28.45, 27.00, 25.20, 24.0 (two peaks), 23.15, 22.45, 21.10, 18.45. (rac)-(4bS, 6R,8S,8aS) -6-Ethylsulfanyl-8a-methyl-8- (3-methyl-butyl)-4b,5,6,7,8,8a,9, 10-octahydro-phenanthren-2-ol: ES/MS m/z: 347.2 (pos, M+H), 345.1 (neg, M-H); 'H NMR (270 MHz, CDC13) δ 7.05 (d, IH), 6.60 (dd, IH), 6.55 (d, IH), 4.40 (s, IH), 3.25-3.35 (m, IH), 3.05 (dd, IH), 2.65-2.95 (m, 2H), 2.60 (q, 2H), 2.30 (br. d, IH), 2.20 (dt, IH), 1.00-2.00 (m, 10H), 1.25 (t, 3H), 0.90 (dd, 6H), 0.85 (s, 3H).
Example 20: Synthesis of (rac)-(lS,4aS,10aS)-33-(propane-l. 3-diyldimercapto)-7-hydroxy-l-(3-methyl-butyI)- lOa-methyl- 1.2.3,4,4a,9., 10.10a-octahydro-phenanthrene (E20 .
The ketone (rac)-(lS,4aS, 10aS)-7-bydxoxyA Oa-methyl- 1- (3-methyl-butyl)- 1, 4,4a,9,10,10a-hexahydro-2H-phenanthren-3-one (11 mg) was treated according to method G ("J" = 3.0, "K" = 1,3-propanedithiol, "L" = 2.0, "M" = 16). The crude product was purified on chromatotron using EtOAc:rø-heptane (2:8, v:v) as eluent to yield (rac)-(lS, 4aS,10aS) -3,3-(propane-l ,3-diyldimercapto)-7-hydroxy-l - (3-methyl-butyl)- 1 Oa-methyl- 1, 2,3 ,4,4a,9, 10,1 Oa-octahydro-phenanthrene (colorless glass). ES/MS m/z: 391.3 (pos, M+Η), 389.2 (neg, M-Η); 'Η NMR (270 MHz, CDC13) δ 7.10 (d, IH), 6.65 (dd, IH), 6.55 (d, IH), 4.50 (s, IH), 2.65-3.20 (m, 8H), 1.70-2.35 (m, 7H), 1.30-1.60 (m, 5H), 1.05-1.15 (m, IH), 0.90 (dd, 6H), 0.85 (s, 3H).
Example 21: Synthesis of (rac)~(4as.l0as)-7-hvdroxy-10a- methyl-1.4.4a. 9.10. 10a-hexahvdro-2H-phenanthren-3-one (E21).
The substrate (rαc)-(¥ S,/0αS)-7-hydroxy-10a-methyl-4a,9,10, lOa-tetrahydro- 4H -phenanthren-3 -one (16 mg) was treated according to method F ("J" = methanol, "K" = 1.5, "L" = 5% Pd/C, "M" = 5, "N" = 16) to obtain (rac)-(4aS, 10aS)-7-bydxoxyA Oa- methyl- l,4,4a,9, 10,10a-hexahydro-2H-phenanthren-3 -one. ES/MS m/z: 229.0 (neg, M-Η); 'Η NMR (270 MHz, CD3OD) δ 6.90 (d, IH), 6.45-6.60 (m, 2H), 2.60-3.00 (m, 5H), 2.25-2.40 (m, 2H), 1.50-1.90 (m, 4H), 0.90 (s, 3H).
Example 22: Synthesis of (mc)- flS' flflS)-3.3-ethanediyldimercapto-7- hydroxy-10a-methyl-l,2,3,4.4a,9.10.10a-octahydro-phenanthrene (E22 .
The ketone (rac)-(4aS, 10aS)-7-bydxoxyA Oa-methyl- l,4,4a,9, 10, lOa-hexahydro- 2H-phenanthren-3-one (12 mg) was treated according to method G ("J" = 3.0, "K" = 1,2-ethanedithiol, "L" = 2.0, "M" = 16). The crude product was purified on chromatotron, using EtOAc:7 -heptane (1:9, 2:8, v:v, stepwise gradient) as eluent to yield (rac)-(4aS,10aS)-3,3- ethanediyldimercapto-7- hydroxy-1 Oa-methyl- 1, 2,3, 4,4a,9, 10,1 Oa-octahydro-phenanthrene as a white powder. ES/MS m/z: 307.3 (pos, M+Η), 305.2 (neg, M-Η); 'Η NMR (270 MHz, CD3OD) δ 6.90 (d, IH), 6.45-6.55 (m, 2H), 3.20-3.40 (m, 4H), 2.55-2.90 (m, 4H), 2.15-2.30 (m, IH), 2.00 (dq, IH), 1.90 (t, IH), 1.50-1.60 (m, 4H), 0.70 (s, 3H).
Example 23: Synthesis of (rac)-(4aS.10aS)- 10a-ethvI-7-hvdroxy-1.4.4a.9.10. lOa-hexahvdro- 2H-phenanthren-3-one (E23).
Step 1: (rac)-2-Ethyl-but-3~en-l-ol. Using the allylic bromide l-bromo-2-pentene (10.0 g) and the aldehyde formaldehyde (37% solution in water) as starting materials according to method D ("J" = 3.0, "K" = 18), a crude product was obtained. This was purified by distillation (68-70 °C/80 mmHg) to yield (rac)-2-ethyl-but-3-en-l-ol as a colorless oil. 'H NMR (270 MHz, CDC13) δ 5.45-5.70 (m, IH), 5.05-5.20 (m, 2H), 3.55 (dd, IH), 3.40 (dd, IH), 2.00-2.20 (m, IH), 1.15-1.60 (m, 2H), 0.90 (t, 3H).
Step 2:
(rac)-(4aR, 1 OaS) -7 -Benzyloxy- 10a-ethyl-4a,9, 10, 1 Oa-tetrahydro-^H-phenanthren-3-one and (rac)-(4aS,10aS)-7 -Benzylox A0a-etbyl-4a,9, 10, lOa-tetrahydro- 4H- phenanthren -3-one. The aryl iodide 4-(4-benzyloxy-2-iodo-phenyl)-but-3-en-2-one (1.0 g) was treated according to method A ("J" = (rac)-2-ethyl-but-3-en-l-ol, "K" = 2.0, "L" = 4.0, "M" = 8.0, "N" = 4.0). The material obtained was then treated according to method C ("N" = 70, "Q" = 16). The crude product obtained was purified by silica gel flash chromatography using EtOAc:τ--heptane (2:8). The first eluted fraction was then further fractionated using PHPLC. (rac)-(4aR, 10aS 7-Benzyloxy- 10a-ethyl-4a,9, 10, phenanthren-3-one (off-white solid) was obtained in the first eluted fraction. (rac)-(4aS, 10aS)-7 -Benzyloxy- 10a-ethyl-4a,9, 10, 1 Oa-tetrahydro-^H-phenanthren-3-one (yellowish solid) was obtained in the second eluted fraction. (rac)-(4aR,10aS)-7- Benzyloxy-10a-ethyl-4a,9,10,10a-tetrahydro-^H-phenanthren-3-one: ES/MS m/z: 333.1 (pos, M+Η); 'Η NMR (270 MHz, CDC13) δ 7.30-7.45 (m, 5H), 7.00 (d, IH), 6.80 (d, IH), 6.75 (d, IH), 6.70 (d, IH), 6.00 (d, IH), 5.05 (s, 2H), 3.15 (dd, IH), 2.75-2.85 (m, 2H), 2.45-2.60 (m, 2H), 1.85-1.95 (m, IH), 1.65-1.75 (m, IH), 1.50 (q, 2H), 0.90 (s, 3H). (rac)-(4aS, 10aS)- -Benzyloxy- 10a-ethyl-4a,9, 10, 10a-tetrahydro-¥H-phenanthren-3-one: ES/MS m/z: 333.1 (pos, M+Η); 'Η NMR (270 MHz, CDC13) δ 7.30-7.50 (m, 5H), 7.00 (d, 2H), 6.82 (d, IH), 6.78 (d, IH), 6.05 (d, IH), 5.05 (s, 2H), 3.30 (dd, IH), 3.05 (dd, IH), 2.85-2.95 (m, 2H), 2.60 (dd, IH), 2.10-2.20(m, IH), 1.65-1.75 (m, IH), 1.35-1.50 (m, 2H), 0.90 (s, 3H).
Step 3: (rac)-(4aS,l OaS) AOa-Eihyl-7-bydxoxy l,4,4a,9,10,10a-hexahydro-2H-phenanthren -3 -one. As substrate, (rαc)-(4αS, 10 S)-7-Benzyloxy-10a-ethyl-4a, 9,10,10a- tetrahydro -^H-phenanthren-3-one (34 mg) was used according to method F ("J" = MeOΗ/EtOAc [4:3], "K" = 4.0, "L" = 5% Pd/C, "M" = 11, N = 24). The crude product was purified on chromatotron, using EtOAc:τ--heptane (1 :9) as eluent. The main fraction contained (rαc)-(4αS, 10αS)A 0a-ethyl-7-hydroxy- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3-one. ES/MS m/z: 241.3 (neg, M-Η), 'Η NMR (500 MHz, CDC13) δ 6.95 (d, IH), 6.70-6.75 (m, 2H), 5.15 (bs, IH) 2.90-3.00 (m, 2H), 2.70-2.80 (m, 2H), 2.35-2.45 (m, 3H), 2.05-2.15 (m, IH), 1.95-2.00 (m, IH), 1.40-1.55 (m, 3H), 1.20-1.30 (m, IH), 0.95 (t, 3H).
Example 24: Synthesis of c)-^ gS 0αS')-3.3-ethanediyldimercapto-10a -ethyI-7-hvdroxy -1.2.3.4.4a,9,10, 10a- octahvdro-phenanthrene (E24 .
The ketone (rac)-(4aS,10aS) -10a-ethyl-7-hydroxy-l,4,4a,9,l 0,10a- hexahydro -2H-phenanthren-3-one (8.9 mg) was treated according to method G ("J" = 0.8, "K" = 1,2-ethanedithiol, "L" = 2.0, "M" = 4). The crude product was purified on chromatotron, using EtOAc :«-heptane (2:8, v:v) as eluent. The first eluted fraction was then further fractionated using PΗPLC to yield (rα )-(^αS,70α^)-3,3-ethanediyldimercapto- 10a- ethyl-7-hydroxy-l,2,3,4,4a,9,10,10a-octahydro-phenanthrene (white solid). ES/MS m/z: 320.9 (pos, M+Η), 319.3 (neg, M-Η); ΗNMR (270 MHz, CDC13) δ 7.10 (d, IH), 6.55-6.60 (m, 2H), 4.50 (bs, IH), 3.25-3.40 (m, 4H), 2.70-2.90 (m, 3H), 2.55-2.65 (m, IH), 1.95 -2.20 (m, 3H), 1.75-1.90 (m, 2H), 1.25-1.50 (m, 3H), 0.95-1.10 (m, IH), 0.75 (t, 3H). ,3C NMR δ 153.29, 138.26, 130.68, 125.83, 115.34, 112.53, 69.22, 46.08, 40.64, 38.99, 38.17, 38.01, 34.66, 34.08, 32.81, 26.1, 17.54, 7.37.
Example 25: A pharmaceutical formulation comprising^rae)- (lR,2R,4aS.10aS) -l-butyl-3. 3-ethanediyldimercapto-7-hvdroxy-2-methyl-1.2.3.4.4a.9. 10. lOa-octahvdro-phenanthrene.
140 mg of (rac)-(lR,2R,4aS,10aS)A-buιyl-3,3-etbanediyldim.excapto -7-hydroxy -2-methyl-l, 2,3, 4,4a,9, 10,1 Oa-octahydro-phenanthrene, from Example 12, is formulated with sufficient finely divided lactose to provide a total amount of 580 to 590 mg to fill a size 0, hard-gelatine capsule.
Example 26: Synthesis of (rac)-(lS,4aS.10aS)-l-(3-met γl-butylY 10a-ethyl-7-hvdroχy-1.4.4a. 9.10.10a-hexahvdro-2H-phenanthren-3-one (E26
Step 1: The enone
(rac)-(4aS, 1 aS)- -benzyloxy- 10a-ethyl-4a,9, 10, 1 Oa-tetrahydro-^H-phenantren-3-one (54.5mg; 0.15mmol), dissolved in 2.0 mL of TΗF, was treated according to method E ("J"= lithium-2-thienylcyanocuprate [Aldrich, no.32,417-5, 0.25M sol. in TΗF], "K"= 2, "M"= TΗF, "L"= 2.0, "N"= 3-methyl-l -butyl magnesium bromide [0.5M sol. in TΗF], "O"= 2eq, "P"= 0, "Q"= 1). The crude product was purified on chromatotron, using EtOAc:rc-heptane (2:8) as eluent to yield 35mg of (rac)-(lS,4aS,10aS)-7-bexxzyloxyA -(3-methyl-butyl)-l,4,4a,9,10,10a-hexahydro-2H-phenanthren-3-one as a yellowish oil. ES-MS m/z: 405.4 (pos, M+Η), 403.0 (neg, M-Η; ΗNMR (CDCL) δ 7.30-7.45 (m, 5Η), 6.95 (d, IH), 6.75 (d, IH), 5.05 (s, 2H), 3.15 (dd, IH), 2.90 (dd, IH), 2.70-2.80 (m, 2H), 2.60 (dd, IH), 2.30-2.45 (m, 2H), 1.40-2.00 (m, 5H), 1.20-1.40 (m, 6H), 0.85 (m, 9H).
Step 2: The reaction was carried out on 32.5mg (0.080mmol) (rac)-(lS,4aS,10aS)-7 -benzyloxy A- (3 -methyl-butyl)- 1,4,4a, 9,10,10a -hexahydro- 2H-phenanthren-3-one according to method F ("J"= TΗF, "K"= 4.0, "L"= 10% Pd/C, "M"= 33, "N"= 20). The crude product was purified by chromatotron using EtOAc: /.-heptane (2:8) as eluent to yield (rac)-(lS,4aS,10aS)A-(3-metbyl-butyϊ) -10a- ethyl- 7-hydroxy-l,4,4a,9,10,10a-hexahydro-2H-phenanthren-3-one (18.6 mg) as a white solid. ES-MS m z: 315.1(pos, M+Η), 313.3 (neg, M-Η); ΗNMR (270MΗz, CDC13) δ 6.90 (d, IH), 6.65 (d, IH), 6.60 (s, IH), 3.15 (dd, IH), 2.90 (ddd, IH), 2.70-2.80 (m, 2H), 2.60 (dd, IH), 2.35-2.45 (m, 2H), 1.40-2.00 (m, 5H), 1.20-1.40 (m, 5H), 1.00-1.10 (m, IH), 0.85 (m, 9H).
Example 27: Synthesis of (lS aSJOaS) -7-hydroxy-10a-methyl-l- (3-methyl-hutvn-1.4.4a.9.10.10a-hexahvdro-2H-phenanthren-3-one nE27^.
Step 1: The racemic mixture of (IS, 4 aS,l OaS) -7-benzyloxy-l Oa-methyl- 1- (3-methyl-butyl)-l,4,4a,9,10,10a-hexahydro-2H-phenanthren-3-one from Example 13 was purified by chiral ΗPLC to afford two pure enantiomers (17 and 21 mg), (lR,4aR, lOaR) -7-benzyloxy- 1 Oa-methyl- 1 -(3-methyl-butyl)- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3 -one resp. (lS,4aS,10aS) -7-benzyloxy- 10a- methyl- 1- (3-methyl-butyl)- 1, 4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3 -one.
Step 2: The reaction was carried out on 17mg (lR,4aR, lOaR) -7-benzyloxy- 1 Oa-methyl- 1 - (3-methyl-butyl)- l,4,4a,9,10,10a-hexahydro-2H-phenanthren-3-one for 20 h according to method F using TΗF (4.0 mL) as solvent, and 10% Pd/C (33.0 mg) as catalyst. The crude product was purified by PΗPLC to yield (lR,4aR,10aR) -7-hydroxy- 1 Oa-methyl- 1 - (3 -methyl-butyl)- l,4,4a,9,10,10a-hexahydro-2H-phenanthren-3 -one (1.5 mg) as a white solid. ES-MS m/z: 301.3 (pos, M+Η); Η NMR (270MΗz, CDC13) δ 6.90 (d, IH), 6.60-6.65 (m, 2H), 4.50 (s, IH), 3.05 (dd, IH), 2.70-3.05 (m, 4H), 2.25-2.45 (m, 2H), 1.90-2.05 ( , IH), 1.40-1.75 (m, 4H), 1.25-1.40 (m, IH), 0.95-1.20 (m, 2H), 1.05 (s, 3H), 0.85 (t, 6H).
Example 28: Synthesis of (lR.4aRS.10aR) -7-benzvIoxy-10a-methyl-l- (3-methyl-butvD-1.4.4a. 9.10. 10a-hexahvdro-2H-phenanthren-3-one (E28).
The reaction was carried out on 21 mg (lS,4aS,10aS) -7-hydroxy-l Oa-methyl- 1- (3-methyl-butyl)-l,4,4a,9,10,10a-hexahydro-2H-phenanthren-3-one for 20 h according to method F using TΗF (4.0 mL) as solvent, and 10% Pd/C (33.0 mg) as catalyst. The crude product was purified by PΗPLC to yield (lS,4aS,1 aS) -7-benzyloxy- 10a- methyl- 1- (3-methyl-butyl)-l,4,4a,9,10,10a-hexahydiO-2H-phenanthren-3-one (3.9 mg) as a white solid. ES-MS m/z: 301.3 (pos, M+Η); Η MR (270MΗz, CDC13) δ 6.90 (d, IH), 6.60-6.65 (m, 2H), 4.65 (s, IH), 3.05 (dd, IH), 2.70-3.00 ( , 4H), 2.25-2.45 (m, 2H), 1.90-2.00 (m, IH), 1.40-1.75 (m, 4H), 1.25-1.40 (m, IH), 0.95-1.20 (m, 2H), 1.05 (s, 3H), 0.85 (t, 6H).
Example 29: Synthesis of (rac)-(lS.4aS.10aS)A-(3-met xl-butvϊ)-3. 3-ethanediyldimercapto-7- hydroxy-1.4,4a, 9.10.10a-octahvdrophenanthrene (E29).
The reaction was carried out on 15 mg (0.048 mmol) of (rac)-(lS,4aS,l OaS) A-(3~metbyl- butyl)-7-hydroxy-l,454a,9,10,10a-hexahydro-2H-phenanthren-3-one, according to method G ("J"=1.0, "K"= 1,2-ethanedithiol, "L"=2.0, "M"=4), using 1 eq of BF3 OEt2. The crude product was purified by chromatotron using EtOAcn-heptane (2:8) as eluent and then by PΗPLC to yield (rac)-(lS,4aS,10aS)A- (3-methyl-butyl)-3,3 -ethanediyldimercapto-7- hydroxy-l,4,4a,9,10,10a-octahydrophenanthrene (7.7 mg) as a white solid. ES-MS m z: 391.3 (pos, M+Η), 389.2 (neg, M-Η); ΗNMR (270MΗz, CDC13) δ 7.05 (d, IH), 6.60 (dd, IH), 6.55 (s, IH), 4.50 (bs, OH), 3.35 (m, 4H), 3.00 (dd, IH), 2.55-2.80 (m, 4H), 2.35-2.45 (dd, IH), 2.15-2.25 (m, 1H9, 2.00-2.10 (m, IH), 1.40-1.80 (m, 8H), 1.05-1.30 (m, IH), 0.90 (d, 6H), 0.75 (t, 3H).
Example 30: Synthesis of ^•gc)-( aR.10flR)-7-hydroxy-4a,lOa-dimethyl -3,4.4a.9,10.10a-hexahvdro-iH-phenanthren-2-one fE30 .
Step 1:. 7-Methoxy-4-methyl-l,2-dihydro-naphthalene: A solution of 31.8 g (180 mmol, 1.0 eq.) of 6-methoxy-l -tetralone in dry THF (100 mL) was added dropwise while stirring to a solution of methyl lithium (1.6 M in diethyl ether, 2.3 eq.) during approximately 1 h. Stirring was continued for another 2 h before slow addition of 200 mL of 5.0 M aqueous HCl. The phases were separated after vigorous stirring for 3 h. The aqueous phase was extracted with diethyl ether (4 x 100 mL) and the combined organic phases were dried over anhydrous sodium sulfate. Concentration of the extract in vacuo affored a brown oil which was purified by silica gel flash chromatography using EtOAc:n-heptane (0:10, 1 :9, stepwise gradient) as eluent to give 7-Methoxy-4-methyl-l,2-dihydro-naphthalene as a colorless oil. 'H NMR (CDC13) δ 7.22 (d, IH), 6.80-6.85 (m, 2H), 5.75-5.80 ( , IH), 3.85 (s, 3H), 2.75-2.85 (m, 2H), 2.25-2.35 (m, 2H), 2.15 (s, 3H).
Step 2: (rαc -6-Methoxy-l-methyl-3,4-dihydro-7H-naphthalen-2-one: The reaction was carried out on 24.8 g (142 mmol) of 11, dissolved in 600 mL DCM according to method L to give r c -6-Methoxy-l-methyl-3,4-dihydro-iH-naphthalen-2-one as a yellowish oil after purification of the crude product by silica gel flash chromatography, using EtOAc :n-heptane (1:9, 2:8, stepwise gradient) as eluent. Η NMR (CDCU) δ 7.10 (d, 1Η), 6.80 (d, 1Η), 6.75 (s, 1Η), 3.80 (s, 3Η), 3.45 (m, IH), 3.00-3.10 (m, 2H), 2.45-2.65 (m, 2H), 1.45 (t, 3H); 13C NMR (CDCI3) δ 213.18, 158.77, 138.31, 139.22, 127.36, 113.35, 112.34, 55.15, 46.48, 36.93, 27.95, 14.04. Step 3: (rαc)-7-Methoxy-4a-methyl-4,4a,9,10-tetrahydro-5H-phenanthren-2-one: Coupling of a solution of (7-αc)-6-Methoxy-l-methyl-3,4-dihydro-7H-naphthalen-2-one (2.10 g, 11.0 mmol) dissolved in toluene (10 mL) with but-3-en-2-one in accordance with method M after purification of the crude product by silica gel flash chromatography using EtOAc :rø-heptane (3:7) as eluent, afforded (rac -7-Methoxy-4a-methyl-4,4a, 9,10-tetrahydro-5H-phenanthren-2-one as a yellowish solid. ES-MS m/z: 243.4 (pos, M+Η); Η NMR (CDC13) δ 7.10 (d, 1Η), 6.70 (dd, 1Η), 6.50 (d, 1Η), 5.80 (s, 1Η), 3.70 (s, 3Η), 1.80-2.85 (m, 8H), 1.40 (s, 3H); 13C NMR (CDC13) δ 199.26, 170.35, 157.96, 136.22, 127.38, 124.26, 113.40, 112.99, 54.93, 38.38, 36.80, 34.51, 30.98, 30.80, 27.37.
Step 4. 7-Methoxy-4a, 10a-dimethyl-3,4,4a,9, 10, 10a-hexahydro-7H-phenanthren-2-one: The reaction was carried out on 200 mg (0.83 mmol) of (rας -7-Methoxy-4a-methyl-4, 4a,9,10-tetrahydro-3H-phenanthren-2-one dissolved in TΗF (10 mL), according to method Q using the following conditions: Titanium (IN) isopropoxide (1.3 eq, suspension in 3 mL TΗF), methylmagnesium chloride (3M solution in TΗF, 1.3 eq.), nickel(II)acetylacetonate (0.05 eq.), reaction-time and temperature (1 h from -15°C to 0 °C, quenching at r.t.). The crude product was purified using PΗPLC to yield 7-Methoxy-4a, 10a-dimethyl-3 ,4,4a, 9,10,10a-hexahydro-iH-phenanthren-2-one as a yellowish oil. ES-MS m/z: 259.0 (pos, M+Η); Η ΝMR (CDC13) δ 7.30 (d, 1Η), 6.80 (dd, 1Η), 6.60 (d, 1Η), 3.75 (s, 3Η), 2.85 (t, 3H), 1.80-2.50 (m, 7H), 1.25 (s, 3H), 1.00 (t, 3H); 13C ΝMR (CDC13) δ 157.85, 136.33, 135.25, 127.04, 113.89, 113.01, 54.97, 50.17, 40.00, 39.29, 38.40, 35.67, 31.38, 25.87, 25.41, 23.06.
Step 5:
(rac)-(4aR, 10aR)-7-Bydxoxy-4a, 10a-dimethyl-3 ,4,4a,9, 10, 1 Oa-hexahydro-iH-phenanthren- 2-one: The reaction was carried out on 55 mg of 7-Methoxy-4a,10a-dimethyl-3, 4,4a,9,10, lOa-hexahydro-iH-phenanthren-2-one dissolved in 1.0 mL DCM, using 3.5 eq. of BBr3 for 4 h according to method O. The crude product was purified by PΗPLC to yield (rαc)- (4αR,10αR)-7- Ηydroxy-4a, 10a-dimethyl-3,4,4a,9,10,10a-hexahydro- iH-phenanthren -2-one as a yellowish oil. ES-MS m/z: 245.2 (pos, M+Η), 243.4 (neg, M-Η); Η ΝMR (CDCI3) δ 7.20 (d, 1Η), 6.70 (dd, 1Η), 6.55 (d, 1Η), 5.30 (b s, 1Η), 2.80 (t, 3Η), 1.80-2.40 (m, 7H), 1.25 (s, 3H), 1.00 (t, 3H). Example 31: Synthesis of (rac)-(lS,4aS,10aS) -7-hydroxy-10a-methyl-4-phenyl- 1.4.4a,9,10.10a-hexahydro-2H-phenanthren-3-one (E31).
(E31)
Step 1: (2)-5-(4-Benzyloxy-2-iodo-phenyl)-4-phenyl-pent-4-en-2-one. The reaction was carried out on 2.0 g (5.9 mmol) of 4-benzyloxy-2-iodo-benzaldehyde, according to method L ("J"= 10, "K"= 1.02, "L"= 0.1, "M"= 20). The crude product was purified by flash chromatography using EtOAc :n-heptane (2:8) as eluent to yield (Z)-5-(4-Benzyloxy-2-iodo-phenyl)-4-phenyl-pent-4-en-2-one as a yellowish oil. ES-MS m/z: 455.2 (pos, M+H), 452.9 (neg, M-H); Η NMR (270 MHz, CDC13) δ 7.65 (s, IH), 7.50 (d, IH), 7.20-7.40 (m, 7H), 7.05-7.10 (m, 2H), 7.15-7.20 (m, IH), 6.60 (d, 2H), 5.00 (s, 2H), 2.45 (s, 3H).
Step 2:
( αS,/0α^-7-Benzyloxyl0a-methyl-4-phenyl-4a,9,10,10-tetrahydro- H-phenantren-3-one. The reaction was carried out on 630 mg (1.39 mmol) of (Z)-5-(4-benzyloxy- 2-iodo -phenyl)-4-phenyl-pent-4-en-2-one, according to method A ("J"= 2-methyl-but-3-en-l-ol, "K"= 1.5, "L"= 4.0, "M"= 2.9, "N"= 4). The material obtained was then treated according to method C to obtain crude (¥αS,10αSj-7-benzyloxy- 10a-methyl-4-phenyl-4a, 9,10, 10-tetrahydro-¥H-phenantren-3-one (90 mg).
Step 3:
(4R, 4aS, 10aS)- -Benzyloxy- 10a-methyl-4-phenyl-4a,9, 10, 10-tetrahydro-¥H-phenantren-3 - one. ( αS7 αS^-7-Benzyloxyl0a-methyl-4-phenyl-4a,9,10,10- tetrahydro - H-phenantren -3-one was purified with flash chromatography using EtOAc:«-heptane (5:l)as eluent to yield two isomers with the ratio 2.5:1. Separation by PΗPLC to yield (4R,4aS,10aS)- -Benzyloxy A Oa-methyl- 4-phenyl-4a, 9,10, 10-tetrahydro-^H- phenantren- 3-one. ES-MS m/z: 395.2(pos, M+Η), 393.1(neg, M-Η); 'Η NMR (270MΗz, CDC13) δ 7.10-7.20 (m, 10H), 7.00 (d, IH), 6.95 (d, IH), 6.90 (d, IH), 6.50 (dd, IH), 6.05 (d, IH), 5.00 (s, 2H), 3.95 (d, IH), 3.90 (d, IH); 3.00 (m, IH), 2.95 (m, IH); 2.05(m, IH), 1.95(m, 1H),0.90 (s, 3H).
Step 4:
(4R, 4aS, 10aS)-7-Bydxoxy- 1 Oa-methyl-4-phenyl-l ,4,4a,9, 10, 10-hexahydro-2H-phenantren- 3 -one. The reaction was carried out on 13 mg of : (4R,4aS,10aS)-7-benzyloxy- 10a-methyl-4-phenyl-4a,9,10,10-tefrahydro- H-phenantren-3-one, according to method F ("J"= ethanol, "K"= 5, "L"= 10% Pd/C, "M"= 2, "N"=24). The crude product was purified by PΗPLC to obtain 9.0 mg of : (4R,4aS, 10aS)-7-bydxoxyA0a-metbyl-4-pbeny\A, 4,4a, 9,10,10-hexahydro-2H-phenantren-3-one. ES-MS m/z: 307.3(pos, M+Η), 305.2(neg, M-Η);. 'Η NMR (270 MHz, CDC13) δ 7.20-7.40 (m, 5H), 6.70 (d, IH), 6.60 (d, IH), 6.35 (dd, IH), 4.80 (s, b IH), 3.80 (d, IH), 3.50 (d, IH); 2.80 (m, 2H), 2.60 (m, 2H); 2.00(m, 2H), 1.80(m, IH), 1.65(m, IH), 0.85(s, 3H).
Example 32: Synthesis of fmc)-(¥R. fl.y.i0gS)-3.3-ethanediyldimercapto- 7-hvdroxy-10a-methyl-4-phenvI-l,4,4a,9,10,10a-octahvdro-phenanthrene (E32
(E31) (E32)
The reaction was carried out on 7.0 mg (0.023 mmol) (4R, 4aS, 10aS)-7-bydxoxy- 1 Oa-methyl-4-phenyl- 1 ,4,4a,9, 10, 10-hexahydro-2H-phenantren-3 -one, according to method G ("J"= 1.0, "K"= 1,2-ethanedithiol, "L"= 9, "M"= 2), using 6 eq of BF3-OEt2. The crude product was purified by prep. TLC using EtOAc:rø-heptane (1 :7) as eluent to yield (rac)-(4R,4aS,l 0aS)-3,3-et anediyldmxexcapto- 7-hydroxy- 1 Oa-methyl - 4-phenyl-l,4,4a,9, 10,1 Oa-octahydro-phenanthrene (5.3 mg) as a white solid. ES-MS m/z: 383.2 (pos, M+Η); 'Η NMR (270 MHz, CDC13) δ 7.55 (d, IH), 7.35(d, lH),7.30(m, IH), 7.20(m, IH), 7.10(m, IH), 6.60 (d, IH), 6.45 (d, IH), 6.25 (dd, IH), 4.40 (bs, IH), 3.50 (d, IH), 3.20 (d, IH); 3.00(m, 1H),2.85 (m, 2H), 2.65 (m, IH), 2.50(m, IH), 2.35(m, 2H), 1.85(m, 4H), 1.45(m, IH), 0.55(s, 3H).
Example 33: Synthesis of ^mc)-fiS. ffS flg ')-3,3-(ethane-l,2-divIdimercapto)- 7- hydroxy- l-(2-phenylethylV10a-methyl-1.2.3.4.4a.9.10.10a-octahydro-phenanthrene
(E15) (E33)
Step 1:
(rαc)-(lS, 4αS, 10αS)-3,3 -(ethane- 1 ,2-diyldimercapto)-7-hydroxy- 1 -phenylethyl- 1 Oa-methyl -1, 2,3, 4,4a,9, 10,1 Oa-octahydro-phenanthrene. The reaction was carried out on 8 mg (24 mmol) of (rαc)-(lS,4αS, 10αS)- -bydxoxyA-pbenyletbylAOa-metbylA, 4,4a,9, 10,10a-hexahydro-2H-phenanthren-3-one, according to method G ("J"= 2.0, "K"= 1,3-ethanediol, "L"= 2.0, "M"= 6). The crude product was purified on chromatotron using EtOAc:^-heρtane (2.8, v:v) as eluent to yield (rαc)-(lS,4αS,10αS) -3,3- (ethane-1, 2- diyldimercapto) -7-hydroxy- 1- phenylethyl- 1 Oa-methyl- 1 Oa-methyl- 1, 2,3, 4,4a,9, 10, 1 Oa-octahydro-phenanthrene as a colorless glass. ES/MS m/z: 409.3 (neg, M-Η): Η NMR (270MHz, CDC13) δ 7.10-7.30 (m, 5H), 7.05-7.10 (d, IH), 6.50-6.65 (m, 3H), 4.50 (s, OH); 3.30-3.45 (m, 4H),2.40-3.00 (m, 7H), 1.80-2.10 (m, 3H), 1.10-1.65 (m, 3H), 0.90 (s, 3H). 13C NMR (270MHz, CDCl3) δ 153.3, 143.0, 137.9, 131.1, 128.5, 128.4, 127.0, 126.0, 115.3, 112.8, 68.9, 45.3, 43.4, 40.4, 38.8, 37.5, 37.4, 35.0, 34.7, 33.8, 30.0, 26.8, 18.5.
Example 34: Synthesis of
(rac)-(lS.4aSJ0aS)-33-ethanedwldioxy-7-h\droxy-10a-met yl-1. 23AΛa.9. lO.lOa-octahydro-phenanthrene (E34a and (rac)-(lS.4aS,10aR)-3, 3-ethanediyldioxy -7-hydroxy-10a-methyM, 2,3,4,4a,9,10.10a-octahvdro-phenanthrene (E34fr).
(E21) (E34a) (E34b)
rαc (^αSi0αS -3,3-ethanediyldioxy-7-hydroxy-10a-methyl-l,2,3,4,4a,9,10,10a-octahydro -phenanthrene. The reaction was carried out on 320mg (1.39 mmol) of a (1:1) mixture of (rac)-(4aS, 10aS)-7 -by dxoxy- 1 Oa-methyl- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3-one and (rac)-(lS,4aS,10aR)-7-bydxoxy-\ Oa-methyl- l,4,4a,9, 10, 10a- hexahydro- 2H-phenanthren-3-one, according to method Η ("J' - 1,2-dihydroxyethane, "K"= 10, "L"= 500, "N"= 20, "O"= 16). The crude product was purified by MPLC, using CΗ2C12: MTBE (100:0, 90:10, v:v) as eluent to yield colorless glasses of (rac)-(4aS,10aS)-3,3- ethanediyldioxy-7-hydroxy- 1 Oa-methyl- 1 ,2,3 ,4,4a,9, 10, 1 Oa-octahydro-phenanthrene (E34a), contaminated with 10% of E34b and (rflς)-( αS, 0 R -3,3-ethanediyldioxy -7-hydroxy- 1 Oa-methyl- 1 ,2,3,4,4a,9, 10, 1 Oa-octahydro-phenanthrene (E 101 b), contaminated with 10% of ElOla. ES/MS m/z: 275.2 (pos, M+H), 273.1 (neg, M-H); 'H NMR (270MHz, CDC13, isomer A) δ 7.00 (d, IH), 6.65-6.70 (m, 2H), 4.80 (bs, OH), 3.90-4.10 (m, 4H), 2.75-2.90 (m, 2H), 2.70-2.75 (m, IH), .20-2.30 (m, IH), 1.80-1.90 (m, IH), 1.65-1.70 (m, IH), 1.50-1.65 (m, 5H), 0.75 (s, 3H).; 'H NMR (270MHz, CDC13, selected signals from isomer B which differ from isomer A) δ 6.90 (d, IH), 6.55 (m, 2H), 3.90-4.00 (m, 4H), 5.10 (bs, OH), 0.80 (s, 3H).
Example 35: Synthesis of (rac)-(3S,4aS J0aS)-7- vdroxy-3-Oentyl-10a-metkyl~l. 2,3,4.4a,9.10.10a-octahvdro-phenanthrene (E35a) and (rac)-(3R.4aS.10aS) -7-hydroxy-3-pentvI-10a-methvI-l, 2,3,4,4a,9.1,10a-octahydro-phenanthrene (E35h).
( E35a) ( E3b)
Stepl:
(rac)-(4aS, 10aS)- -benzyloxy- 1 Oa-methyl- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3 -o ne and (rac)-(4aR,10aS)-7-benzyloxy-l Oa-methyl- 1,4,4a, 9,10, lOa-hexahydro -2H- phenanthren-3-one. The reaction was carried out on 707 mg (2.22 mmol) of a (6:4) mixture of (rac)-(4aS, 1 OaS) -7 -benzyloxy- 10a-methyl-4a,9,10, lOa-tetrahydro- ^H-phenanthren -3-one and (rας - αR,i0 ^)-7-benzyloxy-10a-methyl-4a,9,10, 10a-tetrahydro- H-ρhenanthren-3-one from Example 3, according method F ("L"= 5% Pd/C, "M"=70, TΗF/ΗOAC (95:5, v:v), r.t. 8 days). The crude mixture was purified by MPLC using EtoAC.-n-heptane (0:100, 10:90, v:v) as eluent to yield (rac)-(4aS, 10aS)- -benzyloxy A Oa-methyl- 1,4, 4a,9,10, lOa-hexahydro -2H- phenanthren -3 -one and (rac)-(4aR,l 0aS)-7 -be zyloxy A Oa-methyl- l,4,4a,9,10,10a-hexahydro -2H- phenanthren-3-one as a yellowish solid. ES/MS m/z: 321.1 (pos, M+Η).
Step2: Crae -(3S^αS)i0αS -7-benzyloxy-3- hydroxy-3-(l-pentyl)-10a-methyl-l,2,3,4, 4a,9, 10,1 Oa-octahydro-phenanthrene and (rac)-(3S,4aR,10aS)-7 - benzyloxy-3 -hydroxy-3 -( 1 -pentyl-5-en)- 1 Oa-methyl- 1 ,2,3 ,4,4a,9, 1 , 1 Oa-octahydro- phenanthrene. The reaction was carried out on 40 mg (0.125 mmol) of (rac)-(4aS, 10aS)-l '-benzyloxy- 1 Oa-methyl- 1 ,4,4a,9, 10, 1 Oa-hexahydro-^H-phenanthren -3-one and (rας - αR,70α<S^-7-benzyloxy-10a-methyl-l, 4,4a,9,10, lOa-hexahydro- 2H-phenanthren-3-one (85:15 mixture), according method N, to give a crude product which was used without purification in the next step.
Step 3: (rac)-(3S,4aS,10aS)-7-bydxoxy-3-( -pentyl)- 1 Oa-methyl- 1, 2,3 ,4,4a,9, 10,10a- octahydro-phenanthrene. The crude material from step 2 was treated with phosphoric acid (85%) at 140 °C for 1 hour, followed by extraction with EtOAc/ Η2O and dried with anhydrous sodium sulphate. The resulting yellow-brownish oil was reacted according to method F, ("L"=10% Pd/C, "J"= MeOH/THF, "M"= 15). The crude product is purified on chromatotron using EtOAc/n-heptane (1:9, v:v) as eluent, followed by PHPLC to yield a mixture of (rac)-(3S,4aS,10aS)-7 -bydxoxy- 3-(l-pentyl)-10a-methyl-l, 2,3,4,4a,9,10, 1 Oa-octahydro-phenanthrene (E35a) and (rac)-(3R,4aS,10aS)-7 -bydxoxy- 3-(l -pentyl) -1 Oa-methyl- 1, 2,3, 4,4a,9, 10,1 Oa-octahydro-phenanthrene. (E35b) ES/MS m/z: 287.2 (pos, M+H), 285.1 (neg, M-H); 'H ΝMR (270MHz, CDC13, selected signals) δ 7.10 (d, IH), 6.50-6.60 (m, 3H), 2.60-2.90 (m, 3H), 2.00-2.40 (m, 4H), 0.90 (s, 3H), 0.70 (s, 3H).
Example 36: Synthesis of (rac)~(lS.2R.4aS.10aS)-2Λ0a-dimethyl-33- fethane-1. 2-diyldimercapto) -7-hvdroxy-l-(3-methyl-butyl-1.2.3.4.4a. 9.10. 10a- octahydro-phenanthrene E36).
(rac) -(IS, 2R, , 4aS, 10aS)-2, 10a-dimethyl-3 ,3 -(ethane- 1 ,2-diyldimercapto)-7-hydroxy- 1 -(3 -m ethyl-butyl- l,2,3,4,4a,9, 10,1 Oa-octahydro-phenanthrene. The reaction was carried out on 9 mg (30 μmol) of (rac)-(lS,2R,4aS,10aS)-2,\ Oa-dimethyl-7-hydroxy-l- (3 -methyl-butyl)- 1, 4,4a,9,10,10a-hexahydro-2H-phenanthren-3-one, according to method G ("J"= 1.0, "K"= 1,2-ethanediol, "L"= 2.0, "M"= 6). The crude product was purified on chromatotron using EtOAc:rc-heptane (1:9, 2:8, 3:7, v:v) as eluent to yield (rac)-(lS,2R,4aS,10aS)-3,3- (ethane- 1 ,2-diyldimercapto)-7-hydroxy- 1 -phenylethyl- 1 Oa-methyl- 1 ,2,3 ,4,4a,9, 10, 1 Oa-octa hydro-phenanthrene as a colorless glass. ES/MS (mixture) m/z: 391.3 (pos, M+Η), 389.2 (neg, M-Η): Η NMR (270MΗz, CDC13, selected signals of the mixture) δ 7.10 (d, IH), 6.50-6.70 (m, IH), 3.30-3.50 (m, 4H isomer A) 3.10-3.30 (m, 4H isomer B), 0.85-0.90 (m, 9H). ,3C NMR (270MHz, CDC13, mixture) δ 153.2, 137.8, 131.2, 127.0, 115.2, 112.8, 73.9, 52.9, 45.9, 43.4, 40.6, 39.1, 38.2, 36.4, 33.3, 31.9, 29.1, 28.8, 26.7, 22.8, 22.6, 22.4, 18.8, 15.9, 14.2.
Example 37: Synthesis of (rac)~(lS.4aSJ0aS)- 7-Hvdroxy-l- G'-methyl-butyf. -1.4. 4a.9.10.10a-hexahvdro-2H-phenanthren-3-one (E37).
(E37)
Step 1: (r c (^αS,i0-.S 7-Benzyloxy-4a,9,10,10a-tefrahydro-^H-phenanthren-3-one. The aryl iodide 4-(2-iodo-4-Benzyloxy-phenyl)-but-3-en-2-one (6.12 g) was treated according to method A ("J" = but-3-en-l-ol, "K" = 1.3, "L" = 4.0, "M" = 2, "N" = 2.0). The material obtained was then treated according to method C ("N" = 150, "Q" = 14). The crude product obtained was purified by silica gel flash chromatography using EtOAc:«-heptane (5:95, 1 :8 stepwise gradient) as eluent, followed by fractionation with PΗPLC to yield (rac)-(4aS, 10α -7-benzyloxy-4a,9,l 0,1 Oa-tetrahydro-^H-phenanthren-3-one (white solid). ES/MS m/z: 305.2 (pos, M+Η); ΗNMR (500 MHz, CDC13) δ 7.30-7.50 (m, 5H), 7.10 (d, IH), 6.90 (d d, IH), 6.80 (dd, IH), 6.75 (d, IH), 6.10 (d, IH), 5.05 (s, 2H), 3.20 (dd, IH), 2.90-3.10 (m, 3H), 2.45 (t, IH), 2.35 (dd, IH), 2.10-2.20 (m, IH), 1.65-1.75 (m, IH).
Step 2 : '-methyl-butyl)- 1 ,4,4a,9, 10, 1 Oa-hexahy- dro-2H-phenanthren-3-one. The enone (rac)-(4aS,10aS)-7-benzyloxy-4a_9,lO, 10a-tetrahydro-¥H-phenanthren-3-one (50 mg) dissolved in TΗF (5.0 mL), was treated according to method E ("J" = lithium 2-thienylcyanocuprate (Aldrich, no. 32,417-5, 0.25M solution in TΗF), "K" = 2.0, "N" = 3-methyl-l -butyl magnesium bromide (0.5M solution in TΗF), "O" = 2.0, "P" = 0, "Q" = 2). The crude product was by silica gel flash chromatography using EtOAc:rø-heptane (1 :8) as eluent, followed by fractionation with PΗPLC to yield 23 mg of (rac)-(lS,4aS,10aS)-7- benzyloxy-1- (3 '-methyl-butyl)- 1, 4,4a,9,10,10a-hexahydro-2H-phenanthren-3-one as a white powder that was used in the next step (step 3). ES/MS m/z: 377.2 (pos, M+Η).
Step 3 : (rac)-(lS, 4aS, 10aS)- -Bydxoxy- 1 -(3 '-methyl-butyl)- 1 ,4,4a,9, 10, 1 Oa-hexahy- dro-2H-phenanthren-3-one. The substrate (rac)-(lS,4aS,10aS)- 7-benzyloxy- 1 - (3 '-methyl-butyl)- l,4,4a,9,10,10a-hexahydro-2H-phenanthren-3-one (14 mg) was treated according to method F ("J" = TΗF:ΗOAc [95:5], "K" = 4.0, "L" = 10 % Pd/C, "M" = 4, "N" = 2). The crude product was purified using PHPLC to yield (rac)-(lS,4aS,10aS)- 7-hydroxy- 1 -(3 '-methyl-butyl)- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3-one (white solid). ES/MS m/z: 285.1 (neg, M-Η); 'Η NMR (500 MHz, CDC13) δ 8.00 (s, IH), 7.00 (d, IH), 6.60 (dd, IH), 6.55 (d, IH), 2.75-2.95 (m, 4H), 2.55 (dd, IH), 2.40 (dt, IH), 2.20 (t, IH), 1.95-2.05 (m, IH), 1.65-1.85 (m, 2H), 1.40-1.55 (m, 2H), 1.20-1.35 (m, 2H), 1.05-1.15 (m, lH), 0.85 (t, 6H).
Example 38: Synthesis of (rac)-(4aS.10aS)-33-(propane-l, 3-diyldimercaptoV7-hydroxy-1.2.3,4,4a.9.10.10a-octahvdro-phenanthrene (E38).
(E1) (E38)
The ketone (mc)-(4αS, 10αS)-7-bydxoxyA,4,4a,9,l0,10a-bexabydxo-2H-pbenantbxen-3-one (18 mg) was treated according to method G ("J" = 4, "K" = 1,3-propanedithiol, "L" = 2.0, "M" = 12). The crude product was purified by column chromatography on silica gel, using EtOAc :«-heptane (2:8, v:v) as eluent to yield (rαc)-(4αS, 10αS)-3,3-pxopanediyldimexcapto -7-hydroxy-l,2,3,4,4a,9,10,10a-octal ydro-phenanthrene. ES/MS m z: 307.3 (pos, M+H), 305.2 (neg, M-H); 'H NMR (270 MHz, CD3OD) δ 7.05 (d, IH), 6.55 (dd, IH), 6.45 (d, IH), 2.90-3.00 (m, 2H), 2.60-2.85 (m, 6H), 2.40 (m, IH), 1.95(m, 2H), 1.55-1.85 (m, 4H), 1.35-1.50 (m, 3H), 1.20-1.30 (m, IH).
Example 39:(rac)-(lS,4S.4aSJ0aS)-7-Jivdrox\-l-butyl-4Λ0a-dimeth\l 1.4. 4a.9. 10. 10a-hexahvdro-2H-phenanthren-3-one (E39).
Step 1: (rac)-(4R, 4aS, 70αS 7-Benzyloxy-4,10 -dimethyl-4a,9, 10, lOa-tetrahydro- ¥H-phenanthren-3-one and (rac)-(4S, 4aS,10aS)-7-benzyloxy-4, 10α-dimethyl-4a, 9,10, 10a-tetrahydro- H-phenanthren-3-one. The enone (rac)-(4aS,10aS)-7 -benzyloxy- 10a- methyl-4a,9,10,10a-tetrahydro- H-phenanthren-3-one. (101 mg) from Example 15 dissolved in TΗF (3.0 mL), was treated according to method E ("J" = diisopropylamine, "K" = 10, "L" = 2.0, "M" = TΗF, "N" = n-butyl lithium [1.6M solution in hexanes], "O" = 10, "P" = -78, "Q" = 1) with the following exception. Methyl iodide (10 eq.) was added to the reaction mixture, and stirring was continued for another 20 h at room temperature before quenching. The crude product was purified on chromatotron, using EtOAc: ^-heptane (1 :8, v:v) as eluent, to yield 71 mg of (rac)-(4R, 4aS, 10aS)- -benzy oxy-4, 10<2-dimethyl-4a,9,10,10a-tetrahydro-^H-phenantlιren-3-one and (rac)-(4S, 4aS,10aS)-7- benzyloxy-4, 10α-dimethyl-4a,9, 10, 1 Oa-tetrahydro-^H-phenanthren-3 -one. Step 2: (rac)-(lS,4S,4aS,10aS)-7-BenzyloxyA-butyl-4, 1 Oa-dimethyl- 1,4,4a, 9, 10,10a-hexahydro-2H-phenanthren-3-one. The enone (rac)-(4R, 4aS, 10aS)-7- benzyloxy-4, 10 -dimethyl-4a,9, 10, 1 Oa-tetralιydro-^H-phenanthren-3-one and (rac)-(4S, 4aS,10aS)-7-benzyloxy-4, 10α-dimethyl-4a,9, 10, 1 Oa-tetrahydro-^H-phenanthren-3-one (25 mg) dissolved in TΗF (2.0 mL), was treated according to method E ("J" = CuCN, "K" = 2, "L" = 2.0, "M" = TΗF, "N" = «-butyl lithium [1.6M solution in hexanes], "O" = 4.0, "P" = -78, "Q" = 2) with the following exception; CuCN and /.-butyl lithium ixed at 0°C and stirred at RT for lh. The crude product was purified on PΗPLC to yield 18mg of (rac)-(lS,4S, 4aS, 10aS)-7- Benzyloxy- l-butyl-4, 1 Oa-dimethyl- 1,4, 4a,9,10, lOa-hexahydro -2H-phenanthren-3-one (white powder) that was used in the next step (step 3). ES/MS m/z: 379.0 (pos, M+Η); 'ΗNMR (270 MHz, CD3C1) δ 7.30-7.50 (μ, 5H), 7.00 (d,lH), 6.75-6.85 (m, 2H), 5.05 (s, 2H), 2.60-2.75 (m, 5H), 2.45 (dd, IH), 2.00-2.15 (m, IH), 1.65-1.75 (m, 2H), 1.0-1.5 (m, 9H), 0.90 (t, 3H), 0.75 (s,3H).
Step 3: (rac)-(lS,4S,4aS,10aS)-7-Bydxoxy- l-butyl-4, 1 Oa-dimethyl- l,4,4a,9, 10, 10a- hexahydro-2H-phenanthren-3-one. As the substrate, (rac)-(lS,4S,4aS,10aS)-7-Benzyloxy- l-butyl-4,1 Oa-dimethyl-1, 4,4a,9,10,10a-hexahydro-2H-phenanthren-3-one (12 mg) from the previous step (step 2) was treated according to method F ("J" = TΗF:ΗOAc [95:5], "K" = 3.0, "L" = 5% Pd/C, "M" = 5, "N" = 24). The crude product was purified using PHPLC to yield (rac)-(lS,4S,4aS,10aS)-7-Bydxoxy-l- butyl-4,1 Oa-dimethyl- 1,4,4a, 9,10,10a-hexahydro-2H-phenanthren-3-one. ES/MS m/z (mixture): 301.3 (pos, M+Η), 299.2 (neg, M-Η); 'Η NMR (270 MHz, CD3C1) δ 6.95 (d,lH), 6.65-6.75 (m, 2H), 4.77 (s, IH), 2.60-2.75 (m, 5H), 2.45 (dd, IH), 2.00-2.15 (m, IH), 1.65-1.75 (m, 2H), 1.0-1.5 (m, 9H), 0.90 (t, 3H), 0.70 (s,3H).
Example 40: Synthesis of fmc)-t S. flS.i0aS)-3,3-ethanediyldimercapto-7-hvdroxy-4. 10a-dimethyl-1.2,3.4.4a.9.10.10a-octahvdro-phenanthrene (E40
Step 1: (rac)-(4S,4aS,10aS)- -Bydxoxy-4, 1 Oa-dimethyl- l,4,4a,9, 10,10a- hexahydro -2H-phenanthren-3-one. As the substrate, a mixture of (rac)-(4R, 4aS, 10aS)-7- benzyloxy-4, 10 -dimethyl-4a,9, 10, 1 Oa-tetrahydro-^H-phenanthren-3-one and (rac)-(4S, 4aS, 1 S 7-benzyloxy-4, 10α-dimethyl-4a,9, 10, 10a-tetrahydro-¥H-phenanthren-3 -one (20 mg) from Example 39 was treated according to method F ("J" = TΗF:ΗOAc [95:5], "K" = 4.0, "L" = 10% Pd/C, "M" = 7, "N" = 12). The crude product was purified using PHPLC to yield (rac)-(4S,4aS,10aS)- -Bydxoxy-4, 1 Oa-dimethyl- 1,4,4a, 9,10,10a-hexahydro- 2H-phenanthren-3-one. ES/MS m/z (mixture): 245.2 (pos, M+Η), 243.1 (neg, M-Η); 'Η NMR (270 MHz, CD3C1) δ 6.95 (d,lH), 6.65-6.75 (m, 2H), 5.05 (s, IH), 2.65-2.08 (m, 3H), 2.40-2.55 (m, 3H), 1.55-1.90 (m, 4H), 1.30 (t, 3H), 0.60 (s,3H).
Step 2. (rac)-(4S, 4aS, 10aS)-3, 3 -ethanediyldimercapto-7- hydroxy-4, 1 Oa-dimethyl- 1, 2,3 ,4,4a,9, 10, 1 Oa-octahydro-phenanthrene. The ketone (rac)-(4S, 4aS, 10aS)-7 -Bydxoxy-4, 1 Oa-dimethyl-1, 4,4a,9,10,10a-hexahydro-2H-phenanthren-3-one (9.4 mg) was treated according to method G ("J" = 5.0, "K" = 1,2-ethanedithiol, "L" = 2.0, "M" = 12). The crude product was purified using PΗPLC to yield (rac)-(4S,4aS,10aS)-3, 3 -ethanediyldimercapto-7-hydroxy-4, 1 Oa-dimethyl- 1 ,2,3 ,4,4a,9, 10, 10a- octahydro- phenanthrene as a glass. ES/MS m/z: 321.1 (pos, M+Η), 319.0 (neg, M-Η); 'Η NMR (270 MHz, CD3OD) δ 7.00 (d, IH), 6.60-6.70 (m, 2H), 4.60 (s, IH), 3.20-3.35 (m, 4H), 2.70 (dt, IH), 2.35-2.55 (m, 2H), 2.10- 2.25 (m, 3H), 1.45-1.85 (m, 4H), 1.35 (d, 3H), 0.35 (s, 3H).
Example 41: (rac)-(4S.4aS.10aS)-7-Η.vdroxy-4-benzyl- lOa-methyl-1 . 4.4a.9.1 0. 10a-hexahydro- H-phenanthren-3-one (E41a) and (rac)-(4aS 0aS)-7- vdrox\-4A-dibenzyl-10a- methyl-1.4,4a.9. 10.10a- hexahydro -2H -phenanthren-3-one (E41b).
Step 2 Step 3
(E41a) (E41b)
Step 1: r c -( S,^αS,i0αS 7-Benzyloxy-4-benzyl-10a-methyl-l, 4,4a,9, 10, 10a- hexahydro-2H-phenanthren-3-one and (rac)-(4aS,10aS)-7-benzyloxy-4, 4-dibenzyl- 1 Oa-methyl- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-3 -one. The enone (rac)-(4aS, 10aS)- -benzyloxy- 10a-methyl-4a,9, 10, 1 Oa-tetrahydro-^H-phenanthren-3 -one. (50 mg) dissolved in TΗF (3.0 mL), was treated according to method E ("J" = diisopropylamine, "K" = 10, "L" = 2.0, "M" = TΗF, "N" = n-butyl lithium [1.6M solution in hexanes], "O" = 10, "P" = -78, "Q" = 0.1) with the following exception. Benzyl bromide (1 eq.) was added to the reaction mixture, and stirring was continued for another 14 h at room temperature before quenching. The crude product was purified using PΗPLC to yield 12 mg of (rac)-(4S,4aS,10aS)-7- benzyloxy-4-benzyl-10a-methyl-l,4,4a,9, 10, 10a-hexahydro-2H-ρhenanthren-3-one. ES/MS m/z: 409.3 (pos, M+Η); and 23 mg of (rac)-(4aS, 10αS 7-benzyloxy-4,4-dibenzyl- 1 Oa-methyl- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phe nanthren-3-one. ES/MS m/z: 499.6 (pos, M+Η);
Step 2 raeA^ S 10αS 7-hydroxy-4-benzyl- 1 Oa-methyl- l,4,4a,9, 10, lOa-hexahydro - 2H-phenanthren-3-one. As the substrate, røA 4S, S,i0α -7-benzyloxy-4-benzyl- 1 Oa-methyl- l,4,4a,9,10,10a-hexahydro-2H-phenanthren-3 -one (8 mg) was treated according to method F ("J" = TΗF:ΗOAc [95:5], "K" = 3.0, "L" = 10% Pd/C, "M" = 4, "N" = 12). The crude product was purified by chromatography on silica gel column, using EtOAc : -heptane (1:8 2:8, v:v5 stepwise gradient) as eluent to yield (rac)-(4S,4aS,10aS) -7-hydroxy-4-benzyl-l Oa-methyl- 1, 4,4a,9,10, lOa-hexahydro- 2H-phenanthren-3-one. ES/MS m/z (mixture): 321.1 (pos, M+Η), 319.0 (neg, M-Η); 'Η NMR (270 MHz, CD3C1) δ 7.15-7.25 (m, 5H), 7.00 (d,lH), 6.60-6.70 (m, 2H), 2.95-3.30 (m, 3H), 2.70 (d, 2H), 2.45-2.55 (m, IH), 2.25-2.35 (m, IH), 1.60-1.85 (m, 3H), 1.30-1.50 (m, 2H), 0.60 (s,3H).
Step 3 fr c -( S 0 S 7-Hydroxy-4,4-dibenzyl-l Oa-methyl- l,4,4a,9, 10, lOa-hexahydro -2H-phenanthren-3-one. As the substrate, (rac)-(4aS,10aS)-7-benzyloxy-4,4-d!benzyl -1 Oa-methyl- l,4,4a,9,10,10a-hexahydro-2H-phenanthren-3 -one (17 mg) was treated according to method F ("J" = TΗF:ΗOAc [95:5], "K" = 3.0, "L" = 10% Pd/C, "M" = 5, "N" = 24). The crude product was purified by chromatography on silica gel column, using EtOAc: /.-heptane (1 :8, 2:8, v:v, stepwise gradient) as eluent to yield 13 mg of (rac)-(4aS,10aS)- -bydxoxy-4,4- dibenzyl-1 Oa-methyl- l,4,4a,9, 10,10a-hexahydro- 2H- phenanthren-3-one. 'Η MR (270 MHz, CD3C1) δ 7.85 (δ, IH), 7.15-7.30 (μ, 5H), 7.00-7.05 (m, 3H), 6.80-6.90 (m, 3H), 6.65 (d,lH), 3.45 (dd, 2H), 2.95-3.10 (m, 4H), 2.75-2.90 (m, 2H), 2.45-2.60 ( , 2H), 2.20-2.35 (m, 2H), 1.60-1.70 (m, IH), 1.00 (s,3H).
Example 42: Synthesis of ^αc)- ^flS 0gS')-7-hydroxy-10a-methyl-3. 3-methylene-1.2.3.4.4a.9.10. IQa-octahvdrophenanthrene fE42
(E21) (E42)
(rac)-(4aS, 10aS)-7 -bydxoxy- 1 Oa-methyl-3 ,3-methylene- 1 ,2,3 ,4,4a,9, 10, 1 Oa-octahydrophen anthrene. rø-BuLi (2.0 mL of 1.6 M solution in hexanes, 3.15 mmol) was added to a well-stirred suspension of methyltriphenylphosphonium bromide (1.13 g, 3.15 mmol) in THF (80 mL) at -78°C. The cooling bath was removed and the resulting mixture was allowed to warm to r.t. The resulting yellow solution was cooled to 0°C and a solution of (rac)-(4aS, 10aS)~7 -bydxoxy- 1 Oa-methyl- 1 ,4,4a,9, 10,10a-hexahydro-2H-phenanthren-3 -one (145 mg, 0.63 mmol) in TΗF (5 mL) was added. The resulting mixture was stirred at r.t. for 3 days and then quenched with sat. aq. NΗ4C1 (10 mL) together with water (10 mL). The organic phase was separated and the aqueous phase was additionally extracted with EtOAc (3x15 mL). The combined organic solutions were washed with brine, dried with anhydrous Na2SO4 and evaporated. The crude product was purified by silica gel flash chromatography using Et2O : WO-hexane (1:4) as eluent to yield (rac)-(4aS,10aS)-7 - hydroxy- 10a-methyl-3, 3-methylene-l,2,3,4,4a,9, 10,10a-octahydrophenanthrene (132 mg) as a white oil. ES-MS m/z: 229.3 (pos, M+H), 227.2 (neg, M-H); 'H NMR (270 MHz, CDCI3) δ 7.05 (d, IH), 6.60 (dd, IH), 6.55 (d, IH), 4.75 (d, IH), 4.70 (d, IH), 4.50 (bs, IH), 3.00-2.70 (m, 3H), 2.50-1.95 (m, 4H); 1.70-1.45 (m, 3H), 1.40-1.15 (m, IH), 0.80 (s, 3H).
Example 43: Synthesis of (rac)-(4aS.10aS)-33-ethanediyl -7-hydroxy -10a- methyl-1. 2.3,4, 4a,9.10, lOa-octahydrophenanthrene (E43 .
(E42) (E43)
(rac)-(4aS, 1 OaS) -3 ,3 -ethanediyl-7-hydroxy- 1 Oa-methyl- 1 ,2,3 ,4,4a,9, 10,1 Oa-octahydrophen anthrene. Me3Al (0.24 mL of 2.0 M solution in hexanes) was added to a well-stirred solution of (rac) -(4aS, 1 OaS) -7-hydroxy- 10a- methyl-3,3-methylene-l,2,3,4,4a,9,10, lOa-octahydrophenanthrene (50 mg, 0.219 mmol) and CH2I2 (63 mg, 0.263 mmol) in w -hexane (10 mL) at r.t. The resulting mixture was stirred at r.t. for 3h and then quenched with 1 aq. HCl (20 mL). The product was extracted with Et2O (3x15 mL), the combined extracts were washed with brine, dried with anhydrous sodium sulfate and evaporated. The crude product was purified by PHPLC to yield (rac)-(4aS,10aS)-3,3-etbanediyl-7- hydroxy-1 Oa-methyl- 1,2, 3,4,4a,9,10, 10a- octahydrophenanthrene (20 mg) as a white oil. ES-MS m/z: 259.9 (pos, M+NH ), 241.0 (neg, M-H); 'H NMR (270 MHz, CDC13) δ 6.92 (d, IH), 6.65-6.50 (m, 2H), 4.60 (bs, IH), 2.95-2.70 (m, 2H), 2.65 (dd, IH); 2.10 (dddd, IH), 1.80 (ddd, IH), 1.70-1.35 (m, 4H), 1.25 (ddd, IH), 0.75 (s, 3H), 0.75-0.60 (m, IH), 0.45-0.29 (m, 2H), 0.29-0.15 (m, 2H).
Example 44: Synthesis of c)-t3R. «S'.i0gS')-l,.2,.3,.4,-tetrachloro-7-hvdroχy-10a- methyl-1.2,3,4,4a,9.10.10a-octahvdrospiro[phenanthrene-3,6'-cyclohexane -lf.3/-diene fE44^.
(E42) (E44) (rac)-(3R, 4aS, 1 OaS) A ',2',3 ' ,4' -tetrachloro-7-hydroxy- 1 Oa-methyl- 1 ,2,3 ,4, 4a,9, 10, 10a-octahydiOspiro[phenanthrene-3,6'-cyclohexane]- ,3'-diene. A solution of (rac)-(4aS, 1 OaS)- 7 -hydroxy- 1 Oa-methyl-3, 3 -methylene- 1 ,2,3,4,4a,9, 10, 10a octahydrophenanthrene (75 mg, 0.33 mmol) and tetrachlorothiophen- 1,1 -dioxide (167 mg, 0.66 mmol) in dichloroethane (20 mL) was refluxed at 100°C for 2 days. An additional amount of tetrachlorothiophen- 1,1 -dioxide (419 mg, 1.65 mmol) was added and the reaction mixture was refluxed for additional 2 days. The solvent was evaporated and the residue was purified by silica gel flash chromatography using Et2O : wo-hexane (1 :3) as eluent to give 90 mg of crude (-70% purity) product. The following PHPLC separation afforded 54 mg of higher purity (-80%) product. For further purification the hydroxy group was converted into t-butyldimethylsilyloxy moiety according the following procedure. A solution of crude (rac)-(3R,4aS,l OaS) A', 2', 3', 4' -tetxaclxloxo- 7-hydroxy- lOa-methyl-1, 2,3,4,4a,9, 10, 1 Oa-octahydrospiro [phenanthrene-3, 6'-cyclohexane]-r,3'-diene (54 mg, -0.13 mmol), t-butyldimethylsilylchloride (TBDMS) (196 mg, 1.30 mmol) and Et3N (132 mg, 1.30 mmol) in CH2C12 (10 mL) was stirred at 40°C overnight, then the solvent was evaporated and the residue was flashed through a short silica gel column using Et2O : .so-hexane (1:1) as eluent. Crude TBDMS-protected compound was purified using PHPLC to give 31 mg of the pure product. 9 mg of that compound was deprotected using a solution of tetrabutylammonium fluoride (TBAF) (52 mg, 0.20 mmol) in THF (10 mL). The mixture was stirred at r.t. for 1 h, then the solvent was evaporated, water (5 mL) was added to the residue and the product was extracted with CH2C12 (4x5 mL). The solvent was evaporated to give pure (rac)-(3R,4aS,l OaS) A', 2', 3', 4' -tetxach oxo-7- hydroxy- 1 Oa- methyl- 1 ,2,3 ,4, 4a,9, 10, 1 Oa-octahydrospiro [phenanthrene-3 ,6'-cyclohexane]- 1 ',3 '-diene (7 mg) as a white oil. ES-MS m/z: 417.2 (neg, M-H); 'HNMR (270 MHz, CDC13) δ 7.00 (d, IH), 6.64-6.55 (m, 2H), 4.62 (bs, IH), 2.98-2.73 (m, 3H), 2.90 (s, 2H), 2.52 (dd, IH); 2.20-2.03 (m, 2H), 1.84 (dd, IH), 1.70-1.35 (m, 5H), 0.73 (s, 3H).
Example 45: Synthesis of r c)-t3S'.^5'.i<yg>y)-3.7-dihvdroχy-10a-methyl-3- [l- henvIthio yclopropylI-1.2.3.4,4a.9.10.10a-octahydrophenanthrene (E45
(E21) (E45)
rα^-^S^βSi αS^-S -dihydroxy-lOa-methyM-fl- henyltlu^cycloprop y-l^^^^a^, 10,10a-octalιydrophenanthrene. «-BuLi (2.36 mL of 1.6 Msolution in hexanes, 3.78 mmol) was added to a solution of cyclopropylphenylsulphide (379 mg, 2.52 mmol) in THF (15 mL) under cooling to 0°C. The reaction mixture was allowed to warm to r.t. and then was stirred at r.t. for 2 h. The resulting solution was cooled to 0°C and a solution of the ketone (rac)-(4aS, 10aS)- -by dxoxy- 1 Oa-methyl- 1 ,4,4a,9, 10,10a-hexahydro-2H-phenanthren-3 -one (145 mg, 0.63 mmol) in TΗF (5 mL) was added. The resulting mixture was stirred at r.t. overnight and then was quenched with water (5 mL) together with sat. aq. NΗ4C1 (1 mL). The organic phase was separated and the aqueous phase was additionally extracted with EtOAc (3x10 mL). The combined organic solutions were washed with brine, dried with anhydrous Na2SO and evaporated. The crude product was purified by PHPLC to yield dihydroxy-10a-methyl-3-[l- (phenylthio)cyclopropyl]-l,2,3, 4,4a,9,10,10a-octahydrophenanthrene (100 mg) as a pale yellow oil. 'H NMR (270 MHz, CDC13) δ 7.50-7.43 (m, 2H), 7.31-7.22 (m, 2H), 7.14 (tt, IH), 6.90 (d, IH), 6.59-6.52 (m, 2H), 4.70 (bs, IH), 2.90-2.67 (m, 3H), 2.20 (ddd, IH), 1.88-1.74 (m, IH); 1.68-1.48 (m, 5H), 1.42-1.24 (m, 3H), 1.10-0.95 (m, 2H), 0.64 (s, 3H); 13C NMR (CDC13) δ 153.17, 137.96, 137.49, 131.53, 128.62 (2C), 128.41 (2C), 125.60 (2C), 115.24, 112.43, 74.44, 39.57, 37.62, 36.17, 35.71, 33.97, 32.08, 29.55, 26.21, 14.59, 13.58, 13.32.
Example 46: Synthesis of (rac)-(3S.4aS.10aS)-7-hvdroxy-10a-vιιethyl- 23ΛΛa.9. 10,10a-octahydrospiro[phenanthrene-3,2'-cvcIobutanej-r-one fE46a) and (rαc)-(3R.4αS.10αS)-7- vdroxy-10a-met v\A .2.3.4.4a.9.10. lOa-octahvdrospiro [phenanthrene-3,2,-cyclobutane -l'-one (E46b
(E45) (E46a) (E46b)
(rαc^- 3S,^αS,i0α-^-7-hydroxy-10a-methyl-l,2,3,4,4a,9,10,10a-octahydrospiro[phenanthre ne-3,2'-cyclobutane]-l'-one and (rac)-(3R,4aS,10aS)- -bydxoxy- 1 Oa-methyl- 1,2,3, 4, 4a,9, 10, 1 Oa-octahydrospiro [phenanthrene-3 ,2'-cyclobutane]- 1 '-one. A mixture (rac)-(3S,4aS,10aS)-3, 7-dihydroxy-10a- methyl-3-[l- (ρhenylthio)cyclopropyl]-l, 2,3, 4, 4a,9,10,10a-octahydrophenanthrene (80 mg, 0.21 mmol) and 4-toluenesulfonic acid monohydrate (200 mg, 1.05 mmol) in toluene (20 mL) was stirred at 100°C overnight. The resulting mixture was quenched with sat. aq. NaHCO3 (10 mL), the organic layer was separated and the solvent was evaporated. The residue was separated using PHPLC to give two diastereomeric products, (rac)-(3S,4aS,10aS)-7 -bydxoxy A Oa-methyl- 1,2,3, 4,4a,9, 10,1 Oa-octahydrospiro [phenanthrene-3 ,2'-cyclobutane]-l '-one (32 mg) and (rac)-(3R,4aS,10aS)-7-bydxoxy- 1 Oa-methyl- 1,2,3 ,4,4a, 9,10,10a- octahydrospiro [phenanthrene-3,2'-cyclobutane]-l'-one (10 mg) as white oils. (rac)-(3S,4aS,10aS) -7-hydroxy- 1 Oa-methyl- 1, 2,3, 4,4a,9, 10, 1 Oa-octahydrospiro [phenanthrene-3 ,2'- cyclobutane]- '-one: ES-MS m/z: 288.2 (pos, M+NH4 +), 268.8 (neg, M-H); 'H NMR (270 MHz, CDCJj) δ 6.95 (d, IH), 6.65-6.50 (m, 2H), 5.26 (bs, IH), 3.07 (t, 2H), 2.92-2.68 (m, 2H), 2.44 (d, IH), 2.25 (ddd, IH), 2.00-1.80 (m, 3H), 1.66-1.45 (m, 5H), 1.34 (ddd, IH), 0.68 (s, 3H). (rac)-(3R,4aS,10aS)-7-bydxoxyA0a-xnetbylA,2,3,4, 4a,9,10, 10a- octahydrospiro[phenanthrene-3,2'-cyclobutane]- -one: ES-MS m/z: 288.2 (pos, M+NH4 +), 270.2 (neg, M-H); 'HNMR (270 MHz, CDC13) δ 6.97 (d, IH), 6.64-6.46 (m, 2H), 4.84 (bs, IH), 3.00 (t, 2H), 2.90-2.68 (m, 2H), 2.43 (dd, IH), 1.97-1.35 (m, 10H), 0.68 (s, 3H).
Example 47: Synthesis of trαc)-^iS,^αS.i0tfS')-l',l'-ethanediyldimercapto-7- hvdroxy-10a-methvI-1.2.3.4.4a.9.10.10a-octahydrospiro phenanthrene-3.2 '-cvclobutanel (E41).
(E46a) (E47)
(rac)-(3S, 4aS,10aS)-V, 1 '-ethanediyldimercapto-7-hydroxy- 1 Oa-methyl- 1 ,2,3,4,4a, 9, 10, 10a-octahydrospiro[phenanthrene-3,2'-cyclobutane]. The reaction was carried out on 28.0 mg (0.10 mmol) (rac)-(3S,4aS,10aS)-7-bydxoxyA0a-metby\A, 2,3,4,4a,9, 10, 10a-octahydrospiro[phenanthrene-3,2'-cyclobutane]- -one, according to method G ("J"= 10, "K"= 1,2-ethanedithiol, "L"= 2, "M"= 18), using 3 eq. of BF3OEt2 complex. The crude product was purified by silica gel flash chromatography using Et2O : iso-bexane (1 :1) as eluent to yield (rαc)-(3S,4αS,10αS)-V,l'-etbanediyldimexcapto-7 -bydxoxy- 1 Oa-methyl- 1, 2,3,4,4a,9,10,10a-octahydrospiro[phenanthrene-3,2'-cyclobutane] (31 mg) as a white oil. ES-MS m/z: 347.2 (pos, M+H), 391.0 (neg, M+HCOOH-H); 'H NMR (270 MHz, CDC13) δ 7.12 (d, IH), 6.62 (dd, IH), 6.55 (d, IH), 4.60 (bs, IH), 3.30-3.10 (m, 4H), 2.90-2.70 (m, 2H), 2.60-2.46 (m, 2H), 2.45-2.34 (m, 2H), 1.98-1.76 (m, 4H), 1.62-1.24 (m, 5H), 0.69 (s, 3H).
Example 48: Synthesis of (rαc)-(4αS.l flαS)-7-hvdroxy-10a-methyl-1.2.3.4.4a.9.10. 10a-octahvdrospiro[phenanthrene-3.1'-cyclobutane] E48).
(E47) (E48) (rac)-(4aS, 10aS)- -bydxoxy- 1 Oa-methyl- 1 ,2,3,4,4a,9, 10, 1 Oa-octahydrospiro [phenanthrene-
3,l'-cyclobutane]. The reaction was carried out on 24.0 mg (0.070 mmol)
(rac)-(3S, 4aS, 1 OaS)- V , V -ethanediyldimercapto-7- hydroxy- 1 Oa-methyl- 1 , 2,3 ,4,4a,9, 10,
10a-octahydrospiro[phenanthrene-3,2'-cyclobutane], according to method J ("J" = 100,
"K" = 15, "L" = 20, "M" = 0, "N" = 24) at 80°C to give
(rac)-(4aS,10aS)-7 -bydxoxy AOa-metbyl -l,2,3,4,4a,9,l 0, 1 Oa-octahydrospiro
[phenanthrene-3, l'-cyclobutane] (18 mg) as a white oil. ES-MS m z: 257.2 (pos, M+H),
255.1 (neg, M-H); 'H NMR (270 MHz, CDC13) δ 7.08 (d, IH), 6.61 (dd, IH), 6.55 (d, IH),
4.40 (bs, IH), 2.94-2.67 (m, 2H), 2.33 (dd, IH), 2.20 (ddd, IH), 1.98-1.18 (m, 13H), 0.67
(s, 3H).
Example 49: Synthesis of frac)- α£iflgS')-3-(l-cvclopenten-l-vf)-7- hvdroxy-10a-methyl-l,4,4a,9,10,10a-hexahydrophenanthrene (Ε49 .
Step 1. (r-ϊς)- S,70α5^)-3,7-dihydroxy-10a-methyl-3- [l-(phenylsulphinyl) cyclopentyl] -l,2,3,4,4a,9,10,10a-octahydrophenanthrene (mixture of diastereomers). rø-BuLi (1.60 mL of 1.6 M solution in hexanes, 2.40 mmol) was added to a solution of cyclopenthylphenylsulphoxide (466 mg, 2.40 mmol) in THF (15 mL) under cooling to -70°C. The reaction mixture was allowed to warm to r.t. and then was cooled to 0°C. A solution of (røc)-( αS,i0αS)-7-hydroxy- 1 Oa-methyl- l,4,4a,9, 10, 10a-hexahydro-2H- phenanthren-3-one (110 mg, 0.478 mmol) in TΗF (5 mL) was added and the resulting mixture was stirred at r.t. overnight. The resulting mixture was quenched with sat. aq. NΗ C1 (10 mL) together with water (10 mL). The organic phase was separated and the aqueous phase was additionally extracted with EtOAc (3x15 mL). The combined organic solutions were washed with brine, dried with anhydrous Na2SO and evaporated. The product, a mixture of diastereomers of (rac)-(4aS, 10aS)-3, 7-dibydxoxyA0a- metbyl~3- [l-(phenylsulphinyl)cyclopentyl]-l,2,3,4,4a,9,10,10a-octahydrophenanthrene, was used in the next step without purification or separation.
Step 2. (rac)-(4aS, 10aS)-3-(l-cyclopenten-l-yϊ)-7-bydxoxy- 1 Oa-methyl- l,4,4a,9, 10, lOa-hexahydrophenanthrene. TiCl (1.43 mmol, 271 mg) was added to a well-stirred mixture of Zn powder (2.87 mmol, 188 mg) and (røς)-(¥αS,i0α -3,7-dihydroxy- 10a-methyl-3-[ 1 -(phenylsulphinyl)cyclopentyl]- 1 ,2,3 ,4,4a, 9,10, lOa-octahydrophenanthrene (crude mixture of diastereomers from the previous step, about 0.48 mmol) in THF (25 mL) under cooling to 0°C. The resulting mixture was stirred at r.t. for 2 h and then quenched with sat. aq. NaHCO (10 mL). The organic phase was separated and the aqueous phase was additionally extracted with Et2O (3x15 mL). The combined organic solutions were washed with brine, dried with anhydrous Na2SO and evaporated. The residue was separated using PHPLC to give (rac)-(4aS, 10aS)-3-(l-cyclopentenA-yl)- 7-hydroxy-l Oa-methyl- 1,4,4a, 9, 10,10a-hexahydrophenanthrene (20 mg) as a pale yellow oil. ES-MS m/z: 281.2 (pos, M+H); 'HNMR (270 MHz, CDC13) δ 7.19 (d, IH), 6.66 (dd, IH), 6.57 (d, IH), 5.79 (s, IH), 5.68 (dd, IH), 4.55 (bs, IH), 3.33-2.81 (m, 2H), 2.86-2.60 (m, 2H), 2.55-2.38 (m, 4H), 2.14-1.84 (m, 5H), 1.72-1.50 (2H), 0.75 (s, 3H); 13C NMR (CDCl3) δ 153.15, 144.35, 137.87, 132.85, 131.85, 127.26, 123.92, 123.05, 115.08, 112.93, 41.65, 40.78, 37.11, 33.06, 32.22, 30.97, 28.43, 26.31, 23.08, 16.19.
Example 50: Synthesis of (rac)-(3S.4aS.10aS)- -hvdroxy-lOa-methyl-l.2.3. 4.4a.9.10,10a.2',3'.4'.5'- dodecahvdrospiro[phenanthrene-3.2'-furanl (E50a) and trac)-t3R. S.i0 S')-7-hvdroxy-10a-methyl-1.2.3.4.4a.9.10. 10a.2'.3'. 4'.5'-dodecahvdrospiro[phenanthrene-3.2'-furan] (E50b).
Step 2
(E50a) (E50b)
Step 1.
(rαc -(^ S70αS 3,7-dihydroxy-10a-methyl-3-[3-(phenylmethoxy)proρyl]-l,2,3,4,4a,9,10,l Oa-octahydrophenanthrene (mixture of diastereomers). A mixture of Mg pulver (114 mg, 4.70 mmol) and benzyl 3-bromopropyl ether (538 mg, 2.35 mmol) in THF (20 mL) was stirred at 60°C for 2 h. A solution of (rac)-(4aS,l 0aS)- -bydxoxy A Oa-methyl- l,4,4a,9, 10,10a-hexahydro-2H-phenanthren-3-one (108 mg, 0.47 mmol) in TΗF (5 mL) was added to the resulting mixture at r.t. The resulting mixture was stirred at r.t. overnight and then quenched with sat. aq. NΗ4C1 (10 mL) together with water (10 mL). The organic phase was separated and the aqueous phase was additionally extracted with EtOAc (3x15 mL). The combined organic solutions were washed with brine, dried with anhydrous Na2SO and evaporated. The product, a mixture of diastereomers of (rac)-(4aS, 1 OaS) -3, -diby dxoxy- 1 Oa-methyl-3 - [3 -(phenylmethoxy)propyl]- 1 ,2,3 ,4,4a,9, 10,1 Oa-octahydrophenanthrene, was used in the next step without purification or separation.
Step 2. (racA¥αSJi0αS 3,7-dihydroxy-3-(3-hydroxyρropyl)- 1 Oa-methyl- 1,2,3, 4,4a,9,10, 1 Oa-octahydrophenanthrene (mixture of diastereomers). The crude mixture of diastereomers of (rac)-(4aS, 10aS)-3 ,7-dihydroxy- 1 Oa-methyl-3 - [3 -(phenylmethoxy) propyl]- 1, 2,3, 4,4a,9, 10,1 Oa-octahydrophenanthrene from the previous step (about 0.47 mmol) was treated according to method F ("J" = THF, "K" = 20, "L" = 10% Pd/C (wet, 50% of water), "M" = 140, "N" = 72) to obtain a mixture of diastereomers of (rac)-(4aS, 1 S 3,7-dihydroxy-3-(3-hydroxypropyl) - 1 Oa-methyl- 1 ,2,3,4,4a,9, 10, 1 Oa-octahydrophenanthrene, which was used in the next step without purification or separation.
Step 3. (rac)-(3S,4aS,10aS)-3, -dibydxoxy-3-[3-[ (4-methylphenyl) sulphonyloxy] propyl] - 1 Oa-methyl- 1 ,2,3,4,4a,9, 10, 1 Oa-octahydrophenanthrene and (rac)-(3R, 4aS,10aS)-3, 7-dihydroxy-3- [3 -[(4-methylphenyl) sulphonyloxy]propyl]- 1 Oa-methyl- 1,2, 3,4,4a,9,10, 1 Oa-octahydrophenanthrene. A mixture of the diastereomers of (rac)-(4aS, 10αS 3,7-dihydroxy- 3-(3-hydroxypropyl)-l Oa-methyl- 1, 2,3 ,4,4a,9, 10, 1 Oa-octahydrophenanthrene from the previous step (about 0.47 mmol), 4-methylphenylsulphonyl chloride (448 mg, 2.35 mmol), 4-dimethylaminopyridine (57 mg, 0.47 mmol) and pyridine (372 mg, 4.70 mmol) in CH2C12 (25 mL) was stirred at 40°C overnight. The resulting mixture was diluted with CHC13 (50 mL) and washed subsequently with sat. aq. NaHCO3 (2x15 mL), IMaq. HCl (2x15 mL), water (10 mL) and then again with sat. aq. NaHCO (15 mL). The resulting solution was dried with anhydrous Na2SO and the solvent was evaporated. The residue was separated using PHPLC to give pure (rac)- (3S, 4aS, 0α^)-3,7-dihydroxy-3-[3-[ (4-methylphenyl)sulphonyloxy]propyl]- 1 Oa-methyl- 1, 2,3, 4,4a,9, 10,1 Oa-octahydrophenanthrene (53 mg) and (rac)-(3R, 4aS,10aS)-3,7- dihydroxy-3- [3 -[(4-methylphenyl) sulphonyloxyjpropyl]- 10a-methyl-l,2,3,4,4a,9,10,10a-octahydrophenanthrene (65 mg) as white oils. (rac)-(3S, 4aS,10aS)-3, -dibydxoxy -3-[3-[(4-methylphenyl)sulphonyloxy]propyl] -10a-methyl-l,2,3,4,4a,9,10,10a octahydrophenanthrene: ES-MS m/z: 444.4 (pos, M+H), 485.2 (neg, M+HCOOH-H); 'H NMR (270 MHz, CDC13) δ 7.70 (d, 2H), 7.29 (d, 2H), 7.04 (d, IH), 6.75 (d, IH), 6.65 (dd, IH), 3.87 (t, 2H), 2.90-2.66 (m, 2H), 2.43 (s, 3H), 2.38 (dd, IH), 2.07 (ddd, IH), 2.02-1.88 (m, 2H), 1.88-1.42 (m, 7H), 1.35-1.17 (m, 2H), 0.70 (s, 3H). (rac)-(3R,4aS,10aS)-3,7-dibydxoxy-3- [3-[(4-methylphenyl)sulphonyloxy] propyl]- 10a-methyl-l,2,3,4,4a,9,10,10a-octahydrophenanthrene: ES-MS m/z: 444.4 (pos, M+H), 485.2 (neg, M+HCOOH-H); Η NMR (270 MHz, CDC13) δ 7.67 (d, 2H), 7.27 (d, 2H), 7.02 (d, IH), 6.71 (d, IH), 6.62 (dd, IH), 3.81 (t, 2H), 2.86-2.64 (m, 3H), 2.42 (s, 3H), 2.11 (dd, IH), 2.00-1.86 (m, 2H), 1.78-1.46 (m, 9H), 1.44-1.29 (m, 2H), 0.64 (s, 3H).
Step 4. (rac)-(3S,4aS,l 0aS)-7-bydxoxyA0a-methylA,2,3,4,4a,9, 10,10a,2',3',4',5' -dodecahydrospiro [phenanthrene-3 ,2'-furan]. Potassium tert-butoxide (t-BuOK) (67 mg, 0.595 mmol) was added to a solution of (rαc)-(3S,4αS,10αS)-3,7-dibydxoxy-3-[3- (4-methylphenyl- sulphonyloxy)propyl]- 1 Oa-methyl- 1 ,2,3 ,4,4a,9, 10, 1 Oa-octahydrophenanthrene (53 mg, 0.119 mmol) in THF (20 mL). The reaction mixture was stirred at r.t. for 30 min, and then quenched with sat. aq. NH4C1 (10 mL) together with water (10 mL). The organic phase was separated and the aqueous phase was additionally extracted with EtOAc (3x15 mL). The combined organic solutions were washed with brine, dried with anhydrous Na2SO4 and evaporated. The crude product was purified by silica gel flash chromatography using Et2O : wø-hexane (1 : 1) as eluent to yield (rαc)-(3S, 4αS,10αS) -7-hydroxy-10a-methyl-l,2,3,4,4a,9,10, 10a,2',3',4',5' -dodecahydrospiro [phenanthrene-3, 2'-furan] (26 mg) as a white solid. ES-MS m z: 273.2 (pos, M+H); Η NMR (270 MHz, CDC13) δ 7.00 (d, IH), 6.68-6.50 (m, 2H), 5.76 (bs, IH), 3.92 (t, 2H), 2.94-2.68 (m, 2H), 2.37 (dd, IH), 2.23 (ddd, IH), 2.06-1.42 (m, 9H), 1.35-1.17 (m, 2H), 0.72 (s, 3H); 13C NMR (CDCl3) δ 153.65, 137.61, 131.03, 125.66, 115.31, 112.58, 84.63, 66.47, 43.06, 38.53, 37.88, 36.15, 34.89, 32.80, 32.36, 26.34, 26.00, 15.14.
Step 5. (rαc)-(3R, 4αS,10αS)-7 -by dxoxy AOa-xne bylA, 2,3, 4,4a,9,10, 10a,2',3',4',5'-dodecahydrospiro[phenanthrene-3,2'-furan]. (rαc)-(3R,4αS,10αS)-3, 7-dihydroxy -3-[3-[(4-methylphenyl)sulphonyloxy]propyl]- 1 Oa-methyl- l,2,3,4,4a,9, 10, lOa-octahydiOphenanthrene (65 mg, 0.146 mmol) was treated according to procedure, described above in Step 4 to give
(rαc)-(3R,4αS,10αS)- 7-hydroxy- 1 Oa-methyl- 1 ,2,3,4,4a,9, 10, 10a,2',3',4',5'-dodecahydrospiro [phenanthrene-3, 2'-furan] (37 mg) as a white solid. ES-MS m/z: 273.4 (pos, M+H), 271.4 (neg, M-H); 'H NMR (270 MHz, CDC13) δ 6.98 (d, IH), 6.65-6.47 (m, 2H), 5.71 (s, IH), 3.87 (td, 2H), 2.90-2.64 (m, 2H), 2.19 (dd, IH), 2.06-1.24 (m, 11H), 0.68 (s, 3H); 13C NMR (CDCl3) δ 153.27, 137.94, 131.75, 125.57, 115.27, 112.37, 84.41, 66.73, 40.52, 38.81, 37.81, 36.71, 35.22, 32.00, 31.94, 26.25, 25.27, 14.89.
Example 51: Synthesis of (rac)-(3S,4aS 0aS)-7-hvdroxy-10a- ethyl- 23Λ, 4a,9,10,10a,3',4',5'.6'-dodecahvdrospiro[phenanthrene-3,2'-2H-pyran] E51a) and trαc)-riR.^αS.i0 S)-7-hvdroxy-10a- methyl-1.2.3.4.4a.9.10.10a.3'.4'.5,.6'- dodecahv drospiro [phenanthrene-3,2'-2H-pyran] (E51b>.
(E51a) (E51b) Step 1. (rac)-(3S,4aS, 10aS)-3,7-dibydxoxy-3- (4-bydxoxybuiyl)- 1 Oa-methyl- 1,2,3, 4,4a, 9,10, 1 Oa-octahydrophenanthrene and (rac)-(3R,4aS,l 0aS)-3,7-dibydxoxy-3- (4-hydroxybutyl)- 1 Oa-methyl- 1, 2,3, 4,4a,9, 10,1 Oa-octahydrophenanthrene. Benzyl 4-bromobutyl ether (571 mg, 2.35 mmol) was added to a well-stirred suspension of Rieke® Mg (114 mg, 4.70 mmol) in THF (20 mL) at r.t. and the resulting mixture was stirred at 50°C for 2 h. A solution of (rac)-(4aS, 10aS)-7 -bydxoxy A Oa-methyl- 1,4,4a, 9,10, 10a-hexahydro-2H-phenanthren-3-one (108 mg, 0.47 mmol) in TΗF (5 mL) was added to the mixture at r.t. and the resulting mixture was stirred at r.t. for 3 days. The mixture was quenched with sat. aq. NΗ C1 (10 mL) together with water (10 mL). The organic phase was separated and the aqueous phase was additionally extracted with EtOAc (3x15 L). The combined organic solutions were washed with brine, dried with anhydrous Na2SO and evaporated. The residue was separated by silica gel flash chromatography using Et2O : MeOH (97:3) as eluent to yield (rac)-(3S, 4aS,10aS)-3, 7 -dibydxoxy-3- (4-hydroxybutyl) -10a-methyl-l,2,3,4,4a,9,10,10a-octahydrophenanthrene (49 mg) and 1 Oa-octahydrophenanthrene (76 mg) as white solids.
Step 2. (rac)-(3S,4aS,10aS)-3,7-dibydxoxy- 1 Oa-methyl-3- [4- [ (4-methylphenyl) -sulphonyloxy]butyl]- 1 ,2,3 ,4,4a,9, 10,1 Oa-octahydrophenanthrene. (rac)-(3S, 4aS, 1 aS)-3,7- dihydroxy-3 -(4-hydroxybutyl)- 1 Oa-methyl- 1 ,2,3 ,4,4a,9, 10,1 Oa-octahydrophenanthrene (49 mg, 0.161 mmol) was treated according to procedure, described above in Example 50, Step 3 to give (rac)-(3S,4aS,10aS)-3,7- dihydroxy-3-[4-[ (4-methylphenyl) sulphonyloxy] - 1 -butyl]- 1 Oa-methyl- 1, 2,3, 4,4a,9, 10,1 Oa-octahydrophenanthrene, which was used for the next step without purification.
Step 3. (rac)-(3S,4aS,10aS)- -bydxoxy A0a- methyl- 1, 2,3, 4,4a,9, 10,10a,3',4',5',6'-dodecahydrospiro[phenanthrene-3,2'-2H-pyran]. Crude (rac)-(3S,4aS,10aS)-3, 7-dihydroxy-l Oa-methyl-3- [4- [(4-methylphenyl) sulphonyloxy] butyl] -1, 2,3, 4,4a,9, 10,1 Oa-octahydrophenanthrene from the previous step (about 0.16 mmol) was treated according to procedure, described above in Example 50, Step 4 to give (rac)-(3S, 4aS, 1 OaS) -7-hydroxy- 10a- methyl- 1 ,2,3, 4,4a,9, 10,10a,3',4',5',6'- dodecahydrospiro[phenanthrene-3,2'-2H-pyran] (31 mg) as a white oil. ES-MS m/z: 287.2 (pos, M+Η), 285.0 (neg, M-Η); 'Η NMR (270 MHz, CDC13) δ 7.04 (d, IH), 6.67-6.55 (m, 2H), 5.71 (s, IH), 3.90-3.71 (m, 2H), 2.95-2.69 (m, 2H), 2.50-2.37 (m, 2H), 1.98 (dd, IH), 1.82-1.20 (m, 12H), 0.72 (s, 3H); 13C NMR (CDC13) δ 153.59, 137.76, 131.20, 125.57, 115.32, 112.57, 74.62, 61.25, 41.02, 37.89, 37.06, 34.88, 33.02, 31.70, 30.17, 26.33, 26.25, 19.02, 15.31.
Step 4. (racA3R^ S70αS 3,7-dihydroxy-10a-methyl-3- [4- [(4-methylphenyl) sulphonyloxy]butyl]- 1 ,2,3 ,4,4a,9, 10,1 Oa-octahydrophenanthrene.
(rac)-(3R,4aS,10aS)-3, 7 -dibydxoxy-3- (4-hydroxybutyl)- 1 Oa-methyl- 1,2,3, 4,4a,9, 10,1 Oa- octahydrophenanthrene (76 mg, 0.25 mmol) was treated according to procedure, described above in Example 50, Step 3 to give (rac)-(3R,4aS,10aS)-3, 7-dihydroxy-3-[4- [(4-methylphenyl) sulphonyloxy]- 1 -butyl]- 1 Oa-methyl- 1 , 2,3 ,4,4a,9, 10, 1 Oa-octahydrophenanthrene, which was used for the next step without purification.
Step 5. (rac (3R,^ S70αS -7-hydroxy-10a-methyl-l,2,3,4,4a,9,10,10a,3',4',5',6'- dodecahydrospiro [phenanthrene-3 ,2 '-2H-pyran]. Crude (rac)-(3R,4aS,10aS) -3,7 -dihydroxy- 1 Oa-methyl-3 -[4- [(4-methylphenyl) sulphonyloxy]butyl] -l,2,3,4,4a,9, 10, 1 Oa-octahydrophenanthrene from the previous step (about 0.25 mmol) was treated according to procedure, described above in Example 50, Step 4 to give (rac)-(3R, 4aS, 10aS)-7 -bydxoxy- 1 Oa-methyl- 1 ,2,3,4,4a,9, 10, 10a,3',4',5',6'-dodecahydro spiro [phenanthrene-3 ,2' -2H-pyran] (56 mg) as a white oil. ES-MS m/z: 287.2 (pos, M+Η), 285.2 (neg, M-Η); Η NMR (270 MHz, CDCh) δ 7.02 (d, IH), 6.63-6.52 (m, 2H), 5.78 (s, IH), 3.66 (dd, 2H), 2.91-2.64 (m, 3H), 2.50 (ddd, IH), 1.93 (ddd, IH), 1.78-1.34 (m, 10H), 1.26 (ddd, IH), 1.14 (dd, IH), 0.67 (s, 3H); 13C NMR (CDC13) δ 153.24, 138.07, 131.85, 125.52, 115.29, 112.39, 72.58, 60.56, 38.61, 37.89, 37.59, 35.08, 32.63, 32.52, 29.65, 26.30, 26.14, 19.00, 15.08.
Example 52: Synthesis of (rac)-(lS R aS.lOaS)- 7-hvdroxy- lOa-methyl-1- (3-methylbutyr>-1.2.3.4.4a.9.10. 10a.2'.3'.4'.5'- dodecahydrospiro fphenanthrene -3.2'-furan1 fE52 .
Step 1. (rac)-(lS,3R,4aS,10aS)-3,7-dibydxoxyA0a-xnetbylA- (3-methylbutyl)-3- [3-(phenylmethoxy)propyl]- 1 ,2,3 ,4,4a,9, 10, 1 Oa-octahydrophenanthrene. (rac) -(IS, 4aS, 10aS)-7-bydxoxy- 1 Oa-methyl- 1 -(3-methylbutyl)- 1 ,2,3 ,4,4a,9, 10, 1 Oa-octahy drophenanthrene-3 -one (83 mg, 0.277 mmol) was treated according to procedure, described above in Example 50, Step 1, but the reaction mixture was stirred overnight at 50°C. The crude product was purified by silica gel flash chromatography using Et2O : wo-hexane (1:1) as eluent to give the only diastereomer, (rac)-(fS,3R,4aS 0aS)-3,7-dibydxoxy- l0a-metbylA-(3-metbylbn yl) -3-[3-(phenylmethoxy)propyl]-l,2,3,4,4a,9,10,10a-octahydrophenanthrene (119 mg), as a white oil.
Step 2. (rαc)-(lS,3R,4αS,10αS)-3,7-dibydxoxy-3- (3 -hydroxypropyl)- 10a-methyl-l- (3 -methylbutyl)- 1 ,2,3 ,4,4a,9, 10,1 Oa-octahydrophenanthrene. ^ ς)-( S,5R,^ S,-70βS -3,7-dihydroxy- 10a-methyl-l-(3-methylbutyl)-3- [3-(phenylmethoxy)propyl]-l,2,3,4,4a,9,10,10a-octahydrophenanthrene (119 mg, 0.264 mmol) was treated according to method F ("J" = THF, "K" = 20, "L" = 10% Pd/C (wet, 50% of water), "M" = 140, "N" = 72), to yield (rαc)-(lS,3R,4αS,10αS)-3,7-άibydxoxy- 3 -(3 -hydroxypropyl)- 1 Oa-methyl- 1 -(3-methylbutyl)- 1 ,2,3 ,4,4a,9, 10,1 Oa-octahydrophenanth rene (95 mg) as a white solid. 'H NMR (270 MHz, CD3COCD3) δ 7.93 (s, IH), 7.06 (d, IH), 6.58 (dd, IH), 6.54 (d, IH), 3.87 (t, IH), 3.60 (d, IH), 3.57 (d, IH), 3.21 (s, IH), 3.03 (dd, IH), 2.83 (ddd, IH), 2.71 (ddd, IH), 2.20 (ddd, IH), 2.00-1.25 (m, 15H), 1.17-1.05 (m, IH), 0.89 (d, 3H), 0.86 (d, 3H), 0.80 (s, 3H); 13C NMR (CDC13) δ 155.47, 138.16, 131.85, 127.27, 115.76, 113.58, 79.10, 72.45, 63.34, 45.35, 43.30, 39.27, 38.16, 35.94, 34.92, 34.86, 34.23, 29.09, 27.50, 27.46, 23.51, 22.69, 18.44.
Step 3. (rac)-(lS,3R,4aS,10aS)-3,7-dibydxoxy- 1 Oa-methyl-1 -(3 -methylbutyl)- 3-[3-[(4-methylphenyl)sulphonyloxy]propyl]-l ,2,3,4,4a,9, 10, 1 Oa-octahydrophenanthrene. (rac)-(lS, 3R, 4aS, 1 c7Sj-3,7-dihydroxy-3-(3-hydroxypropyl)-l Oa-methyl-1 -(3-methylbutyl)- l,2,3,4,4a,9,10,10a-octahydrophenanthrene (47 mg, 0.13 mmol) was treated according to procedure, described above in Example 50, Step 3 to give (rac)-(lS,3R,4aS,10aS)-3, 7-dihydroxy-l Oa-methyl-1- (3-methylbutyl)-3-[3- [(4-methylphenyl) sulphonyloxy]propyl] -l,2,3,4,4a,9,10,10a-octahydrophenanthrene, which was used in the next step without further purification.
Step 4. (rαc (7S5R,^S,i0αS -7-hydroxy-10a-methyl-l-(3-methylbutyl)-l,2,3,4,4a,9,10, 10a,2',3',4',5'-dodecahydrosρiro[phenanthrene-3,2'-furan]. f cA S,5R^αS,70αS 3,7- dihydroxy-1 Oa-methyl-1 -(3-methylbutyl)-3-[3-[(4-methylphenyl)sulphonyloxy]propyl]-l,2, 3,4,4a,9,10,10a-octahydrophenanthrene from the previous step (about 0.13 mmol) was treated according to procedure, described above in Example 13, Step 4 to give Crac -(7S3R^ Si0 S 7-hydroxy-10a-methyl-l-(3-methylbutyl)-l,2,3,4,4a,9,10, 10a,2',3',4',5'-dodecahydrospiro[phenanthrene-3,2'-furan] (34 mg) as a white oil. ES-MS m/z: 343.4 (pos, M+H); 'H NMR (270 MHz, CDC13) δ 7.07 (d, IH), 6.57 (dd, IH), 6.52 (d, IH), 5.00 (s, IH), 3.95-3.76 (m, 2H), 2.94 (dd, IH), 2.92-2.63 (m, 2H), 2.19 (ddd, IH), 2.00-1.82 (m, 3H), 1.82-1.63 (m, 5H), 1.58-1.21 (m, 6H), 1.26-1.10 (m, IH), 0.88 (d, 3H), 0.86 (d, 3H), 0.81 (s, 3H); 13C NMR (CDC13) δ 152.91, 137.97, 132.44, 126.85, 115.04, 112.63, 82.81, 67.13, 44.78, 40.00, 38.60, 36.76, 35.54, 34.89, 33.86, 32.80, 28.38, 26.96, 25.69, 25.18, 23.30, 22.34, 18.15.
Example 53: Synthesis oft>flc)- iS'.^αS.i0 5')-7-hydroxy-10a-methyl-l- 3-methylbutyl)-1.2,3,4,4a.9,10,10a-octahydrospirofphenanthrene-3,l'-cyclobutane|
(E53 .
Step 1. (rac)-(lS,3R,4aS,10aS)-3,7-dibydxoxyA0a-metbylA- (3-methylbutyl)-3- [ 1 -(phenylthio)cyclopropyl]- 1 ,2,3 ,4,4a,9, 10, 1 Oa-octahydrophenanthrene. (rαc)-(lS, 4αS, 1 OαS) -7-hydroxy- 1 Oa-methyl- 1 -(3-methylbutyl)- 1 ,2,3 ,4,4a,9, 10, lOa-octahydrophenanthrene-3-one (34 mg, 0.112 mmol) was treated according to procedure, described above in Example 45 to give the only diastereomer, (rαc 7S3R,^Si0αS -3,7-dihydroxy-10a-methyl-l-(3-methylbutyl)-3- [l-(phenylthio) cyclopropyl]-l, 2,3 ,4,4a,9, 10,1 Oa-octahydrophenanthrene (27 mg), as a white oil. 'H NMR (270 MHz, CDC13) δ 7.50-7.42 (m, 2H), 7.31-7.22 (m, 2H), 7.15 (tt, IH), 7.01 (d, IH), 6.58 (dd, IH), 6.53 (d, IH), 4.90 (s, IH), 3.56 (d, IH), 2.99 (dd, IH), 2.83 (ddd, IH), 2.70 (ddd, IH), 2.12 (ddd, IH), 2.00-1.00 (m, 15H), 0.88 (d, 3H), 0.84 (d, 3H), 0.77 (s, 3H).
Step 2. (rαc)-(lS, 4αS, 10αS)-7-bydxoxyA Oa-methyl-1 -(3 -methylbutyl)- 1 ,2,3,4,4a,9,
10, 10a-octahydrospiro[phenanthrene-3,2'-cyclobutane]-l '-one (mixture of diastereomers). dihydroxy-lOa-methyl-l-(3-methylbutyl)-3- [l-(phenylthio) cyclopropyl]-l, 2,3, 4,4a,9, 10,1 Oa-octahydrophenanthrene was treated according to procedure, described above in Example 45 to give a mixture of diastereomers of
(rαc)-(lS, 4αS, 1 OαS) -7-hydroxy- 1 Oa-methyl- 1 -(3 -methylbutyl)- 1 ,2,3 ,4,4a,9, 10, 10a-octahydrospiiO[phenanthrene-3,2'-cyclobutane]-l'-one, which was used in the next step without further purification or separation.
Step 3. (rac)-(lS, 4aS, 1 OaS) A', I '-ethanediyldimercapto-7-hydroxy- 1 Oa-methyl- 1 - (3 -methylbutyl)- 1 ,2,3 ,4,4a,9, 10, 1 Oa-octahydrospiro [phenanthrene-3 ,2'-cyclobutane] (mixture of diastereomers). (rac)-(lS, 4aS, 1 OaS) - -bydxoxy- 1 Oa-methyl- 1 - (3 -methylbutyl)- 1 ,2,3 ,4,4a,9, 10,1 Oa-octahydrospiro [phenanthrene-3,2'-cyclobutane]- 1 '-one from the previous step (about 0.05 mmol) was treated according to method G ("J"= 10, "K"= 1,2-ethanedithiol, "L"= 2, "M"= 18), using 3 eq. of BF3OEt2 complex. The crude product was purified by silica gel flash chromatography using Et2O : wo-hexane (1 :1) as eluent to give a mixture of diastereomers of
(r c -CiS, αS10αS - ,r-ethanediyldimercapto-7-hydroxy-10a-methyl-l- (3-methylbutyl) -l,2,3,4,4a,9,10, 1 Oa-octahydrospiro [phenanthrene-3 ,2' -cyclobutane] (17 mg) as a white oil.
Step 4. (rac)-(lS,4aS, 70αS 7-hydroxy-10a-methyl-l-(3-methylbutyl)-l,2,3,4,4a,9,10, 1 Oa-octahydrospiro [phenanthrene-3 , 1 '-cyclobutane] . (rac)-(lS, 4aS, 10aS)- 1 ', 1 '-ethanediyldimercapto-7-hydroxy- 1 Oa-methyl- 1 - (3 -methylbutyl)- 1 ,2,3 ,4,4a,9, 10, 1 Oa-octahydrospiro [phenanthrene-3 ,2'-cyclobutane] (17 mg, 0.041 mmol) was treated according to procedure, according to method J ("J" = 100, "K" = 15, "L" = 20, "M" = 0, "N" = 24) at 80°C to give the crude product, which was purified by PHPLC to yield (rac)-(lS, 4aS, WaS)- 7-hydroxy- 1 Oa-methyl- 1 -(3-methylbutyl)- 1 ,2,3,4,4a,9, 10,10a-octahydrospiro[phenanthrene-3, -cyclobutane] (5.4 mg) as a white oil. ES-MS m/z: 327.4 (pos, M+H), 325.3 (neg, M-H); 'H NMR (270 MHz, CDC13) δ 7.20 (d, IH), 6.63 (dd, IH), 6.55 (d, IH), 4.48 (bs, IH), 2.86 (ddd, IH), 2.71 (ddd, IH), 2.64 (dd, IH), 2.43 (ddd, IH), 2.10-1.16 (m, 17H), 0.89 (d, 3H), 0.87 (d, 3H), 0.80 (s, 3H).
Example 54: Synthesis of tϊrflc -^i>S',^αS' 0 S')-7-hydroxy-3-(3-hydroxypropylV c)- >S'.iS'. gS'.10gS)-7-hvdroχy-10a-methyl-l-r3-methylbutvIV1.2.3.4.4a.9.10. 10a,2',3',4f,5'-dodecahydrospirofphenanthrene-3.2'-furan] (E54bV
(rac)-(lS, 4aS, i0αi9-7-hydroxy-3-(3-hydroxypropyl)-l Oa-methyl-1 -(3 -methylbutyl)- 1,4,4a, 9,10,10a-hexahydrophenanthrene and (rac)-(lS,3S,4aS, 1 OaS) -7-hydroxy- 1 Oa-methyl- 1 - (3 -methylbutyl)- 1, 2,3, 4,4a,9, 10, 10a,2',3',4',5'-dodecahydrospiro[phenanthrene--3,2'-furan]. A mixture of (rac)-(lS,3R,4aS,10aS)-3, 7-dihydroxy-3 -(3 -hydroxypropyl)- 1 Oa-methyl- 1 - (3-methylbutyl)-l,2,3,4,4a,9,10,10a-octahydrophenanthrene (47 mg, 0.13 mmol) and 4-toluenesulfonic acid monohydrate (2.5 mg, 0.013 mmol) in toluene (20 mL) was stirred at 100°C overnight. The resulting mixture was quenched with sat. aq. NaHCO3 (10 mL), the organic layer was separated and the solvent was evaporated. The residue was separated by silica gel flash chromatography using Et2O : iyø-hexane (1 :1) as eluent to yield pure (rac)-(lS,4aS, 7 -7-hydroxy-3-(3-hydroxypropyl)- lOa-methyl-1- (3-methylbutyl)- 1, 4,4a,9,10,10a-hexahydrophenanthrene (18 mg) and (rac)-(lS,3S,4aS,10aS)-7- hydroxy- 10a-methyl-l-(3-methylbutyl)-l,2,3,4,4a,9,10, 10a,2',3',4',5'-dodecahydrospiro [phenanthrene-3 ,2'-furan] (5.3 mg) as white oils. (rac)-(lS,4aS,10aS)-7-bydxoxy-3- (3 -hydroxypropyl)- 1 Oa-methyl- 1 -(3-methylbutyl)- 1 ,4, 4a,9, 10, lOa-hexahydrophenanthrene: ES-MS m/z: 343.4 (pos, M+H), 387.4 (neg, M+HCOOH-H); 'H NMR (270 MHz, CDC13) δ 7.11 (d, IH), 6.64 (dd, IH), 6.55 (d, IH), 5.56 (d, IH), 5.10 (bs, IH), 3.68 (t, 2H), 2.94-2.61 ( , 3H), 2.54 (dd, IH), 2.13 (t, 2H), 1.88-1.04 (m, 11H), 0.88 (d, 3H), 0.85 (d, 3H), 0.77 (s, 3H). (rac)-(lS,3S,4aS,10aS) -7-hydroxy-10a-methyl-l-(3-methylbutyl)-l,2,3,4,4a,9, 10,10a,2',3',4', 5'-dodecahydiOSpiro[phenanthrene-3,2'-furan]: ES-MS m/z: 343.4 (pos, M+H), 387.4 (neg, M+HCOOH-H); 'H NMR (270 MHz, CDC13) δ 7.09 (d, IH), 6.60 (dd, IH), 6.56 (d, IH), 4.75 (s, IH), 3.94-3.74 (m, 2H), 2.94-2.66 (m, 2H), 2.60 (dd, IH), 2.19-1.60 (m, 8H), 1.60-1.06 (m, 8H), 0.89 (d, 3H), 0.87 (d, 3H), 0.85 (s, 3H); 13C NMR (CDCh) δ 153.27, 137.95, 131.78, 126.83, 115.23, 112.83, 82.62, 65.55, 44.87, 38.46, 37.70, 36.69, 36.49, 35.21, 34.53, 33.87, 28.48, 27.06, 26.63, 25.52, 23.24, 22.33, 18.49.
Example 55: Synthesis of (rac)-(4aR,l flaR)-10a-Butyl-7-hydroxy- 4a-methyl-3. 4.4a.9,10. lOa-hexahvdro- XH-phenanthren-2-one (E55).
Step l: (rβc αR,i0αR -10a-Butyl-7-methoxy-4a-methyl-3,4,4a,9,10, 10a-hexahydro-jH-phenanthren-2-one: The reaction was carried out on 200 mg (0.83 mmol) of r c)-7-methoxy-4a-methyl-4,4a59, 10-tetrahydro-5H-phenanthren-2-one dissolved in diethylether (3 mL), according to method P except that Cul was used instead of CuCN employing the following conditions; Cul (1.2 eq, suspension in 10 mL diethyl ether), alkyl lithium (n-BxxLi [1.6M solution in hexanes], 2.2 eq.), reaction-time and temperature (30 min. at -78°C, quenching at -40 °C). The crude product was fractionated on a chromatotron using EtOAc:n-heptane (3:7, v:v) as eluent. The first collected fraction from the chromatotron was further purified using PΗPLC to yield (rac)-(4aR,10aR) -10a-Butyl-7-methoxy-4a-methyl-3,4,4a,9,10, lOa-hexahydro-iH- phenanthren-2-one as a yellowish oil. ES-MS m/z: 301.3 (pos, M+Η); 'Η NMR (CDC13) δ 7.25 (d, 1Η), 6.75 (dd, 1Η), 6.60 (d, 1Η), 3.75 (s, 3Η), 2.70-2.75 (m, 2H), 2.10-2.30(m, 5H), 1.90-2.05 (m, IH), 1.65-1.70 (m, 2H), 1.40 (s, 3H), 1.20-1.40 (m, 6H), 0.90 (t, 3H).
Step 2: (rac)-(4aR, 1 OaR) A 0a-Butyl-7-hydroxy-4a-methyl-3,4,4a,9,l 0,
10a-hexahydro-7H-phenanthren-2-one (E55): The reaction was carried out on 11.9 mg of (rac)-(4aR, 1 OaR) A 0a-Butyl-7-methoxy-4a-methyl-3 ,4,4a,9, 10,1 Oa-hexahydro-/H-phenant hren-2-one dissolved in 1.0 mL DCM, using 3.5 eq. of BBr3 for 16 h according to method O. The crude product was purified on a chromatotron using EtOAc:«-heptane (3 :7,v:v) as eluent to yield E55 as a yellowish oil. ES-MS m/z: 287.2 (pos, M+Η), 285.1 (neg, M-Η); 'Η NMR (DMSO) δ 7.20 (d, 1Η), 6.60 (dd, 1Η), 6.45 (s, 1Η), 3.60 (s, 3Η), 2.60 (t, 2H), 1.50-2.20 (m, 10H), 1.20-1.40 (m, 4H), 0.95 (t, 3H).
Example 56: Synthesis of rtfc)-7-Hydroxy-4a-methyl-4.4a,9,10-tetrahydro-3H-phenanthren-2-one fE56)..
The reaction was carried out on 50 mg of (r c -7-methoxy-4a-methyl-4,4a,9, 10-tetrahydro-3H-phenanthren-2-one dissolved in 3.0 mL DCM, using 2.5 eq. of BBr3 for 4 h according to method O. The crude product was purified on a chromatotron using EtOAc :«-heptane (4:6, v:v) as eluent to yield E56 as a yellowish solid. GC-MS m/z: 228.5 (M), 213.4 (M-CΗ3); 'HNMR (CD3OD) δ 7.15 (d, IH), 6.65 (dd, IH), 6.50 (d, IH), 5.85 (s, IH), 2.35-2.90 (m, 7H), 1.95-2.00 (m, IH), 1.55 (s, 3H); 13C NMR (CD3OD) δ 201.15, 173.43, 155.44, 135.99, 134.93, 127.17, 123.15, 114.23, 114.07, 38.41, 36.69, 33.99, 30.64, 30.53, 26.32.
Example 57: Synthesis of trflc)-4b-methyl-4b.5.6.7.9.10-hexahydro-phenanthren-2-ol <E57).
The reaction was carried out on 5.0 mg of røc)-7-hydroxy-4a-methyl-4,4a,9, 10-tetrahydro-JH-phenanthren-2-one dissolved in acetonitrile (2.0 mL), according to method R. The crude product was purified on a chromatotron using EtOAc:n-heptane (3:7) as eluent to give E57. ES-MS m/z: 213.0 (neg, M-Η); 'Η MR (CD3OD) δ 7.10 (d, 1Η), 6.55 (dd, 1Η), 6.40 (d, 1Η), 5.40 (s, 1Η), 1.45-2.80 (m, 10Η), 1.40 (s, 3Η).
Example 58: rgc>-7-Hydroxy-l,4a-dimethyl-4,4a,9,10-tetrahvdro-iH-phenanthren-2-one E58).
Stepl : r c -7-Methoxy- 1 ,4a-dimethyl-4,4a,9, 10-tetrahydro-5H~phenanthren-2-one: Coupling of 200 mg (1.05 mmol) of 6-methoxy-l-methyl-3,4-dihydro- iH-naphthalen -2-one, dissolved in toluene (2.0 mL) with pent- l-en-3 -one in accordance to method M gave (rαc -7-Methoxy- 1 ,4a-dimethyl-4,4a,9, 10-tetrahydro-3H-phenanthren-2-one which was used without further purification in the next step. ES-MS m/z: 257.2 (pos, M+Η).
Step 2 : (rac -7-Ηydroxy- 1 ,4a-dimethyl-4,4a,9, 10-tetrahydro-5H-phenanthren-2-one (E58): The reaction was carried out on crude Craς -7-Methoxy-l,4a-dimethyl-4,4a,9, 10-tetrahydro-5H-phenanthren-2-one dissolved in 2.0 mL DCM, using 3.5 eq. of BBr3 for 16 h according to method O. A V* portion of the crude product was purified using PΗPLC to yield E58 as a yellow solid. ES-MS m/z: 243.4 (pos, M+Η), 241.3 (M-Η); . 'Η NMR (CD3OD) δ 7.20 (d, 1Η), 6.65 (dd, 1Η), 6.50 (d, 1Η), 2.40-2.90 (m, 7Η), 1.80-1.95(m, IH), 1.89 (s, 3H), 1.45 (s, 3H); 13C MR (CD3OD) δ 200.05, 165.26, 155.30, 136.88, 135.90, 127.92, 126.64, 114.04, 113.91, 38.86, 35.84, 33.46, 29.30, 26.74, 25.64, 9.10.
Example 59: Synthesis of tmc)-4a,8-dimethyl-4b,5,6,7,9, 10-hexahvdro- phenanthren-2-oI (E59).
The reaction was carried out on a % portion of the crude (røc -7-hydroxy-l, 4a-dimeti yl-4,4a,9,10-tefrahydro-3H-phenanthren-2-one (max. 0.262 mmol) dissolved in a mixture of acetonitrile and DCM (2.0+2.0 mL) according to method R (0.20 mL of trifluoro acetic acid was used). The crude product was purified on a chromatotron using EtOAc:rc-heptane (15:85) as eluent followed by PΗPLC, to yield E59. ES-MS m/z: 229.3 (pos, M+Η); 'Η NMR (CDC13) δ 7.10 (d, 1Η), 6.70 (bs, 1Η), 6.65 (dd, 1Η), 6.50 (d, 1Η), 2.65-2.70 (m, 2Η), 1.50-2.15 (m, 8H), 1.70 (s, 3H), 1.35 (s, 3H).
Example 60: Synthesis of fmc)-4b.8-dimethyl-4b,5,6.7.9. 10-hexahydro -phenanthren-2-ol (E60a. E60b. E60c. E60d .
(E60a + E60b + E60c + E60d) The reaction was carried out on 4.0mg of (r c -4b,8-dimethyl-4b,5,6,7,9,
10-hexahydro-phenanthren-2-ol for 12 h according to method S with one exception - the reaction was run under pressure (5.0 bar) - using methanol (3.0 mL) as solvent and 5%
Pd/C (5.0 mg) as catalyst. The crude product consisted of a mixture of the four possible diastereomers E60a + E60b + E60c + E60d. GC-MS m/z: 215.2 (M-CH3) 230.2 (M).
Example 61: Synthesis of mc)-t3S'. flR)-7-hydroxy-3,4a-dimethvI-4,4a.9. 10-tetrahvdro-5H-phenanthren-2-one (E61).
(E61)
Step 1: (rac)-(3S,4aR)-7-Metboxy-3,4a-dimetbyl-4,4a,9, 10-tetrahydro-3H- phenanthren-2-one: Coupling of 200 mg (1.05 mmol) of (røς)-6-methoxy-l-methyl-3, 4-dihydro-7H-naphthalen-2-one dissolved in toluene (2.0 mL) with 3-methyl-but-3-en- 2-one in accordance to method M gave crude (rac)-(3S,4aR)- -M.exboxy-3, 4a-dimethyl-4,4a,9,10-tetrahydro-3H-phenanthren-2-one which was used without further purification in the next step. GC-MS m/z: 256.1 (M), 241.1 (M-CΗ3).
Step2: (rac)-(3S, αR 7-Hydroxy-3,4a-dimethyl-4,4a,9, 10-tetrahydro-JH- phenanthren-2-one (28): The reaction was carried out on crude (rac)-(3S,4aR)- 7-Methoxy-3,4a-dimethyl-4,4a,9,10-tetrahydro-3H-phenanthren-2-one using 3.3 eq. of BBr3 for 16 h according to method O. The crude product was purified using PΗPLC to yield E61. GC-MS m/z: 242.1(M), 227.1 (M-CΗ3); 1H NMR (CDC13) δ 7.15 (d, IH), 6.75 (dd, IH), 6.55 (d, IH), 5.86 (s, IH), 5.15 (bs, IH), 2.40-3.00 (m, 6H), 2.30 (dd, IH), 1.55 (s, 3H), 1.15 (d, 3H). Example 62: Synthesis of (rac)-(4S, flR)-7-Hvdroxy-4a-methyl-4-propyl-4.4a,9. 10-tetrahydro-JH-phenanthren-2-one (E62).
(E62)
Step 1: (rac)-(4S, αR^-7-Methoxy-4a-methyl-4-propyl-4,4a,9,10-tefrahydro-3H-phenanthren-2-one: Coupling of 200 mg (1.05 mmol) of r ς)-6-Methoxy-l-methyl-3,4-dihydro-iH-naphthalen-2-one dissolved in toluene (2.0 mL) with hept-3-en-2-one in accordance to method M gave crude (rac)-(4S, αR -7-Methoxy-4a-methyl-4-propyl-4,4a,9, 10-tetrahydro-3H-phenanthren-2-one which was used without further purification in the next step. ES-MS m/z: 285.1 (pos, M+Η).
Step 2: (rac)-(4S, R)-7-Ηydroxy-4a-methyl-4-propyl-4,4a,9, 10-tetrahydro-3H-phenanthren-2-one (E62): The reaction was carried out on crude (rac)-(4S, αR -7-Methoxy-4a-methyl-4-propyl-4,4a, 9, 10-tetrahydro-3H- phenanthren-2-one using 3.3 eq. of BBr3 for 16 h according to method O. The crude product was purified using PΗPLC to yield E62. GC-MS m/z: 270.0(M); Η NMR (CDC13) δ 7.15 (d, 1Η), 6.75 (dd, 1Η), 6.60 (d, 1Η), 6.35 (bs, 1Η), 5.90 (s, 1Η), 2.80-2.85 (m, 1Η), 2.75-2.80 (m, 1Η), 2.60 (dd, 1Η), 2.55 (m, 2Η), 2.30 (dd, IH), 2.00-2.10 (m, IH), 1.60-1.70 (m, IH), 1.45 (s, 3H), 1.30-1.45 (m, 2H), 0.95-1.1 (m, IH), 0.85 (t, 3H); 13C NMR (CDCl3) δ 139.55, 133.0, 130.72, 123.68, 115.26, 113.0, 43.96, 43.59, 39.73, 33.13, 32.11, 22.0, 19.89, 13.86. Example 63: Synthesis of fmc)-t¥Jg. ffR)-7-Hydroxy-4,4a-dimethyl-4,4a.9. 10-tetrahydro-3H-phenanthren-2-one (E63a) and (rac)-(4S.4aR)-7-Ilvdroxy-4. 4a-dimethyl-4,4a,9,10-tetrahvdro-iH-phenanthren-2-one (E63b).
(E63a + E63b)
Step 1: (rαc)-(4R,4aR)-7-Methoxy-4,4a-dimethyl-4,4a,9,
10-tetrahydro-3H-phenanthren-2-one and (rac)-(4S, ¥ R)-7-Methoxy-4,4a-dimethyl-4,4a,9, 10-tetrahydro--?H-phenanthren-2-one: Coupling of 200 mg (1.05 mmol) of frαcj-6-methoxy-l-methyl-3,4-dihydro-7H-naphthalen-2-one dissolved in toluene (2.0 mL) with pent-3-en-2-one in accordance to method M gave a crude mixture of (r c)-(4R,4aR)-7-Methoxy-4,4a-dimethyl-4,4a,9, 10-tetrahydro-3H-phenanthren-2-one and (rac)-(4S, αR)-7-Methoxy-4,4a-dimethyl-4,4a,9, 10-tetrahydro-3H-phenanthren-2-one which was used without fiirther purification in the next step. GC-MS m/z: 256.0 (M).
Step 2: (rac)-(4R,4aR)-7 -Bydxoxy-4,4a-dixnetbyl-4,4a,9, 10-tetrahydro- 3H-phenanthren- 2-one (E63a) and (rac)-(4S,4aR)- -Bydxoxy-4, 4a-dimethyl-4,4a,9, 10-tetrahydro -JH-phenanthren-2-one (E63b): The reaction was carried out on the crude mixture of (rαc)-(4R,4aR)-7-Methoxy-4,4a-dimethyl-4,4a,9, 10-tetrahydro-3H-phenanthren-2-one and (rac)-(4S, R)-7-Methoxy-4,4a-dimethyl-4,4a,9, 10-tetrahydro-3H-phenanthren-2-one using 3.3 eq. of BBr3 for 16 h according to method O. The crude product was purified using PΗPLC to yield a mixture of E63a and E63b. 'Η NMR (CD3OD) δ 7.15 (d, 1Η), 6.65 (dd, 1Η), 6.55 (d, 1Η), 5.80 (s, 1Η), 2.00-2.80 (m, 7Η), 1.45 (s, 3H), 1.10 (d, 3H).
Example 64: Synthesis of gc)-l-EthyI-7-hvdroxy-4a-methyl-4,4a ,9. 10-tetrahvdro-jH-phenanthren-2-one (E64).
(E64)
Step 1 : (rac) A -Ethyl-7-methoxy-4a-methyl-4,4a,9, 10-tetrahydro-3H-phenanthren-2-one. Coupling of 569 mg (2.99 mmol) of (rας -6-methoxy-l-methyl-3,4-dihydro- /H-naphthalen-2-one dissolved in toluene (5.0 mL) with hex-l-en-3-one in accordance to method M gave crude (rac)- l-Ethyl-7-methoxy-4a-methyl-4,4a, 9,10-tetrahydro-3H- phenanthren-2-one, which was used without fiirther purification in the next step. ES-MS m/z: 271.3 (pos, M+Η).
Step 2 : (rac) A -Ethyl-7-hydroxy-4a-methyl-4,4a,9, 10-tetrahydro-3H-phenanthren-2-one. The reaction was carried out on crude (r ς -l-Ethyl-7-methoxy-4a-methyl-4,4a, 9,10-tetrahydro-3H-phenanthren-2-one (max. 2.99 mmol) dissolved in 6.0 mL DCM, using 3.0 eq. of BBr3 for 5 h according to method O. The crude product was purified on a chromatotron using EtOAc:«-heptane (3:7, 6:5, 5:5, v:v, stepwise gradient) as eluent to yield E64. ES-MS m/z: 257.2 (pos, M+Η), 255.4 (neg, M-Η); 'Η MR (CD3OD) δ 7.1-7.2 (m, 1Η), 6.10 (dd, 1Η), 6.55 (d, 1Η), 2.25-3.00 (m, 10Η), 1.55 (s, 3Η), 1.25 (t, 3H).
Example 65: Synthesis of trac)-8-Ethyl-4b-methyI-4b,5,6.7.9. 10-hexahvdro- phenanthren-2-ol (E65V
(E65) The reaction was carried out on 33 mg (0.13 mmol) of
(rac) A -ethyl-7-hydroxy-4a-methyl-4,4a,9, 10-tetrahydro-5H-phenanthren-2-one dissolved in acetonitrile (5.0 mL) according to method R. The crude product was purified using PΗPLC to yield E65. ES-MS m/z: 243.4 (pos, M+Η), 241.3 (neg, M-Η); 'Η NMR (CDC13, 500MΗz) δ 7.15 (d, IH), 6.65 (dd, IH), 6.50 (d, IH), 2.65-2.85 (m, 3H), 2.15-2.25 (m, IH), 2.10-2.15 (m, IH), 1.95-2.10 (m, 4H), 1.70-1.80 (m, 2H), 1.50-1.55 (m, IH), 1.35 (s, 3H), 0.95 (t, 3H).
Example 66: Synthesis of ^• c)-(^αR 0aR S')-l-Ethyl-7-hvdroxy-4a-methyl-1.4.4a.9. 10,10a-hexahydro-3H-phenanthren-2-one (E66).
(E66)
The reaction was carried out on 55 mg of (rac) A -etbyl-7 -bydxoxy- 4a-methyl-4,4a, 9,10-tetrahydro-5H-phenanthren-2-one for 16 h according to method S using methanol (3.0 mL) as solvent and 5% Pd/C (31 mg) as catalyst. The crude product was purified using PΗPLC to yield E66. ES-MS m/z: 259.3 (pos, M+Η), 257.2 (neg, M-Η); 'Η NMR (CD3OD, 500MΗz) δ 7.15 (d, IH), 6.70 (dd, IH), 6.45 (d, IH), 2.80-2.85 (m, 2H), 2.60-2.70 (m, IH), 2.50-2.60 (ddd, IH), 2.35-2.44 (m, 2H), 1.90-1.95 (m, IH), 1.80-1.90 (m, IH), 1.65-1.80 (m, 3H), 1.55-1.65 (m, IH), 1.30 (s, 3H), 0.85 (t, 3H).
Example 67: Synthesis of (mc)-l-Butyl-7-hvdroxy-4a-methyl-4.4a. 9.10-tetrahvdro-5H-phenanthren-2-one (E67).
Step 1 : (rac)- 1 -Butyl-7-methoxy-4a-methyl-4,4a,9, 10-tetrahydro-3H-phenanthren-2-one: Coupling of 220 mg (1.16 mmol) of (rαc -6-methoxy-l-methyl-3, 4-dihydro-iH-naphthalen-2-one dissolved in toluene (2.0 mL) with oct-l-en-3-one in accordance to method M gave, after purification of the crude product by silica gel flash chromatography using EtOAc:rø-heptane (3:7) as eluent, (rac) A -Butyl-7-xnetboxy- 4a-methyl-4,4a,9,10-tetrahydro-3H-phenanthren-2-one as a yellowish oil. ES-MS m/z: 299.2 (pos, M+Η); Η NMR (CDC13) δ 7.15-7.20 (m, 1Η), 6.70-6.85 (m, 1Η), 6.55-6.65 (m, 1Η), 3.75 (s, 3Η), 2.00-3.00 (m, 10H), 1.45-1.50 (m, IH), 1.25-1.30 (m, 6H), 0.90 (t, 3H).
Step 2 : (rac) A -Butyl-7-hydroxy-4a-methyl-4,4a,9, 10-tetrahydro-3H-phenanthren-2-one (40). The reaction was carried out on 220 mg of (røς -l-Butyl-7-methoxy-4a- methyl-4,4a,9,10-tetrahydro-3H-phenanthren-2-one dissolved in 5.0 mL DCM using 3.5 eq. of BBr3 for 4 h according to method O. The crude product was purified on a chromatotron, using EtOAc :rø-heptane (3:7,v:v) as eluent to yield E67 as a yellowish oil. ES-MS m/z: 285.1 (pos, M+Η), 283.0 (neg, M-Η); 'ΗNMR (CDC13) δ 7.15 (d, 1Η), 6.75 (dd, 1Η), 6.60 (d, 1Η), 2.20-3.00 (m, 10Η), 1.31 (s, 1Η), 1.25-1.30 (m, 6Η), 0.90 (t, 3H). 13C NMR (CDCI3) δ 199.22, 164.04, 154.11, 136.79, 136.64, 133.43, 127.16, 114.60, 114.40, 39.35, 36.51, 34.51, 31.97, 30.86, 27.67, 26.84, 25.02, 22.96, 14.13.
Example 68: Synthesis of fmc)-8-Butyl-4b-methyl-4b. 5.6.7.9. 10-hexahvdro-phenanthren-2-oHE68 .
The reaction was carried out on 40 mg (6.14 mmol) of (rac) A -Butyl-7- hydroxy-4a-methyl-4,4a,9,10-tetrahydro-3H-phenanthren-2-one dissolved in acetonitrile (10 mL) according to method P. The crude E68 (yellowish oil) was used without further purification. ES-MS m/z: 271.0 (pos, M+Η), 269.2 (neg, M-Η); 'Η NMR (CDC13) δ 7.15 (d, 1Η), 6.65 (dd, 1Η), 6.50 (d, 1Η), 4.50 (b s, 1Η), 2.65-2.75 (m, 3Η), 1.95-2.25 (m, 6H), 1.70-1.75 (m, 2H), 1.50-1.55 (m, IH), 1.25-1.35 (m, 7H), 0.90 (t, 3H).
Example 69: Synthesis of (rac)-(8R.4bR.8aR)-8- utyl-4b- methyl-4b.5.6.7. 8.8a.9. lO-octahvdro-phenanthren-2-ol flE69a): and (rac)-(8S.4bR.8aR)-8-Butyl-4b- methyl-4b.5.6.7,8,8a,9.10-octahvdro-phenanthren-2-oI (Ε69bV
The reaction was carried out on 25 mg of (rαc)-8-butyl-4b-methyl-4b,5,6,7, 9, lO-hexahydro-phenanthren-2-ol for 12 h according to method S except that the reaction was run under pressure (6.0 bar) using methanol (2.0 mL) as solvent, and 5% Pd/C (12 mg) as catalyst. The crude product was fractionated using PHPLC to E69a as the first eluted material and E69b as the second. E69a: ES-MS m/z: 273.1 (pos, M+H) 271.0 (neg, M-H); Η NMR (CDC13) δ 7.10 (d, IH), 6.60 (dd, IH), 6.55 (d, IH), 2.70-2.75 (m, IH), 2.55-2.65 (m, IH), 2.30 (d, IH), 2.00-2.05 (m, IH), 1.80-1.85 (m, IH), 1.65-1.70 (m, IH), 1.45-1.50 (m, 2H), 1.05-1.35 (m, 10H), 1.10 (s, 3H), 0.95-1.00 (m, IH), 0.90 (t, 3H).
E69b: ES-MS m/z: 273.1 (pos, M+H), 271.0 (neg, M-H); 'H NMR (CDC13) δ 7.10 (d, IH), 6.60 (dd, IH), 6.50 (d, IH), 2.80 (dd, 2H), 2.25 (d, IH), 1.90-2.00 (m, IH), 1.65-1.75 (m, 2H), 1.60-1.75 (m, IH), 1.60-1.65 (m, 2H), 1.50-1.60 (m, IH), 1.45-1.50 (m, IH), 1.25-1.45 (m, 8H), 1.10 (s, 3H), 0.90 (t, 3H).
Example 70: Synthesis of frac)-4a-Butyl-7-hvdroxy-l-methyl-4,4a,9. 10-tetrahydro-3H-phenanthren-2-one (E70).
Step 1: 4-Butyl-7-methoxy-l,2-dihydro-naphthalene: A solution of 5.29 g (30 mmol, 1.0 eq.) of 6-methoxy-l -tetralone in dry THF (25 mL) was added dropwise while stirring, to a mixture of butyl lithium (1.6 M solution in hexanes, 2.1 eq.) and THF (40 mL) during approximately 30 min. Stirring was continued for another 30 min. before slow addition of 2.0 M aqueous HCl (150 mL). The phases were separated after vigorous\stirring for 2 h. The aqueous phase was extracted with diethyl ether (3 x 50 mL) and the combined orgranic phases were dried over anhydrous sodium sulfate. The crude product, obtained upon concentration of the extract in vacuo, was purified by silica gel flash cliromatography using EtOAc:τ.-heptane (0:10, 1:9, stepwise gradient) as eluent, to give 4-Butyl-7-methoxy-l, 2-dihydro-naphthalene as a yellowish oil. 'HNMR (CDC13) δ 7.15 (d, IH), 6.70-6.75 (m, 2H), 5.80 (t, IH), 3.80 (s, 3H), 2.70 (t, 2H), 2.30-2.45 (m, 2H), 2.10-2.25 (m, 2H), 1.20-1.55 (m, 4H), 0.90 (t, 3H).
Step 2: (rαc -l-Butyl-6-methoxy-3,4-dihydro-/H-naphthalen-2-one: The reaction was carried out on 1.28 g (5.92 mmol) of 4-Butyl-7-methoxy-l,2-dihydro-naphthalene dissolved in 50 mL DCM according to method L to afford (rac)- l-Butyl-6-methoxy-3, 4-dihydro-iH-naphthalen-2-one as a yellowish oil after purification of the crude product by silica gel flash cliromatography, using EtOAc :n-heptane (5:95, 2:8, stepwise gradient) as eluent. GC-MS m/z: 232.1 'Η NMR (CDC13) δ 7.05 (d, 1Η), 6.75-6.80 (m, 2Η), 3.80 (s, 3H), 3.30-3.40 (m, IH), 2.95-3.15 (m, 2H), 2.45-2.60 (m, 2H), 1.75-1.85 (m, 2H), 1.20-1.30 (m, 4H), 0.85 (t, 3H).
Step 3 : (rac) -4a-Butyl-7-methoxy- 1 -methyl-4,4a,9, 10-tetrahydro-3H-phenanthren-2-one : Coupling of 100 mg (0.43 mmol) of (røc -l-Butyl-6-methoxy-3,4-dihydro- /H-naphthalen-2-one dissolved in benzene (1.0 mL) with pent- l-en-3 -one according to method M, gave after purification of the crude product by silica gel flash chromatography using EtOAc :o-heptane (1:99, 1:9, stepwise gradient) as eluent røc -4a-butyl-7-methoxy-l -methyl-4,4a,9,10-tetrahydro-5H-phenanthren-2-one. ES-MS m/z: 299.0 (pos, M+Η); 'Η NMR (CDCI3) δ 7.15 (d, 1Η), 6.75 (dd, 1Η), 6.65 (d, 1Η), 3.80 (s, 3Η), 1.70-3.00 (m, 10H), 1.80 (s, 3H), 1.00-1.30 (m, 4H), 0.80 (t, 3H).
Step 4: (rαc -4a-Butyl-7-hydroxy-l-me1nyl-4,4a,9,l0-tetrahydro-3H-phenanthren-2-one (E70). The reaction was carried out on 13mg (rαc)-4a-butyl-7-methoxy- l-methyl-4,4a, 9,10-tetrahydro-3H-phenanthren-2-one dissolved in 2.0 mL DCM, using 3.0 eq. of BBr3 for 4 h according to method O. The crude product was purified on a chromatotron, using EtOAc:n-heptane (3:7,v:v) as eluent to afford E70. ΗNMR (CD3OD) δ 7.10 (d, 1Η), 6.55-6.60 (m, 2Η), 2.30-2.80 (m, 10H), 1.75 (s, 3H), 1.00-1.30 (m, 4H), 0.80 (t, 3H).
Example 71: Synthesis of fra -4a-Butyl-7-hydroxy-4,4a. 9,10-tetrahydro- JH-phenanthren-2-one (ETW
(E71)
Step 1: ( αc)-4a-Butyl-7-methoxy-4,4a,9,10-tetrahydro-3H-phenantlιren-2-one: Coupling of 100 mg (0.43 mmol) of (r«cJ-l-butyl-6-methoxy-3,4-dihydro-iH-naphthalen-2-one dissolved in benzene (1.0 mL) with but-3-en-2-one in accordance to method M gave, after purification of the crude product by silica gel flash chromatography using EtOAc:«-heptane (1 :99, 2:8, stepwise gradient) as eluent, (r c -4a-Butyl-7-methoxy-4, 4a,9, 10-tetrahydro -3H-phenanthren-2-one. 'Η NMR (CDC13) δ 7.15 (d, 1Η), 6.80 (dd, 1Η), 6.60 (d, 1Η), 5.90 (s, 1Η), 3.80 (s, 3Η), 1.80-3.00 (m, 10H), 1.10-1.30 (m, 4H), 0.80 (t, 3H); 13C NMR (CDC13) δ 199.72, 170.86, 158.00, 137.39, 134.16, 127.43, 124.93, 113.18, 113.02, 55.02, 41.84, 40.40, 36.06, 34.35, 32.46, 30.49, 27.72, 23.04, 13.53.
Step2: rαc -4a-Butyl-7-hydroxy-4,4a,9,10-tetrahydro-3H-ρhenanthren-2-one (E71). The reaction was carried out on 33 mg of (røc -4a-Butyl-7-methoxy-4,4a,9, 10-tetrahydro-3H-phenanthren-2-one dissolved in 2.0 mL DCM, using 3.0 eq. of BBr3 for 4 h according to method O. The crude product was purified on a chromatotron, using EtOAc :n-heptane (3:7,v:v) as eluent to yield E71 as a yellowish solid. ES-MS m/z: 271.0 (pos, M+Η), 269.0 (neg, M-Η); 'Η NMR (CD3OD) δ 7.20 (d, 1Η), 6.65 (dd, 1Η), 6.55 (d, 1Η), 5.90 (s, 1Η), 1.80-3.00 (m, 10Η), 1.10-1.30 (m, 4Η), 0.80 (t, 3H).
Example 72: Synthesis of (rac)-(4aR.10aR-)4a-Butyl- 7-hvdroxy-3.4.4a.9..0. 10a-hexahydro-JH-phenanthren-2-one (E72a); and (rαc)-(4αR.10αS)- 4a-Butyl-7-hydroxy-3,4,4a,9, 10,10a-hexahydro- JH-phenanthren-2-one (E72b^.
(E72a) (E72b)
The reaction was carried out on 10 mg of røc -4a-Butyl-7-hydroxy-4,4a,9, 10-tetrahydro-3H-phenanthren-2-one for 2 h according to method R using methanol (5.0 mL) as solvent and 5% Pd/C (10 mg) as catalyst. The crude product was fractionated using PΗPLC to give E72a as the first eluted material and E72b as the second. E72a: ES-MS m/z: 273.4 (pos, M+Η), 271.3 (neg, M-Η); ΗNMR (CD3OD) δ 7.15 (d, 1Η), 6.60 (dd, 1Η), 6.50 (d, 1Η), 1.60-2.80 (m, 13Η), 1.20-1.25 (m, 2H), 0.85 (t, 3H); E72b: ES-MS m/z: 273.4 (pos, M+H), 271.3 (neg, M-H); 'HNMR (CD3OD) δ 7.10 (d, IH), 6.55 (dd, IH), 6.50 (d, IH), 1.50-2.80 (m, 13H), 1.20-1.25 (m, 2H), 0.85 (t, 3H).
Example 73: Synthesis of (rac)-(4aR,10aS)-l- hvdroxy-4a-methyl-3,4.4a.9. 10.1Qa-hexahydro-iH-phenanthren-2-one fE73
(E73)
Step 1. raς)-7-Hydroxy-4a-methyl-4,4a,9,10-tetrahydro-3H-phenanthren-2-one: The reaction was carried out on 570 mg (2.35 mmol) of (rαc -7-Methoxy-4a-methyl-4, 4a,9,10-tetrahydro-3H-phenanthren-2-one, dissolved in 10.0 mL DCM, using 3.5 eq. of BBr3 for 20 h according to method O. The crude product was purified on a chromatotron using EtOAc:«-heptane (3:7) as eluent to yield (r c)-7-Ηydroxy-4a-methyl-4,4a, 9,10-tetrahydro-3H-phenanthren-2-one (190 mg) as a yellow solid. ES-MS m/z: 229.3 (pos, M+H), 227.2 (neg, M-H); 'H NMR (CDC13) δ 7.15 (d, IH), 6.70 (dd, IH), 6.55 (d, IH), 5.85 (s, IH), 4.80 (s, OH), 1.80-2.85 (m, 8H), 1.50 (s, 3H).
Step 2: (rac)-(4aR, 10aS)-7-Bydxoxy-4a- etbyl-3,4,4a,9, 10,10a-hexahydro- ZH-phenanthren-2-one (E73): The reaction was carried out on 133.0mg (0.58 mmol) ( αcJ-7-hydroxy-4a-memyl-4,4a,9,10-tefrahydro-3H-phenanthren-2-one for 2 h according to method S using TΗF (6.0 mL) as solvent, and 10% Pd/C (133.0 mg) as catalyst. The crude product was purified by PΗPLC to yield E73 (81 mg) as a white solid. ES-MS m/z: 231.1(pos, M+Η), 229.3(neg, M-Η); 'ΗNMR (CDC13) δ 7.20 (d, 1Η), 6.65 (dd, 1Η), 6.55 (d, 1Η), 5.00 (s, OΗ), 2.75-2.85 (m, 2Η), 2.35-2.50 (m, 2H), 2.20-2.30 (m, 3H), 2.00-2.20 (m, 2H), 1.75-1.90 (m, IH), 1.55-1.60 (m, IH), 1.30 (s, 3H).
Example 74: Synthesis of «c>- R.itfff ')-2.2-ethanediyldimercapto-7-hvdroxy-4a- methyl-1.2.3,4.4a,9.10.10a-octahvdrophenanthrene (E74).
The reaction was carried out on 15 mg (0.065 mmol) of (rac)-(4aR, 10α -7-hydroxy-4a-methyl-3 ,4,4a,9, 10, 10a-hexahydro-7H-phenanthren-2-one, dissolved in 1.0 mL dichloromethane according to method T, using 2eq. of 1,2-ethanedithiol, 1 eq of BF3OEt2, and a reaction time of 5 hours. The crude product was purified by chromatotron using EtOAc :«-heptane (3:7) as eluent to yield E74 (15 mg) as a white solid. ES-MS m/z: 307.3(pos, M+Η), 305.2(neg, M-Η); Η NMR (CDC13) δ 7.15 (d, 1Η), 6.60 (dd, 1Η), 6.50 (d, 1Η), 4.45 (s, OΗ), 3.25 (s, 4Η), 2.60-2.80 (m, 2H), 2.10-2.35 (m, 3H), 1.90 (m, 4H), 1.70-1.80 (m, 2H), 1.50 (s, 3H). Example 75: Synthesis of (rac)-(4aR.10aS)-7-hvdroxy-4a- methyl-3.4.4a.9. 10. lOa-hexahvdro-JH-phenanthren^-one oxime (E75 .
(E75)
The reaction was carried out on 16 mg (0.065 mmol) of (rαc)-(4αR, 1 α -7-hydroxy-4a-methyl-3,4,4a,9, 10, 10a-hexahydro-7H-phenanthren-2-one dissolved in 1.5 mL methanol according to method U, using lOeq. of NΗ2OΗΗCl and lOeq. of sodium acetate. The crude product was purified by chromatotron using EtOAc:rø-heptane (2:8) as eluent to yield two isomers of E75 in the ratio 2:1 (11 mg) as a white solid. ES-MS m/z: 246.1(pos, M+Η); 'Η NMR (CDC13) δ 7.15 (d, 1Η), 6.65 (dd, 1Η), 6.55 (d, 1Η), 2.60-2.80 (m, 2Η), 1.80-2.40 (m, 7H), 1.55-1.75 (m, 2H), 1.30 (s, 3H).
Example 76: A pharmaceutical formulation comprising (mc)-4b.8-dimethyl-4b. 5.6.7.9.10-hexahydro-phenanthren-2-ol.
200 mg of ( * c -4a,8-dimethyl-4b,5,6,7,9,10-hexahydro-phenanthren-2-ol, from Example 59, is formulated with sufficient finely divided lactose to provide a total amount of 580 to 590 mg to fill a size 0, hard-gelatine capsule.
Description of the Scintistrip ER Binding Assay
Introduction
The scintistrip assay differs from a traditional hormone binding assay by not requiring the removal of free tracer prior to the measurement of receptor bound tracer. The scintillating agent is in the polystyrene forming the incubation vial and thus a radioactive molecule in the close proximity to the surface will induce scintillation of the plastic. For 3[H]-labeled ligands, the distance between the free tracer and the scintillating polystyrene surface is too far to induce scintillation of the plastic while 3[H]-labeled ligands bound to receptors immobilized on the surface are close enough to induce scintillation1 thus enabling a convenient way to measure the competition between a non-radioactive estrogen receptor interacting agent (the compound to be tested) and a fixed concentration of tracer (3[H]-Estradiol).
Materials and Methods
3[H]-β-Estradiol (NET 317) hereafter referred to as [H]-E2 was purchased from New England Nuclear, Boston, MA. The scintistrip wells (1450-419) and the scintillation counters (Microbeta™ 1450-Plus and 1450-Trilux) were all from allac, Turku, Finland. Human estrogen receptors (hER) alpha and beta were extracted from the nuclei from SF9-cells infected with a recombinant baculovirus transfer vector containing the cloned hER genes. Recombinant baculovirus was generated utilizing the BAC-TO-BAC expression system (Life Technonlogies) in accordance to instruction from the supplier. The hER coding sequences were cloned into a baculovirus transfer vector by standard techniques. The recombinant baculoviruses expressing hER were amplified and used to infect SF9 cells. Infected cells were harvested 48 hr post infection. A nuclear fraction was obtained as described in2 and the nuclei were extracted with a high-salt buffer (17 mM K-2HPO4, 3 mM KH2PO4, 1 mM MgCl2, 0.5 mM EDTA, 6 mM MTG, 400 mM KC1, 8.7% Glycerol). The concentration of hER' s in the extract was measured as specific [3H]-E2 binding with the G25-assay3 and was determined to contain 400 pmols specific bound [3H]-E2/mL nuclear extract in the case of hER-alpha and 1000 pmols/mL nuclear for hER-beta. The total concentration of proteins (as determined with Bradford Reagent, Bio-Rad according to instructions from manufacturer) in the nuclear extracts were ~ 2 mg/mL. The equilibrium binding constant (Kd) for [3H]-E2 to hER in solution was determined to 0.05 nM for hER-alpha and to 0.07 nM for hER-beta with the G25-assay for highly diluted extracts (hER ~ 0.1 nM). The extracts were aliquoted and stored at -80°C.
The scintistrip assay In brief; the nuclear extracts were diluted (50 fold for hER-alpha and 110 fold for hER-beta) in coating buffer (17 mM K2HPO4, 3 mM KH2PO4, 40 mM KC1, 6 mM MTG). The diluted extracts were added to Scintistrip wells (200 μL/well) and incubated 18-20 hr. at ambient room temperature (22-25 °C). The estimated final concentration of immobilized hER in all experiments was ~ nM. All incubations were performed in 17 mM K2HPO4, 3 mM KH2PO4, 140 mM KC1, 6 mM MTG (buffer A). The wells were washed twice after hER coating with 250 μL buffer prior to addition of the incubation solution. All steps were carried out at ambient room temperature (22-25 °C).
Determination of Equilibrium binding constants to immobilized hER:s: Dilutions of 3[H]-E2 in buffer ± Triton XI 00 were added to the wells (200 μL/well), the wells were incubated for 3 hr and then measured in the Microbeta. After the measurement an aliquot of the buffer was taken out and counted by regular liquid scintillation counting for determination of the "free" fraction of 3[H]-E2. In order to correct for non-specific binding parallel incubations were done in presence of a 200-fold excess of unlabeled 17-β-E2. The equilibrium dissociation constants (Ka) were calculated as free concentration of 3[H]-E2 at half maximum binding by fitting data to the Hill equation; b = (bm!K x L")/(L"+Kd n) where b is specific bound 3[H]-E2, bmax is the maximum binding level, L is the free concentration of [3H]E2, n is the Hill coefficient (the Hill equation equals the Michaelis-Menten equation when n = 1). The equilibrium binding constants were determined to 0.15 - 0.2 nM for both hER subtypes.
Regular competition binding: Samples containing 3 nM [3H]-E2 plus a range of dilutions of the compounds to be tested were added to wells with immobilized hER and incubated for 18-20 hr at ambient room temperature. The compounds to be tested were diluted in 100% DMSO to a concentration 50 fold higher than the desired final concentration, the final concentration of DMSO was thus 2% in all samples. For compounds able to displace 3[H]-E2 from the receptor an IC50-value (the concentration required to inhibit 50% of the binding of 3[H]-E2) was determined by a non-linear four parameter logistic model; b = ((braax-bmm)/(l+(I/IC5o)s))+bmin I is added concentration of binding inhibitor, IC50 is the concentration of inhibitor at half maximal binding and S is a slope factor.1 For determinations of the concentration of 3[H]-E2 in the solutions regular scintillation counting in a Wallac Rackbeta 1214 was performed using the scintillation cocktail Supermix™ (Wallac). The Microbeta-instrument generates the mean cpm (counts per minute) value / minute and corrects for individual variations between the detectors thus generating corrected cpm values. It was found that the counting efficiency between detectors differed with less than five percent.
1) Haggblad, J, Carlsson, B, Kivela, P, Siitari, H, (1995) Biotechniques 18, 146-151
2) Barkhem, T, Carlsson, B, Simons, J, Moller, B, Berkenstam, A, Gustafsson J.A.G, Nilsson, S. (1991 ) J. Steroid Biochem. Molec. Biol. 38, 667-75
3) Salomonsson, M, Carlsson, B, Haggblad, J, (1994) J Steroid Biochem. Molec. Biol. 50, 313-318
4) Schultz, J.R, Ruppel, P.I, Johnson, M.A, (1988) in Biopharmaceutical Statistics for Drug Development (Peace, K.E, Ed.) pp. 21-82, Dekker, New York
The compounds of Examples 1-48 exhibit binding affinities to the estrogen receptor α-subtype in the range of ICso 3 to 10,000 nM and to the estrogen receptor β-subtype in the range of IC5- 3 to 10,000 nM.

Claims

Claims
A compound having the general formula I, II or III:
III
wherein the bond between the CI and C2 carbon atoms (of compounds of general formula I) or the bond between C2 and C3 (of compounds of general formula II) or the bond between CI and CIO (of compounds of general formula III) is either a single or double bond;
Ri (of compounds of general formula I or III) is an RA group other than a phenyl group;
RA is selected from the group hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, aryl or arylalkyl;
Riα and R,β (of compounds of general formula II) are the same or are different and each is an RA group;
R2 (of compounds of general formula I or II) is a hydroxyl or RA group or is a hydroxyalkyl or aminoalkyl group of 1 to 2 carbon atoms;
R3 and R3β (of compounds of general formula I) may together be a single oxygen or sulftu- atom or R3α and R3β may together be a single nitrogen atom which in turn is bonded to a group selected from RA or ORA; or R3α and R3β may together be a single carbon atom which in turn is bonded to two RA groups which may be the same or are different; or R3 and R3β may be the same or are different and each may be selected from RA, ORA, SRA, or N(RA)2 wherein the individual RA groups may be the same or are different and may optionally be taken together with any attached and intervening atoms to form a 3-8 membered ring;
R2α and R2β (of compounds of general formula III) may together be a single oxygen or sulfur atom or R3α and Rsβ may together be a single nitrogen atom (i.e., an imine or oxime nitrogen atom) which in turn is bonded to a group selected from RA or ORA; or R2α and R2β may together be a single carbon atom which in turn is bonded to two RA groups which may be the same or are different; or R2α and R2β may be the same or are different and each may be selected from hydroxyalkyl, aminoalkyl, RA, ORA, SRA, or N(RA)2 wherein the individual RA groups may be the same or are different and may optionally be taken together with any attached and intervening atoms to form a 3-8 membered ring;
R3 (of compounds of general formula II or III) is an RA group;
R, is an RA group;
,a is a hydrogen atom or a methyl or ethyl group in compounds of formula I or II, or a methyl or ethyl group in compounds of formula III.;
R7 is a hydrogen atom or a linear or branched alkyl or cycloalkyl group or acyl group of 1 to 4 carbon atoms;
Rio- is an RA group;
with the proviso that not all of Rj, R , R3 and R4 are hydrogen in compounds of formula I or II, and that Rt is not hydrogen in compounds of formula III. and pharmaceutically acceptable salts and stereoisomers thereof.
2. A compound according to claim 1 wherein the Rta and Rιoa substituents have a trans relative stereochemistry.
3. A compound with the general formula I or III according to claim 2 wherein Ri is RB and RB is selected from hydrogen, n-propyl, 2-propenyl, 2-propynyl, n- utyl, 2-butenyl, 3-butenyl, 2-butynyl, 3-butynyl, rø-pentyl, 3-methylbutyl,
3 -methyl- 1-butenyl, 3-methyl-2-butenyl, 3-methylpentyl, 3-ethylpentyl, cyclopropylethyl, cyclopentylethyl, cyclohexylethyl, cycloheptylethyl, cyclopropylpropyl, cyclopentylpropyl, benzyl, or phenethyl.
4. A compound with the general formula II according to claim 2 wherein Riα is RB (where RB is defined in claim 3) and Riβ is a hydrogen atom or methyl group.
5. A compound according to any one of claims 2 to 4 wherein Rι0a is RB.
6. A compound with the general formula I or II according to any one of claims 2 to 5 wherein R2 is a hydrogen atom or a methyl, ethyl, or hydroxymethyl group.
7. A compound with the general formula III, according to any one of claims 2 to 5 wherein R2α and R2β may be the same or are different and each may be selected from hydroxyalkyl, RA, ORA, or SRA where the individual RA groups (where RA is defined as above) may be the same or are different and may optionally be taken together with any attached and intervening atoms to form a 3-8 membered ring.
8. A compound with the general formula I according to any one of claims 2 to 6 wherein R3α and R3β may be the same or are different and each may be selected from RA, ORA, or SRA where the individual RA groups (where RA is defined in claim 1) may be the same or are different and may optionally be taken together with any attached and intervening atoms to form a 3-8 membered ring.
9. A compound according to any one of claims 2 to 8 wherein Rt is a hydrogen atom or methyl or ethyl group.
10. A compound according to any one of claims 2 to 9 wherein R7 is hydrogen atom or an acyl group of 1 to 4 carbon atoms.
11. A compound with the general formula I or III according to any one of claims 2 to 10 wherein Ri is selected from hydrogen, methyl, or ethyl and Rι0a is RB.
12. A compound with the general formula I or III according to any one of claims 2 to 10 wherein Ri is RB and Rι0a is selected from hydrogen, methyl, or ethyl.
13. A compound of formula III according to any one of claims 2, 9, 10, 11 or 12 wherein R2α and R2β may be the same or are different and each may be selected from hydroxyalkyl, RA ORA, or SRA where the individual RA groups (where RA is defined in claim 1) may be the same or are different and may optionally be taken together with any attached and intervening atoms to form a 3-8 membered ring.
14. A compound with the general formula II according to any one of claims 2 to 10 wherein Riα is RB and Rιoa is selected from hydrogen, methyl, or ethyl.
15. A compound with the general formula II according to any one of claims 2 to 10 wherein Riα is selected from hydrogen, methyl, or ethyl and Rι0a is RB.
16. A compound according to claim 1 which is selected from:
(rac)-(4aS, 10aS)- -bydxoxy- 1 ,4,4a,9, 10,10a-hexahydro-2H-phenanthren-3-one (El); (r ς -f αS70 S^-3,3-ethanediyldimercapto-7-hydroxy-l,2,3,4,4a,9,10,10a-octahydr o-phenanthrene (E2);
(rac)-(4aR, 10aS)- -bydxoxy A 0a-methyl-4a,9, 10, 10a-tetrahydro-¥H-phenanthren-3- one (E3a);
(rac)-(4aS, 10aS)- -bydxoxy- 10a-methyl-4a,9, 10, 1 Oa-tetrahydro-^H-phenanthren-3 - one (E3b);
(rac)-(4aS, 1 OaS) A 0a-butyl-7-hydroxy-4a,9, 10, 10a-tetrahydro- H-phenanthren-3 -on e (E4);
(rac)-(lS, 4aS, 1 OaS) A -butyl-7-hydroxy- 1 ,4,4a,9, 10, 10a-hexahydro-2H-ρhenanthren
-3-one (E5a);
(rac) - (1R, 4aS, 1 OaS) - 1 -butyl-7-hydroxy- 1 ,4,4a,9, 10,10a-hexahydro-2H-phenanthren
-3-one (E5b);
(rac) -(IS, 4aS, 1 OaS) A -butyl-3 ,3-ethanediyldimercapto-7-hydroxy- 1 ,2,3 ,4,4a,9, 10, 10 a-octahydro-phenanthrene (E6a);
(rac)-(lR,4aS,10aS)-
1 -butyl-3 ,3-ethanediyldimercapto-7-hydroxy- 1 ,2,3 ,4,4a,9, 10,1 Oa-octahydro-phenant hrene (E6b);
(rΩc - 7S^ΩS,70ΩS -l-butyl-7-hydroxy-10a-methyl-l,4,4a,9,10,10a-hexahydro-2H- phenanthren-3-one (E7);
(rac)-(lS, 4aS, 1 OaS) A -butyl-3 ,3-ethanediyldimercapto-7-hydroxy- 1 Oa-methyl- 1 ,2,3 ,
4,4a,9, 10, 1 Oa-octahydro-phenanthrene (E8);
(rac) -(IS, 4aS, 1 OaS) A -butyl-7-hydroxy- 1 Oa-methyl- 1 ,2,3 ,4,4a,9, 10, 1 Oa-octahydro-p henanthrene (E9);
(rac)-(4aS, 1 OaR) A 0a-ethyl-7-hydroxy-3 -methyl-4a,9, 10,10a-tetrahydro- H-phenant hren-1-one (ElOa); rα )-( R,10αR)-10a-ethyl-7-hydroxy-3-methyl-4a,9,10,10a-tetrahydro-4H-phenan thren-l-one (E10b);
(rac)-(lR, 2S, 4aS, 1 OaS)- 1 -butyl-7-hydroxy-2-methyl- 1 ,4,4a,9, 10, 10a-hexahydro-2H
-phenanthren-3 -one (Ella);
(rac)-(lR, 2R, 4aS, 1 OaS) A -butyl-7-hydroxy-2-methyl-l ,4,4a,9,l 0, 10a-hexahydro-2H
-phenanthren-3 -one (Ellb); (rαc/ )-(7^ R, αR,70 S l-butyl-7-hydroxy-4-methyl-l,4,4a,9,10,10a-hexahydro-2H
-phenanthren-3 -one (Ellc);
(rac)-(lR, 2R, 4aS, 1 OaS)- 1 -butyl-3,3-ethanediyldimercapto-7-hydroxy-2-methyl- 1 ,2,
3,4,4a,9, 10, 1 Oa-octahydro-phenanthrene (E12a);
(rac) - (1R, 2S, 4aS, 1 OaS)- 1 -butyl-3 ,3 -ethanediyldimercapto-7-hydroxy-2-methyl- 1,2,
3,4,4a,9, 10, 1 Oa-octahydro-phenanthrene (E12b);
(rac)-(lS, 4aS, 10aS)- -bydxoxy- 1 Oa-methyl- 1 -(3 -methyl-butyl)- 1 ,4,4a,9, 10, 1 Oa-hex ahydro-2H-phenanthren-3-one (E13);
(rac) -(IS, 4aS, 1 OaS) -3 ,3 -ethanediyldimercapto-7-hydroxy- 1 -(3 -methyl-butyl)- 1 Oa-m ethyl- 1 ,2,3,4,4a,9, 10, 1 Oa-octahydro-phenanthrene (E14);
(rac)-(lS, 4aS, 10aS)-7 -bydxoxy- 1 Oa-methyl- 1 -phenethyl- 1 ,4,4a,9, 10, 1 Oa-hexahydro-
2H-phenanthren~3-one (E15); r c (7S2S αS70αS 7-hydroxy-2,10a-dimethyl-l-(3-methyl-butyl)-l,4,4a,9,10,l
0a-hexahydro-2H-phenanthren-3-one (E16a);
(rac) -(IS, 2R, 4aS, 10aS)-7-hydxoxy-2, 1 Oa-dimethyl- 1 -(3 -methyl-butyl)- 1 ,4,4a,9, 10, 1
0a-hexahydro-2H-phenanthren-3-one (E16b); frac C bSSS,SflrS 6,6-dimethoxy-8a-methyl-8-(3-methyl-butyl)-4b,5,6,7,8,8a,9,10- octahydro-phenanthren-2-ol (E17a);
(rac)-(lS, 4aS, 1 OaS) - -bydxoxy- 1 Oa-methyl- 1 -(3-methyl-butyl)- 1 ,4,4a,9, 10, 1 Oa-hex ahydro-2H-phenanthren-3-one (E17b);
(rαc -(7S, αS,i0 S^-3,3-ethanediyldioxy-7-hydroxy-l-(3-methyl-butyl)-10a-methyl-
1 ,2,3 ,4,4a,9, 10, 1 Oa-octahydro-phenanthrene (E18);
(rαc ^bS,5R,SαS -8a-metl yl-8-(3-methyl-butyl)-4b,5,6,7,8,8a,9,10-octal ydro-phe nanthren-2-ol (E19a);
(rac)-(4bS, 6R, 8S, SαS 6-ethylsulfanyl-8a-methyl-8-(3-methyl-butyl)-4b,5,6,7,8,8a,9
, 10-octahydro-phenanthren-2-ol (E19b);
(rac) -(IS, 4aS, 10aS)-3 ,3 -(propane- 1 ,3 -diyldimercapto)-7-hydroxy- 1 -(3 -methyl-butyl
)- 1 Oa-methyl- 1 ,2,3 ,4,4a,9, 10, 1 Oa-octahydro-phenanthrene (E20);
(rac)~(4aS, 10aS)-7 -bydxoxy- 1 Oa-methyl- 1 ,4,4a,9, 10, 10a-hexahydro-2Η-phenanthre n-3-one (E21); (rac)-(4aS, 10aS)-3,3 -ethanediyldimercapto-7-hydroxy- 1 Oa-methyl- 1 ,2,3 ,4,4a,9, 10,1
Oa-octahydro-phenantlirene (E22);
(rac)-(4aS, 1 OaS) A Oa-ethyl-7-hydroxy- 1 ,4,4a,9, 10, 10a-hexahydro-2H-phenanthren-
3-one (E23);
(rac)-(4aS, 10aS)-3 ,3-ethanediyldimercaρto- 1 Oa-ethyl-7-hydroxy- 1 ,2,3 ,4,4a,9, 10,10 a-octahydro-phenanthrene (E24);
(rac)-(lS, 4aS, 1 OaS)- 1 -(3 -methyl-butyl)- 1 Oa-ethyl-7-hydroxy- 1 ,4,4a,9, 10, 1 Oa-hexah ydro-2H-phenanthren-3-one (E26);
(7S^αS,/0 SA7-hydroxy-10a-methyl-l-(3-methyl-butyl)-l,4,4a,9, 10,
10a-hexahydro-2H-phenanthren-3-one (E27);
(7R, RS,70βRA7-benzyloxy-10a-methyl-l-(3-methyl-butyl)-l,4,4a,9,10,
10a-hexahydro-2H-phenanthren-3-one (E28);
( c)-(7S,^αS,i0αl5)-l-(3-methyl-butyl)-3,3-ethanediyldimercapto-7-hydroxy-l,4,4a
,9, 10, 1 Oa-octahydrophenanthrene (E29);
(rac)-(4aR, 10aR)-7-bydxoxy-4a, 10a-dimethyl-3,4,4a,9, 10, 1 Oa-hexahydro-iH-phena nthren-2-one (E30);
(rαc)-(lS, 4αS,10αS) -7-hydroxy- 10a-methyl-4-phenyl-l,4,4a,9, 10,
10a-hexahydro-2H-phenanthren-3-one (E31);
(rαc)-(4R, 4αS, 10αS)~3 ,3 -ethanediyldimercapto-7-hydroxy- 1 Oa-methyl-4-phenyl- 1 ,4
,4a,9, 10,1 Oa-octahydro-phenanthrene (E32); frαc)-(7S,^βS,i0 ^)-3,3-(ethane-l,2-diyldimercapto)-7-hydroxy-l-(2-phenylethyl)-
1 Oa-methyl- 1 ,2,3 ,4,4a,9, 10,1 Oa-octahydro-phenanthrene (E33);
(rαc) - (IS, 4αS, 1 OαS) -3 ,3 -ethanediyldioxy-7-hydroxy- 1 Oa-methyl- 1 ,
2,3,4,4a,9, 10, 1 Oa-octahydro-phenanthrene (E34a);
(rαc) -(IS, 4αS, 10αR)-3 ,3 -ethanediyldioxy-7-hydroxy- 1 Oa-methyl- 1 ,
2,3,4,4a,9, 10, 1 Oa-octahydro-phenanthrene (E34b);
(rαc)~(3S, 4αS, 10αS)-7-bydxoxy-3 -pentyl- 1 Oa-methyl-1 ,
2,3 ,4,4a,9, 1 , 1 Oa-octahydro-phenanthrene (E35a);
(rαc)-(3R,4αS,10αS)-7-bydxoxy-3-ρentylA0a- etbyl-l,
2,3,4,4a,9, 1 , 1 Oa-octahydro-phenanthrene (E35b); (rac)-(lS, 2R, 4aS, 10aS)-2, 10a-dimethyl-3 ,3 -(ethane- 1 ,2-diyldimercapto)-7-hydroxy-
1 -(3-methyl-butyl- 1 ,2,3,4,4a,9, 10, 1 Oa-octahydro-phenanthrene (E36);
(rac) -(IS, 4aS, 10aS)- -Bydxoxy- 1 -(3 '-methyl-butyl)- 1 ,4,4a,9, 10, 1 Oa-hexahy- dro-2H-phenanthren-3-one (E37);
(rac) - (4aS, 1 OaS) -3 ,3 -(propane- 1 ,3 -diyldimercapto)-7-hydroxy- 1,2,3,4,4a, 9, 10, 1 Oa-o ctahydro-phenanthrene (E38);
Crαc (7S)^S)^ S,i0αS 7-Ηydroxy-l-butyl-4,10a-dimethyl-l,4,4a,9,10,10a-hexahyd ro-2H-phenanthren-3-one (E39);
(rac)-(4S, 4aS, 10α -3,3-ethanediyldimercapto-7-hydroxy-4,
1 Oa-dimethyl- 1 ,2,3 ,4,4a,9, 10, 1 Oa-octahydro-phenanthrene (E40);
(rac)-(4S, 4aS, 10αS 7-Ηydroxy-4-benzyl- 1 Oa-methyl- 1 ,4,4a,9, 10, 1 Oa-hexahydro-2
H-phenanthren-3-one (E41a);
(rac)- (4aS, 1 OaS) -7-hydroxy-4,4-dibenzyl- 1 Oa-methyl- 1 ,4,4a,9, 10, 10a-hexahydro-2
H-phenanthren-3-one (E41b);
(rac) - (4aS, 10aS)-7 -bydxoxy- 1 Oa-methyl-3 ,3 -methylene- 1 ,2,3 ,4,4a,9, 10, 1 Oa-octahyd rophenanthrene (E42);
(rac)-(4aS, 10aS)-3 ,3 -ethanediyl-7-hydroxy- 1 Oa-methyl- 1 ,2,3,4,4a,9, 10, 1 Oa-octahyd rophenanthrene (E43);
(rac)-(3R, 4aS, 10aS)A',2',3 ',4'-tetrachloro-7-hydroxy- 1 Oa-methyl- 1 ,2,3,4,4a,9, 10,
10a-octahydrospiro[phenanthrene-3,6'-cyclohexane]- ,3'-diene (E44);
(rac) - (3S, 4aS, 1 OaS) -3 ,7-dihydroxy- 1 Oa-methyl-3 - [ 1 -(phenylthio)cyclopropyl] -1,2,3,
4,4a,9, 10, 1 Oa-octahydrophenanthrene (E45);
(rac)-(3S, 4aS, 10aS)- -bydxoxy- 1 Oa-methyl- 1 ,2,3,4,4a,9, 10, 10a-octahydrospiro[phe nanthrene-3,2'-cyclobutane]-r-one (E46a);
(rac)-(3R, 4aS, 10aS)- -bydxoxy- 1 Oa-methyl- 1 ,2,3,4,4a,9, 10, 10a-octahydrospiro[phe nanthrene-3,2'-cyclobutane]-l'-one (E46b);
(rac)-(3S,4aS,10aS)-
1 ' , 1 ' -ethanediyldimercapto-7 -hydroxy- 1 Oa-methyl- 1 ,2,3 ,4,4a,9, 10,
10a-octahydrospiro[phenanthrene-3,2'-cyclobutane] (E47);
(rαc (^αS,i0 SJ-7-hydroxy-10a-methyl-l,2,3,4,4a,9,10,10a-octahydrospiro[phenan threne-3 , 1 ' -cyclobutane] (E48) ; (rac)-(4aS, 10aS)-3-(l -cyclopenten- 1 -yl)-7-hydroxy- 1 Oa-methyl- 1 ,4,4a,9, 10, 1 Oa-hex ahydrophenanthrene (E49);
(rac)-(3S,4aS,10aS)-7-bydxoxyA0a-metbylA,2,3,4,4a,9,l0, 10a,2',3',4',5'-dodecahydrospiro[phenanthrene-3,2'-fixran] (E50a); (rac)-(3R, 4aS, 1 OaS) - -by dxoxy A Oa-methyl-1 ,2,3,4,4a,9, 10, 10a,2',3',4',5'-dodecahydrospiro[phenanthrene-3,2'-furan] (E50b); (rac)-(3S, 4aS, 10aS)- -bydxoxy- 1 Oa-methyl- 1 ,2,3,4,4a,9, 10, 10a,3',4',5',6'-dodecahydrospiro[phenanthrene-3,2'-2H-pyran] (E51a); rαe -^R^ S,70αS -7-hydroxy-10a-methyl-l,2,3,4,4a,9,10, 10a,3',4',5',6'-dodecahydrospiro[phenanthrene-3,2'-2H-pyran] (E51b); (rac)-(lS, 3R, 4aS, 1 OaS) A '-hydroxy- 1 Oa-methyl- 1 -(3 -methylbutyl)- 1 ,2,3 ,4,4a,9, 10, 10 a,2',3',4',5'-dodecahydrospiro[phenanthrene-3,2'-furan] (E52);
(rac)-(lS, 4aS, 10aS)- -bydxoxy A Oa-methyl- 1 -(3-methylbutyl)- 1 ,2,3,4,4a,9, 10, 1 Oa-o ctahydrospiro[phenanthrene-3,l'-cyclobutane] (E53);
(rαc -(7S)^αS,i0flr)_?)-7-hydroxy-3-(3-hydroxypropyl)-10a-methyl-l-(3-methylbutyl)-
1 ,4,4a,9, 10, 1 Oa-hexahydrophenanthrene (E54a);
(rac)-(lS, 3S, 4aS, 1 OaS) -7 -bydxoxy- 1 Oa-methyl-1 -(3-methylbutyl)- 1 ,2,3,4,4a,9, 10,10 a,2',3',4',5'-dodecahydrospiro[phenanthrene-3,2'-furan] (E54b);
(rac)-(4aR, WaR)- 10a-Butyl-7-hydroxy-4a-methyl-3,4,4a,9, 10, 1 Oa-hexahydro-iH-p henanthren-2-one (E55); frαc)-7-Ηydroxy-4a-methyl-4,4a,9, 10-tetrahydro-5H-phenanthren-2-one (E56); rø A4b-methyl-4b,5,6,7,9, 10-hexahydro-phenanthren-2-ol (E57);
(rac)-7 -Bydxoxy- 1 ,4a-dimethyl-4,4a,9, 10-tetrahydro-5H-phenanthren-2-one (E58); frαc)-4a,8-dimethyl-4b,5,6,7,9, 10-hexahydro-phenanthren-2-ol (E59); rαc 4b,8-dimethyl-4b,5,6,7,9,10-hexahydro-phenanthren-2-ol (E60a, E60b, E60c,
E60d); f 'αcJ-(3S,^ RJ-7-hydroxy-3,4a-dimethyl-4,4a,9,10-tefrahydro-5H-phenanthren-2-on e (E61);
(rac)-(4S, ¥αR 7-Ηydroxy-4a-methyl-4-proρyl-4,4a,9,
10-tetrahydro-5H-phenanthren-2-one (E62); (rac)-(4R, ^αR)-7-Hydroxy-4,4a-dimethyl-4,4a,9, 10-tetrahydro-5H-phenanthren-2-o ne (E63a);
(rac)-(4S, αR)-7-Ηycfroxy-4,4a-dimethyl-4,4a,9, 10-tetrahydro-3H-phenanthren-2-o ne (E63b);
(rac) A -Ethyl-7-hydroxy-4a-methyl-4,4a,9, 10-tetrahydro-3H-phenanthren-2-one
(E64); fra c 8-Ethyl-4b-methyl-4b,5,6,7,9, 10-hexahydro-phenanthren-2-ol (E65);
(rac)-(4aR, 1 OaR, IS) A -Ethyl-7-hydroxy-4a-methyl- 1 ,4,4a,9, 10, 10a-hexahydro-3H-p henanthren-2-one (E66);
(rac)- 1 -Butyl-7-hydroxy-4a-methyl-4,4a,9, 10-tetral ydro-5H-phenanthren-2-one
(E67);
(røc 8-Butyl-4b-methyl-4b,5,6,7,9, 10-hexahydro-phenanthren-2-ol (E68);
(rac)-(8R, 4bR, SαR)-8-Butyl-4b-methyl-4b,5,6,7,8,8a,9, 10-octahydro-phenanthren-2
-ol (E69a); rac fSS^bR,SαR 8-Butyl-4b-me l-4b,5,6,7,8,8a,9,10-octahydro-phenanthren-2
-ol (E69b);
(>ας)-4a-Butyl-7-hydroxy-l-methyl-4,4a,9,10-tetrahydro-3H-phenanthren-2-one
(E70);
(rac) -4a-Butyl-7-hydroxy-4,4a,9, 10-tetral ydro-3H-phenanthren-2-one (E71);
(rαcJ-f αR,i0αR- 4a-Butyl-7-hydroxy-3,4,4a,9,10,10a-hexahydro-7H-phenantl ren-
2-one (E72a);
(rac)-(4aR, 1 α -4a-Butyl-7-hydroxy-3 ,4,4a,9, 10, 10a-hexahydro-7H-phenanthren-
2-one (E72b);
(rac)-(4aR,10aS)-7-bydxoxy-4a-xnexbyl-3,4,4a,9, 10, 1 Oa-hexahydro-iH-phenanthren
-2-one (E73);
(7-αc)-(^αR,i067^)-2,2-ethanediyldimercapto-7-hydroxy-4a-methyl-l,2,3,4,4a,9,10,l
Oa-octaliydrophenanthrene (E74);
(rαc)-(4αR, 10α^)-7-hydroxy-4a-methyl-3 ,4,4a,9, 10,10a-hexahydro-7H-phenanthren
-2-one oxime (E75);
and pharmaceutically acceptable salts and stereoisomers thereof.
17. A compound according to any one of claims 1 to 16 for use in medical therapy.
18. A pharmaceutical composition comprising a compound according to any one of claims 1 to 16 and a pharmaceutically acceptable carrier.
19. A process for making a pharmaceutical composition comprising combining a compound according to any one of claims 1 to 16 and a pharmaceutically acceptable carrier.
20. A method of eliciting an estrogen receptor modulating effect in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of a compound according to any one of claims 1 to 16.
21. The method according to claim 20 wherein the estrogen receptor modulation effect is an estrogen receptor agonizing effect.
22. The method according to claim 21 wherein the estrogen receptor agonizing effect is an ERα receptor agonizing effect.
23. The method according to claim 21 wherein the estrogen receptor agonizing effect is an ERβ receptor agonizing effect.
24. The method according to claim 21 wherein the estrogen receptor agonizing effect is a mixed ERα and ERβ receptor agonizing effect.
25. The method according to claim 20 wherein the estrogen receptor modulation effect is an estrogen receptor antagonizing effect.
26. The method according to claim 25 wherein the estrogen receptor antagonizing effect is an ERα receptor antagonizing effect.
27. The method bccording to claim 25 wherein the estrogen receptor antagonizing effect is an ERβ receptor antagonizing effect.
28. The method according to claim 25 wherein the estrogen receptor antagonizing effect is a mixed ERα and ERβ receptor antagonizing effect.
29. A method of treating or preventing a disease regulated by the estrogen receptor in a mammal in need thereof by administering to the mammal a therapeutically effective amount of a compound according to any one of claims 1 to 16.
30. A method of treating or preventing bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restinosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, autoimmune disease, and lung, colon, breast, uterus, and prostate cancer in a mammal in need thereof by administering to the mammal a therapeutically effective amount of a compound according to any one of claims 1 to 16.
31. The use of a compound according to any one of claims 1 to 16 in the manufacture of a medicament for the therapeutic treatment or prevention of bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels in LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restinosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, autoimmune disease, and lung, colon, breast, uterus and prostate cancer.
EP01272663A 2001-01-04 2001-12-24 Novel estrogen receptor ligands and methods i Expired - Lifetime EP1399406B1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0100164 2001-01-04
GB0100163A GB0100163D0 (en) 2001-01-04 2001-01-04 Novel estrogen receptor ligands and methods
GB0100163 2001-01-04
GB0100164A GB0100164D0 (en) 2001-01-04 2001-01-04 Novel estrogen receptor ligands and methods II
GB0106434A GB0106434D0 (en) 2001-03-15 2001-03-15 Novel estrogwen receptor ligands and methods II
GB0106434 2001-03-15
PCT/EP2001/015230 WO2002053522A2 (en) 2001-01-04 2001-12-24 Novel estrogen receptor ligands and methods i

Publications (2)

Publication Number Publication Date
EP1399406A2 true EP1399406A2 (en) 2004-03-24
EP1399406B1 EP1399406B1 (en) 2005-08-10

Family

ID=27256041

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01272663A Expired - Lifetime EP1399406B1 (en) 2001-01-04 2001-12-24 Novel estrogen receptor ligands and methods i

Country Status (11)

Country Link
US (1) US20040127576A1 (en)
EP (1) EP1399406B1 (en)
JP (2) JP2004523508A (en)
KR (1) KR20030076600A (en)
AT (1) ATE301629T1 (en)
AU (2) AU2002219219B2 (en)
CA (1) CA2433828A1 (en)
DE (1) DE60112624T2 (en)
ES (1) ES2247010T3 (en)
IL (1) IL156151A0 (en)
WO (1) WO2002053522A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7524866B2 (en) 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
CA2512000C (en) * 2002-12-26 2011-08-09 Eisai Co., Ltd. Selective estrogen receptor modulator
CN101023085A (en) * 2004-07-19 2007-08-22 詹森药业有限公司 Spiro-benzo[c]chromene derivatives useful as modulators of the estrogen receptors
WO2006042172A2 (en) * 2004-10-09 2006-04-20 The Regents Of The University Of Michigan Gender differences in experimental aortic aneurysm formation
CN113133983B (en) * 2020-01-20 2023-12-12 鲁南制药集团股份有限公司 Pharmaceutical composition for treating prostate cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116865A (en) * 1990-09-05 1992-05-26 Peters Richard H 15,16-seco-19-nor progestins
CA2111138A1 (en) * 1993-01-15 1994-07-16 Thierry Godel Octahydrophenanthrene derivatives
AU7467398A (en) * 1997-04-25 1998-11-24 Eli Lilly And Company Indene compounds having activity as serms
AU4701299A (en) * 1998-06-23 2000-01-10 Stuart R. Adler Therapeutic applications of estrogenic carboxylic acids
ATE524170T1 (en) * 2000-02-14 2011-09-15 Merck Sharp & Dohme ESTROGEN RECEPTOR MODULATORS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO02053522A3 *

Also Published As

Publication number Publication date
US20040127576A1 (en) 2004-07-01
EP1399406B1 (en) 2005-08-10
IL156151A0 (en) 2003-12-23
KR20030076600A (en) 2003-09-26
DE60112624T2 (en) 2006-06-08
WO2002053522A3 (en) 2004-01-08
WO2002053522A2 (en) 2002-07-11
AU2007201347A1 (en) 2007-04-19
CA2433828A1 (en) 2002-07-11
ES2247010T3 (en) 2006-03-01
JP2009067794A (en) 2009-04-02
AU2002219219B2 (en) 2006-12-21
ATE301629T1 (en) 2005-08-15
DE60112624D1 (en) 2005-09-15
JP2004523508A (en) 2004-08-05

Similar Documents

Publication Publication Date Title
AU2002305359B2 (en) Estrogen receptor modulators
US7151196B2 (en) Estrogen receptor modulators
US20240010670A1 (en) C19 scaffolds and steroids and methods of use and manufacture thereof
WO1998058901A1 (en) 3-anilino-2-cycloalkenone derivates
AU2002305359A1 (en) Estrogen receptor modulators
NZ555316A (en) Estrogen receptor modulators
AU2007201347A1 (en) Novel estrogen receptor ligands and methods I
AU2002219219A1 (en) Novel estrogen receptor ligands and methods I
US20110160296A1 (en) Preparation of 6-oxa-8alpha-steroid estrogen analogues - a new group of unnatural estrogens and their use in medicine
US7923568B2 (en) Estrogen receptor modulators
WO2002046134A1 (en) Novel estrogen receptor ligands and methods iii
CN109776523A (en) Heterocyclic compound and application thereof in medicine
JP2004515485A6 (en) Novel estrogen receptor ligands and methods III
US20240228527A1 (en) Stereoselective c9-c10 bond formation
WO2002058639A2 (en) Pyranoflavonoid compounds and their use as estrogen receptor modulators
US20020132802A1 (en) Cytoprotective polycyclic compounds
US20230212215A1 (en) Glucocorticoid receptor modulators
CA2879908A1 (en) Therapeutic compounds
JPS582226B2 (en) Production method of benzylamine derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030627

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20040330

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050810

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050810

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050810

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050810

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050810

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60112624

Country of ref document: DE

Date of ref document: 20050915

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051110

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051110

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051110

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: KELLER & PARTNER PATENTANWAELTE AG

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20051224

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051224

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20051231

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20051231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060110

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2247010

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20060511

PGRI Patent reinstated in contracting state [announced from national office to epo]

Ref country code: IT

Effective date: 20090401

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20121213

Year of fee payment: 12

Ref country code: IE

Payment date: 20121211

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20121219

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20130107

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20121219

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20131112

Year of fee payment: 13

Ref country code: IT

Payment date: 20131107

Year of fee payment: 13

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60112624

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20131224

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20140829

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60112624

Country of ref document: DE

Effective date: 20140701

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140701

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131231

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131231

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131224

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131224

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141224

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20160128

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141225